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ABSTRACT
Pulmonary bacterial infections account for 95% ofmorbidity and mortality in cystic
fibrosis (CF) patients, and include a limited spectrum of bacteria; Staphylococcus
aureus, Haemophilus influenzae, Pseudomonas aeruginosa, and members of the
Burkholderia cepacia complex (Bcc). "B. cepacia" was first recognised in the late
1970's as a cause of life threatening respiratory infections in CF. Initial clinical
observations noted that 20% of colonised CF patients developed "cepacia
syndrome", a rapid and fatal necrotising pneumonia. In addition, epidemiological
evidence highlighted the potential spread of certain "B. cepacia''' strains, that most
isolates were highly resistant to conventional antibiotics and consequently, Bcc
infections are untreatable. Subsequent taxonomic studies have identified the Bcc that
contains ten distinct species of bacteria previously termed "5. cepacia". Clinical
distribution ofBcc species in CF is restricted to mainly B. cenocepacia (50%), B.
multivorans (38%) and B. vietnamiensis (7%).
The aim of this study was to investigate novel antimicrobial agents against the Bcc
and other problematic and emerging CF associated bacterial pathogens including
multi-resistant epidemic P. aeruginosa strains, methicillin resistant S. aureus
(MRSA), and Stenotrophomonas maltophilia. The novel antimicrobial strategies
examined were based on three main themes: First, the use of natural honey, second,
the potential use of bacteriophage and their associated lytic enzymes and third, novel
mammalian cationic P-defensins. The project utilised a vast collection of bacterial
isolates and included relevant clinical, environmental and epidemic strains. The
susceptibility to conventional antibiotics was measured, and resistance was shown to
vary across the Bcc. In general, clinical isolates were statisticallymore resistant to
conventional antibiotics than environmental isolates.
Members of the Bcc, and an extended panel of resistant organisms were shown to be
sensitive to New Zealand manuka honey (NZMh). The MICs ranged from 9 to 17%
(w/v), and the MBCs ranged from 9 to 20% (w/v). The antimicrobial component of
NZMh was investigated, and focussed on osmolality, pH and H2O2. All were found
to contribute to the antibacterial activity, although none were solely responsible for
the activity. Killing-curves suggested that NZMh kills within 24 hours. The NZMh
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preparation was applied to a CF patient infected with B. cenocepacia J2315, and
clinical data highlighted possible benefits to the patient.
Novel Bcc specific bacteriophages were identified from environmental samples and
from lysogeny studies. The spectrum of activity of the novel bacteriophages, and
previously reported Bcc bacteriophage (NS1 and NS2), was determined using a panel
comprising 66 isolates of the Bcc, 55 isolates representing other pseudomonads, and
40 B. pseudomallei strains. The novel phages were shown to be very promiscuous
and had activity across the Bcc, with some active against P. aeruginosa, B. gladioli,
and B. pseudomallei. The wide spectrum of activity was detrimental to therapeutic
use, therefore, the phage-encoded lytic enzymes were the focus for further study:
bacteriophage therapy with a novel twist. Two enzymes were investigated: the B.
cepacia bacteriophage Bcep781 endolysin and the P. aeruginosa phage D3
endolysin. The Bcep781 phage and phage DNA was not available, therefore the
endolysin gene was synthesized using recursive PCR. Briefly, twenty-two
overlapping oligonucleotides encoding the entire gene were synthesized and
constructed into the endolysin gene using a single PCR reaction. Both genes were
cloned into an expression plasmid and the enzymes were recombinantly expressed as
6-His fusion proteins in BL21 E. coli cells. Bcep781 endolysin was purified using
nickel-affinity chromatography, and the D3 lysin was purified using a Resource S®
purification protocol. High-resolution mass spectrometry analysis highlighted
discrepancies in both lysins, and neither proved to active against relevant bacteria
tested.
The activity of cationic antimicrobial peptides (CAMPs) including: a synthetic novel
murine P-defensin (Defrl) with 5-cysteine residues, which forms a covalently bound
dimer; its 6-cysteine analog (Def-cys); a chemically reduced Defrl; polymyxin B and
colistin; were assessed against the Bcc, as well as several multi-resistant bacterial CF
pathogens. Two Bcc isolates, B. cepacia type strain ATCC 25416 and B.
cenocepacia type strain J2315, were found to be inherently resistant to all CAMPs
utilised in this study. Epidemic P. aeruginosa isolates were found to have a MIC of
6 pg/ml for Defrl and a MIC of 50-100 pg/ml for Def-cys, suggesting a possible
relationship between defensin structure and function. Similarly, the MIC of 6 pg/ml
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was also noted for S. maltophilia and Ralstonia sp. that were found to be resistant to
polymyxin B and colistin. The recombinant production ofDefrl was also attempted
in a number of expression systems in E. coli. However, although Defrl was
successfully expressed, the recombinant proteins were highly insoluble.
This study showed that resistance varies within the Bee. However, the data show
that NZMh exerts a bactericidal effect on members of the Bcc, including B.
cenocepacia J2315, and that such activity may be utilised clinically. The novel Bcc
bacteriophage may prove to be a useful panel for further study, either as vectors for
horizontal gene transfer or as therapeutic agents. The data confirm previous
observations that the Bcc are inherently resistant to CAMPs, including a novel 5-
cysteine defensin. Despite this finding, synthetic Defrl was shown to be active
against a panel ofmulti-resistant pathogens associated with infections in CF. Further
research is required to optimise the recombinant expression of Bcep781 endolysin,
D3 lysin, and Defrl, to enable their use in the treatment ofmultiply resistant
infections in CF and the wider hospital environment.
xvii
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CHAPTER ONE INTRODUCTION
1.1 Cystic Fibrosis: Genetics & Pathophysiology
Cystic Fibrosis (CF) is the most common autosomal recessive genetic disorder
affecting the Caucasian population with an incidence of approximately 1 in 2500 live
births. One in twenty-five Caucasians of European decent are asymptomatic
heterozygotes for CF. The hereditary nature of the CF gene is outlined (Fig. 1.1). It
is interesting to note that the carrier rate of CF is population dependent and
considerably more rare in other ethnic populations (Asians 1 in 32,000 and African
Americans 1 in 15, 000). In general, the clinical features of CF are associated with




Offspring-1 homozygote for defect
2 heterozygote-carriers
1 no genetic abnormality
Parents -1 Homozygote for defect
Offspring- 4 heterozygote-carriers
Parents -1 homozygote and
t heterozygote for defect




| | Female-Non carrier
Male-Homozygote
H Female-Homozygote
Fig. 1.1 Inheritance of the cystic fibrosis gene, (a) Both parents are heterozygotes; 1 in 4
chance of an affected child, a 2 in 4 chance of a heterozygote, and 1 in 4 chance of non-
carrier. (b) Non-carrier plus fertile female homozygote; all offspring will be carriers, (c) Fertile
female heterozygote plus homozygote; 1 in 2 chance of affected or carrier offspring.
The CF gene was identified in 1989 (Kerem et al. 1989, Riordan et al. 1989,
Rommens et al. 1989) and encodes the CF transmembrane conductance regulator
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(CFTR). CFTR, a polypeptide of 1480 amino acids (MW -168 kDa), is a member of
the ATP-binding cassette family of transporter proteins and functions as a cAMP-
dependent chloride (CF) channel (Anderson et al. 1991, Sheppard and Welsh 1999).
CFTR is expressed primarily in epithelial tissues (pancreatic ducts, salivaiy glands,
intestinal crypts, pulmonary submucosal glands, testis and endometrium) and
contains five domains: two membrane spanning domains (MSDs), each composed of
six transmembrane segments; an R-domain, containing several consensus
phosphorylation sequences; and two nucleotide binding domains (NBDs), which







Fig. 1.2 CFTR positioned in the cellular membrane. CFTR contains 2 membrane spanning
domains, each composed of 6 transmembrane segments; an R-domain; and 2 nucleotide
binding domains.
Mutation in the CF gene, mapped to the long arm of chromosome 7 (7q31.2), result
in defective CFTR, and thus disease (Gibson et al. 2003, Wainwright et al. 1985).
To date over 1200 mutations in CFTR have been identified. However, the severity
of disease, and indeed the nature of CFTR expression at the molecular level, is
2
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mutation specific. The most common CF mutation is a three base pair deletion at
position 508 (AF508), accounting for up to 70% of the mutations within the
Caucasian population and resulting in loss of a phenylalanine at position 508 in the
CFTR protein. Although a large number of mutations can result in a CF phenotype
(http://www.genet.sickkids.on.ca/cftr/), some are extremely rare. In this section only
the most common will be examined. Each mutation gives rise to a varied CFTR
protein defect, which alters the fate of the mature peptide within the cell. To date,
six classes ofCFTR mutations have been described (Table 1.1).
Table 1.1 Classes of CFTR mutations and outcome on expression
Class Common CFTR Mutation Outcome
I G542X, 3905insT No synthesis
II AF508, N1303K No maturation
III G551D*, G551S Blocked regulation
IV R347P, R117H, R334W Decreased conductance
V 3849 + 10kb C-»T, 5T Decreased abundance
VI G551D* Defective regulation
*G551D affects both activation of CFTR and eliminates ORCC regulation
Class I mutations, characterised by G542X, contain premature stop codons, resulting
in truncated mRNA and no protein expression. Class II mutations, which are usually
missense mutations and include AF508, cause misfolding and result in the failure of
mature CFTR to traffic to the correct cellular location. Class III mutations, ofwhich
G551D is the most common, are localised within the NBDs of CFTR. Since the
regulation ofCFTR as a chloride channel is dependent on adenosine triphosphate
(ATP) stimulation, any mutation occurring in these domains will result in a defective
phenotype. Class IV mutations, exemplified by R347P, produce the correct
expression and localisation of CFTR, but there is a marked reduction in the chloride
conductance of the channel. Such mutations are localised to the MSDs. Class V
mutations, for example 3849 + lOkb C-»T, result in decreased production of
functional CFTR (in contrast to Class I), and are caused by alternative splicing.
Class VI mutations (G551D) relate to CFTR's role as a regulator of other channels
including outwardly rectified chloride channels (ORCC) (Fulmer et al. 1995).
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Defective regulation ofORCCs may decrease whole cell chloride conductance, thus,
normal function is impaired
Despite increased understanding ofCF mutations, in general disease severity does
not appear to relate to genotype. Although CFTR genotype, including AF508, is
closely correlated with pancreatic status, the same cannot be applied to respiratory
disease. In general, mutations that are associated with some functional activity of
CFTR tend to relate to milder or late onset phenotypes. R117H and R334W are
associated with pancreatic sufficiency, although the latter genotype is attributed to
late-onset pancreatic insufficiency (Mickle and Cutting. 1998). Likewise, 3849+lOkb
C—»T, is associated with "mild" CF, and up to 66% ofpatients are pancreatic
sufficient (Augarten et al. 1993). In contrast, AF508, G542X and G551D are severe
mutations and are associated with the classic CF phenotype including pancreatic
insufficiency (Kerem et al. 1990, Kulczycki et al.2003, Mickle and Cutting. 1998).
Interestingly, although G551S is a class III mutation, pancreatic sufficiency has been
observed (Strong et al. 1991). However, for all CF mutations, lung function is
variable, even between patients who share genotypes (Gibson et al.2003). This
suggests that external factors and other genes play an important role in modifying
lung disease in CF.
Identification of CFTR led to the hope that gene therapy would provide a "cure" for
CF. This expectation is based on the premise that ifCFTR function can be restored to
an adequate level within the lung epithelia, then chronic infections can be prevented
and morbidity and mortality reduced. To date, CFTR DNA has been delivered either
by cationic liposomes (Alton et al. 1999, Caplen et al. 1995, Porteous et al. 1997) or
via a viral vector such as Adenovirus (Bellon et al. 1997, Crystal et al. 1994, Zabner
et al. 1993), adeno-associated virus (Flotte.2002, Flotte et al. 1993) or Lentivirus
(Limbers et al. 2002). However, despite concerted efforts on increasing both research
and funding initiatives, gene therapy remains at the experimental stage. Alternative
pharmacologic therapies that focus on restoring CFTR function are also under
investigation. These include the use of aminoglycosides in CF patients who are
4
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are homozygous for the AF508 mutation. This strategy is based on the interesting
observation that gentamicin can overcome the premature stop mutations and restore
partial CFTR expression (Howard et al. 1996, Wilchanski et al. 2000, Wilchanski et
al. 2003). Since the promise of gene therapy and pharmacologic therapies may be
some way off, the need to consider other features ofCF is essential.
1.2 Cystic Fibrosis- The Disease
CF was clinically identified in 1938, and initially termed 'cystic fibrosis of the
pancreas'. The disease was named according to the characteristic pancreatic lesions
observed at autopsy, however several patients in the study had died from pulmonary
infections (Anderson 1938). In 1945, it was suggested that CF was an exocrine
gland disorder, and termed mucoviscidosis (Farber 1945). Di Sant' Agnese and
colleagues observed that in almost all individuals with CF, there was a characteristic
increase in sodium and chloride levels (Di Sanf Agnese et al. 1953). This
observation led to the diagnostic sweat test based on pilocarpine iontophoresis
(Gibson and Cooke 1959). Diagnosis of CF can still be based on sweat chloride
concentrations although typical gastrointestinal (meconium ileus) and respiratory
symptoms are also diagnostic. Recent advances in genetic analysis, however, have
allowed clinicians to diagnose the disease according to the patient's genotype. This
has led to the introduction of enhanced neonatal screening programmes. Genetic
screening, however, does not include all possible CFTR mutations, and thus may be
prone to delivering false negatives.
There are three main benefits of newborn screening for CF: 1. To allow increased
nutritional management, 2. To allow early management of life-threatening lung
disease (this will be discussed later), 3. To provide genetic counselling for the
parents and families of affected infants.
1.2.1 Clinical Symptoms of CF
The clinical effect of defective CFTR (Table 1.2), with little or no chloride
conductance in epithelial cells, results in thick and viscid secretions (Quinton 1983).
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Table 1.2 Main Clinical manifestations of CF (reviewed by Ratjen and Poring 2Q03)
Newborn Meconium ileus (accumulation of faecal material)
Neonatal jaundice
Infant Bronchiolitis (inflammation of the small airways)
Chronic cough
Staphylococcal infection
Atelectases (failure of part of the lung to expand)
Respiratory
Steatorrhoea (passage of increased amounts of fat)





Childhood Nasal polyps (benign growth from mucosal membrane)
Wheeze










Adult Pseudomonal infection (Mucoid phenotype)
Wheeze, breathlessness Respiratory
Pneumothorax (air in the pleural cavity)
Haemoptysis (coughing up blood)
Delayed puberty
Infertility (absence of bilateral Vas Deferens)
Cholecystitis (inflammation of the gall bladder) Other
Pancreatitis (as a result of autodigestion)
Diabetes mellitus
_ _ Obstruction of hepatic ducts (resulting in liver disease) __ ___ _ ________
6
CHAPTER ONE INTRODUCTION
Clinical features in neonatal CF predominantly affect the gastrointestinal tract, with
the most common complication being meconium ileus. This syndrome affects 10-
20% of newborn CF individuals and is almost diagnostic of the disease. The
pathological basis of this condition has been attributed to dehydration of intestinal
contents caused by epithelial transport dysfunction in utero. Complications include
abdominal distension, perforation and peritonitis.
Pancreatic enzyme insufficiency is also present at birth, and causes fat and protein
maldigestion, producing bulky, greasy and foul-smelling stools. Perhaps the most
serious consequence of this disorder is the failure ofneonates to thrive. This has
implications for respiratory fitness and general well-being of CF patients throughout
life. Maintaining nutritional status is also an important consideration for the
clinician. Diabetes mellitus may present in older CF patients, as well as pathological
changes in the liver. Liver transplantation is not uncommon in CF patients.
Infertility in CF males is approximately 95%, and is due primarily to the absence or
blockage of the Vas Deferens. In females, infertility can be as low as 10%.
Menstruation can be affected by chronic lung infection and poor nutritional status,
and dehydrated cervical mucus may complicate conception.
Despite the considerable number and complexity of clinical symptoms associated
with the pathophysiology ofCF, between 80 and 95% of the morbidity and mortality
in CF patients relates to progressive lung deterioration secondary to chronic
endobronchial sepsis and recurrent inflammatory exacerbations.
1.2.2. Lung Disease in CF: Infection vs. Inflammation- Chicken or the Egg?
The lungs ofCF patients are usually normal at birth; however, chronic bacterial
infections accompanied by recurrent exacerbations result in the extensive morbidity
and mortality. Debate continues as to whether inflammation is secondary to
microbial infection (Armstrong et al. 1995) or is the primary event in the CF lung
(Balough et al. 1995, Khan et al. 1995). An argument favouring the latter hypothesis
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was the observation of increased inflammation in the gastro-intestinal tract, an organ
not influenced by CF related bacterial infections (Smith et al. 2000).
CF lung infections tend to localize in the major and minor airways rather than the
alveoli, although the interstitium and alveolar spaces are affected at end-stage
disease. Chronic infection and acute, recurring and debilitating inflammatory
exacerbations continue throughout the life of the patient (Fig 1.3). Progressive
reduction in lung function results in respiratory failure and death. Further pulmonary
complications include bronchiolitis, atelectasis, haemoptysis, bronchiectasis,
pneumothorax and fibrosis.
The inflammatory process in the CF lung is dominated by a polymorphonuclear
leukocyte influx. The predominant immunological cell type is the neutrophil, which
accumulates in the airways along with high concentrations of neutrophil-derived
mediators, including proinflammatory cytokines such as interleukin-8 (IL-8) and
tumour necrosis factor-alpha (TNF-a) (Bonfield et al. 1995). A consequence of this
excessive neutrophil influx and ineffective phagocytic removal of the bacterial
pathogen is the release of toxic compounds, including proteases and reactive oxygen
species (Birrer et al. 1994, Richman-Eisenstat et al. 1993, Witko-Sarsat et al. 1999).
These toxic agents may cause damage to the lower airway and contribute







Fig 1.3 The Pathophysiology of Lung Disease in Cystic Fibrosis: The Vicious Cycle
1.2.3 Innate Defences and the Respiratory Tract
To understand the relationship between CF lung disease and bacterial colonisation
and infection of the respiratory tract, it is necessary to consider not only the
physiological defect that results in CF, but also the innate immune system that is
designed to ensure that lungs are protected from microbial pathogens.
Bacterial infections in CF are rarely associated with systemic spread and thus, CF
patients can be described as "immunocompetent". This is exemplified by the fact
that CF patients exhibit good immune responses to normal vaccination protocols.
For example, P. aeruginosa vaccines are able to generate an antibody response in
most CF patients (reviewed by Holder 2004). Thus, if there is an underlying
immunological defect in CF, it is likely to be within the respiratory tract and
associated with the innate immune system. Furthermore, there may be a predilection
for inflammation and/or infection, as a result of defective CFTR functions.
Innate defences of the respiratory tract are important throughout mammalian species.
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The first line of defence in the upper respiratory tract is the nose. This is particularly
important in the removal of particulate material (larger than 5 pm and less than 0.01
pm), infectious or otherwise, which is trapped in mucus, propelled to the pharynx
and swallowed. Nasal mucus may also contain non-specific antimicrobial substances
such as lysozyme, and specific secretory IgA.
The lower respiratory tract is protected by the mucociliary escalator that acts to trap
and remove particles which otherwise might cause irritation or infection. Each
respiratory epithelial cell has approximately two hundred cilia, which in a normal
person beat at approximately 1000 beats per min. Beating cilia provide the
propulsion to allow the overlying mucus layer to trap particles and act in mucociliary
clearance. The underlying defect in CF, namely the dehydrated and viscid bronchial
secretions, impairs this natural process, and leads to microbial infections.
In addition, it is now thought that the normal respiratory tract is protected by a
barrier of potent chemical mediators present in airway surface liquid (ASL) (Table
1.3).













Surfactant proteins SP-A, SP-D
Anionic peptides
Proline-rich proteins

















Each of these substances present in normal ASL may act individually or
synergistically to produce an antimicrobial effect. The significance of these
10
CHAPTER ONE INTRODUCTION
endogenous antimicrobial substances, in particular the antimicrobial peptides, will be
discussed later.
1.2.4 High Salt vs. Low Volume Hypotheses
Two opposing hypotheses have been proposed to explain how CFTR malfunction
and a defective chloride channel increase susceptibility to bacterial infections in the
CF lung.
The first model, the "high salt hypothesis", predicts that an elevated salt
concentration in CF-ASL inhibits naturally-occurring salt-sensitive defensins,
including human P-defensin 1 & 2 (HBD-1 & 2) (Bals et al. 1998, Goldman et al.
1997). The model proposes that in normal ASL, salt concentration is low and the
antimicrobial activity of defensins prevents potential pathogens from infecting the
lower respiratory tract. However, the defective CFTR function brings about reduced
CF ion flow into airway epithelial cells. This alteration in ionic potential causes the
disruption ofNa+ ion reabsorption, and accounts for the increase in salt content of
CF-ASL (Smith et al. 1996, Zabner et al. 1998) (Fig 1.4). Thus, the increase in salt














Fig 1.4 High salt hypothesis: In this model, non-CF airway surface liquid has a
hypotonic salt concentration. In contrast, CF airways, with defective CFTR,
have a hypertonic salt concentration since chloride ions cannot flow back into
the epithelial cell. Consequently, endogenous salt-sensitive antimicrobial
peptides are inhibited. The ENaC channel is shown in black and CFTR in red.
The second model, "the low volume hypothesis", predicts that fluid absorption is
enhanced in CF and conversely the production of fluid, controlled by CFTR, is
defective (Guggino 2001, Matsui et al. 1998) (Fig 1.5). CFTR is thought to have
additional functions, such as a regulator of other membrane proteins, including an
epithelial sodium channel (ENaC) (Stutts et al. 1997). CFTR appears to regulate the
kinetics ofENaC by ensuring that it is open for the minimal amount of time. Thus,
in the absence of functional CFTR, ENaC remains open allowing the influx ofNa+
across the airway epithelium. Consequently, CF ions follow, from ASL, into airway
epithelial cells via shunt pathways. Furthermore, as the osmotic potential is altered,
water follows leading to dehydrated mucus. The reduction in ASL gives rise to a
reduction in mucociliary clearance, and thus increased potential for bacterial
infection. Tarran and co-workers who examined the nasal epithelium in a CF mouse
model have supported this hypothesis (Tarran et al. 2001). They found a significant
increase in the number and size of goblet cells and a marked reduction in ASL
volume in CF mice compared to wild type mice. Furthermore, the authors did not
observe a reduction in salt concentration.
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Non CF epithelial cell
Na+ CI* H20 Or
CF epithelial cell





Fig 1.5 Low volume hypothesis: In this model, normal CFTR acts as a
regulator of ENaC, thus in its absence in CF, sodium absorption is
increased. Chloride ions follow via alternative shunt pathways, as does
water via osmosis. The result is a low volume of ASL, and defective
mucociliary clearance. ENaC channel is shown in black, CFTR in red.
and alternative chloride channels in green.
The technical difficulties ofmeasuring ionic composition ofASL hinder the
resolution of the debate surrounding both hypotheses. Recent work, however, has
suggested that the ionic composition ofASL in both CF and normal airways is
comparable (Caldwell et al. 2002, Knowles et al. 1997). Nevertheless, controversy
over this issue remains (Widdicombe 2001).
1.2.5 CFTR: More Than Just a Chloride Channel?
Adherence is an important aspect in the bacterial colonisation of the lower
respiratory tract in CF. Thus, the potential for specific bacterial receptors in the CF
host has also been investigated.
It has been suggested that in normal epithelia, CFTR acts as a receptor for P.
aeruginosa, resulting in the internalisation and removal of potential pathogens by
13
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natural cell desquamation. In CF patients, who lack CFTR on the surface of the
airway epithelia, this innate process would be impaired and consequently P.
aeruginosa remain to infect the respiratory tract (Goldberg and Pier 2000, Pier
2000).
1.2.6 Other Receptors: Asialo-gangliotetraosylceramide (Asialo-GMl)
It has also been suggested that Asialo-GMl is an apical bacterial receptor, which is
increased on the surface of CF epithelial cells, and that P. aeruginosa type IV pili
bind to this receptor (Imundo et al. 1995, Krivan et al. 1988, Saiman and Prince
1993). Type IV pili are responsible for twitching motility and are thought to have an
important role in establishing adhesion between the pathogen and the epithelial cell
in the early stages of infection prior to the formation ofbiofilms (Hahn 1997). A
further study suggests that Asialo-GMl is increased on the surface of regenerating
respiratory epithelial cells (De Bentzmann et al. 1996). This is an important
observation when one considers the epithelial damage caused by early viral
infections in CF, and the possibility of increased P. aeruginosa adhesion. Recently,
this theory has been disputed (Schroeder et al. 2001). These authors highlight
several weaknesses in the previous reports including the use of inappropriate
commercial antibodies and the failure to use clinical isolates ofP. aeruginosa.
Despite considerable interest and research, the role of "bacterial receptors" in the
pathogenesis ofCF lung disease remains unproven.
1.3 Microbiology and CF Lung Disease
The microbiology of CF has been described as "a sub-speciality unto itself' (Stutman
and Marks 1987). From birth, respiratory complications, due to non-specific viral
infections (respiratory syncytial virus, parainfluenza virus and influenza virus), play
an important role in the predisposition of the CF child to acute and recurrent
respiratory/inflammatory exacerbations and increased hospitalisation (Hiatt et al.
1999). It is the latter which may predispose the CF infant to colonisation by the
limited spectrum of bacterial pathogens, including P. aeruginosa (Armstrong et al.
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1998), which affect CF patients. The importance of viral infection in CF is unclear,
and may be understated (Wat 2003). Despite the influence of viral pathogens on the
neonatal CF lung, bacterial pathogens play the most important role in the pathology
of chronic CF lung disease.
The spectrum of bacteria capable of infecting the CF lung appears to be limited and
includes Staphylococcus aureus, non-typeable Haemophilus influenzae, P.
aeruginosa, Burkholderia cepacia complex, B. gladioli, Stenotrophomonas
maltophilia and Achromobacter xylosoxidans (Burns et al. 1998, Gilligan 1991,
Govan and Deretic 1996, Krzewinski et al. 2001, Mearns et al. 1972). Other, and
somewhat rarer, bacterial species cultured from CF sputum include, Ralstonia sp.
(Coenye et al. 2002), Pandoraea spp. (Jorgensen et al. 2003, Segonds et al. 2003),
atypical Mycobacteria (Boxerbaum 1980, Olivier et al. 2003), the fungus Aspergillus
fumigatus (Cimon et al. 2001) and the yeast Candida (FitzSimmons 1993). The
contribution of each individual species to the pathogenesis of lung disease is varied,
and dependent on the infecting strain and patient status (the same infecting strain
may give rise to different clinical symptoms in different patients). The significance
of each species in CF is discussed in two recent reviews (Gibson et al. 2003, Saiman
and Siegel 2004). Undoubtedly, P. aeruginosa is the most common and important
pathogen isolated from CF sputum, infecting up to 70% ofCF patients (FitzSimmons
1993). The general trend is that the burden of infection, leading to chronic infection,
increases with time, suggesting a "window of opportunity" to treat some infections
early. This is particularly the case with P. aeruginosa, which is intractable if allowed
to become chronic.
1.3.1 S. aureus and Non-typeable//. influenzae: A Role in CF?
S. aureus is a Gram-positive, facultatively anaerobic, catalase-positive bacterium and
is usually isolated from the nose in non-CF individuals. S. aureus is arguably the
only "classic bacterial pathogen" involved in CF, the rest being environmental or
commensal organisms. The isolation of S. aureus in the respiratory tract of CF
infants (Armstrong et al. 2002) clearly indicates an infection but the degree of
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pathology caused is debatable. Despite extensive debate on whether S. aureus is an
important CF pathogen (Lyczak et al. 2002), it has long been assumed that early
treatment with anti-staphylococcal antibiotics provides clinical benefit (Thomassen
et al. 1987). This dogma, however, has been disputed in a comprehensive review of
antistaphylococcal treatment (McCaffery et al. 1999). The authors report that
although eradication of S. aureus from sputum was achieved, there was little or no
improvement in lung function. Furthermore, the possibility remains that early and
aggressive antistaphylococcal therapy is counter productive and may encourage the
acquisition ofP. aeruginosa (Ratjen et al. 2001). Another consequence of
antistaphylococcal therapy is the emergence ofmethicillin resistant S. aureus
(MRSA). The risk ofMRSA in CF is considered a clinical problem for two main
reasons: First, unlike methicillin sensitive S. aureus (MSSA), MRSA is resistant to
many groups of antibiotics and thus is difficult to eradicate. Although vancomycin
and linezolid can be used to eradicate MRSA (Ferrin et al. 2002), sputum-positive
CF patients require significantly more courses of intravenous antibiotics (Miall et al.
2001). Second, MRSA is able to spread between patients, and such epidemic
transmission of a highly resistant organism, may prove to be an infection control risk
in both the hospital and the CF clinic (Jones and Webb 2003, Saiman and Siegel
2004).
H. influenzae is a Gram-negative bacterium that can be considered a commensal of
the upper respiratory tract. Its pathological role in CF is not well characterised and is
probably underestimated (Hutchison and Govan 1999, Saiman 2004). Historically,
H. influenzae was included as a "classic CF pathogen" because of its frequent
isolation from CF patients in early childhood (Mearns et al. 1972). The isolation of
non-typeable H. influenzae from CF sputum is problematic for the CF clinician for
two main reasons: first, the H. influenzae type B (HiB) vaccine, provided for all
infants, does not provide an effective immunological response against non-typeable
H. influenzae. Second, non-typeable H. influenzae is known to be pathogenic in non-
CF pneumonia, bronchitis and bronchiectasis (Jordans and Slack 1995).
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The role that S. aureus and II. influenzae play in the pathophysiology in CF remains
to be fully elucidated, but since eradication of both organisms is often attempted by
clinicians, antibiotic usage may increase the risk of acquisition ofP. aeruginosa and
members of the Burkholderia cepacia complex. Furthermore, early infection of the
lower respiratory tract by S. aureus and H. influenzae may initiate cell damage and
predispose to P. aeruginosa infection.
1.3.2 P. aeruginosa: The Major CF Pathogen
The genus Pseudomonas includes diverse species that exhibit striking nutritional and
metabolic diversity (Stanier et al. 1966). Pseudomonads are also found in a wide
variety of environmental niches, ranging from water and soil to plants and mammals.
Examples of species within this genus include P. aeruginosa, P. fluorescens, P.
putida, P stutzeri, P. solanacearum and P. tomato. P. aeruginosa is the most
important human pathogen amongst these highly adaptable bacteria.
P. aeruginosa, a Gram-negative bacillus is arguably the most important and
prevalent CF pathogen. This ubiquitous saprophyte is non-spore forming, non
capsulate and usually motile. It is a strict aerobe, but can grow anaerobically in the
presence of nitrate. P. aeruginosa is non-glucose fermenting and oxidase positive.
A distinguishing feature ofP. aeruginosa is that most isolates are pigmented. The
characteristic green pigment is caused by the combination of a soluble blue
phenazine pigment (pyocyanin) and a yellow-green fluorescent pigment (pyoverdin).
The latter is a major siderophore important in competitively binding iron (Fe3+) in the
human host. These features explain the original name 'Bacillus pyocyanea' as the
causative agent ofblue-green pus. Other pigments include pyorubin (red) and
melanin (brown). Infections caused by this opportunistic pathogen are varied. They
include ventilator-associated pneumonia, burn infections, catheter-associated urinary
tract infections, jacuzzi rash (an acute self-limiting folliculitis) and numerous
nosocomial infections of immunocompromised patients. It is important to note, that
P. aeruginosa infections in immunocompromised patients may spread systemically
and cause life-threatening septicaemia.
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P. aeruginosa infection in CF is thought to arise during infancy. Thus, it is
recommended that early and aggressive therapy regimes should be initiated on first
isolation, to attempt eradication of this organism from the lung and prevent the
emergence of the mucoid form (Rosenfeld et al. 2003). The prevalence ofP.
aeruginosa infection increases with age, with 20-30% of infants, 30-40% of young
children, up to 60% of adolescents and approximately 80% of CF adults infected
with this organism (Cystic 2002).
1.3.3 Virulence Determinants of P. aeruginosa
P. aeruginosa has a large genome (~6Mbp) that provides considerable
genotypic/phenotypic plasticity including the ability to adapt to multiple
environmental niches. A major example of in vivo adaptation to a specific human
niche, is the biosynthesis of pseudomonal alginate in CF lung disease. This striking
adaptation is rarely observed in other infections or indeed within the natural
environment. Transition from a non-mucoid to mucoid phenotype is also
undoubtedly the most important microbial virulence factor in CF lung infections.
The initiation of the mucoid phenotype is genetically complex, and highly regulated
(Govan and Deretic 1996). Culture ofmucoid P. aeruginosa from sputum is almost
diagnostic ofCF, and associated with chronic infection and increased respiratory
exacerbations. Mucoidy, together with other factors controlled by bacterial quorum
sensing, contributes to the development ofbiofilm growth in the CF lung.
Biofilms contribute significantly to the pathogenesis of CF lung disease, by
enhancing bacteria resistance to antibiotics and phagocytosis. Consequently,
infections are difficult to eradicate with antibiotics, and frustrated phagocytes release
potent toxic compounds that damage the host epithelium and cause increased
pathology.
Other P. aeruginosa virulence determinants, both cell surface associated and
secreted, contribute to pathogenicity in the CF lung (Table 1.4). Secreted factors
which increase potential to utilise nutrients for growth, become invasive and inflict
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damage on host tissue include proteases (Mclver et al. 1995, Rust et al. 1996),
phospholipases (Vasil et al. 1991), siderophores (Meyer et al. 1999, Vasil et al.
1998) and exotoxins. A particular exotoxin of interest is exotoxin A which acts in a
similarmanner to diphtheria toxin (Iglewski et al. 1977).
















Type III secreted cytotoxins (Exo U, Y, S & T)
Lipopolysaccharide (LPS)
* Quorum-sensing-regulated virulence factors (reviewed by Smith and Iglewski 2003)
1.3.4 Quorum Sensing & P. aeruginosa
Quorum sensing (QS) is the mechanism by which bacteria can "sense" population
density and coordinate gene expression accordingly (Winson et al. 1995). As
outlined (Table 1.4), the expression ofmany P. aeruginosa virulence determinants is
controlled by two independent but related quorum sensing systems, las and rhl
(Gambello and Iglewski 1991, Ochsner et al. 1994 respectively). The first system is
the lasR & lasl system, which was identified due to the high sequence homology to a
similar quorum sensing system from the bacterium Vibrio fischeri (Dunlap and
Greenberg 1988). The transcriptional activator LasR acts with its iV-acyl homoserine
lactone (AHL), A/-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL). 3-
oxo-C12-HSL is synthesized by the Lasl autoinducer synthase. LasR-3-oxo-C12-
HSL regulates many virulence factors, including elastase and exotoxin A (Pearson et
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al. 1997, Smith and Iglewski 2003). The second system, rhl, is composed ofRhlR
and the autoinducer Rhll that directs the synthesis of A-butyryl-L-HSL (C4-HSL).
This system controls the expression of rhamnolipids, and secondary metabolites such
as pyocyanin and hydrogen cyanide (Pearson et al. 1997, Smith and Iglewski 2003).
An important feature of quorum sensing in P. aeruginosa is that it appears to
contribute to the regulation of biofilm development (Parsek and Greenberg 1999).
The cross-talk between both QS-systems is limited within P. aeruginosa, and operate
almost autonomously. In contrast, A-acylhomoscrine-lactones expressed by P.
aeruginosa can exert a unidirectional effect on the B. cepacia complex (Lewenza et
al. 2002, Riedel et al. 2001).
1.3.5 Antibiotic Resistance & Hypermutability in P. aeruginosa
An important consideration in the pathogenesis of P. aeruginosa infection in CF is
that many isolates exhibit inherent resistance to antibiotics; this has been attributed to
low outer membrane permeability, efflux pumps and other resistance mechanisms
(Stover et al. 2000). A recent seminal study observed that CF-associated P.
aeruginosa exhibited a higher degree ofhypermutable isolates than expected in non-
CF infections (Oliver et al. 2000). The significance of such observations is that
within a CF lung there might exist a significant percentage of organisms with the
potential to evolve rapidly when selection pressure is applied. Such pressure
includes antibiotics, and thus their use may rapidly drive an increase in resistance
and a highly adaptable bacterial population.
1.3.6 Cross-Infection & P. aeruginosa
Despite the high prevalence ofP. aeruginosa in CF patients, it has long been
accepted that each patient acquires, and becomes chronically infected with, a unique
strain from the natural environment (Kelly et al. 1982). Until recently, cross-
infection had never appeared to be a problem, except amongst siblings or patients
with close epidemiological connections (Grothues et al. 1988). The potential for
cross-infection with P. aeruginosa infection was first highlighted in a study by
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Pedersen and colleagues, in which a multiresistant strain spread throughout a Danish
CF centre (Pedersen et al. 1986). The observation ofmultiresistance was significant,
and the overuse of antibiotics, in particular third generation cephalosporins, was
blamed for selecting resistance. A major caveat in the Danish study was the reliance
on epidemiological data based on serology and phage typing, which are important for
typing mucoid isolates but inappropriate for LPS-deficient CF isolates. However, in
a seminal study in a large CF clinic in Liverpool, Cheng and co-workers observed the
extensive spread of a [3-lactam resistant P. aeruginosa (Cheng et al. 1996). In
contrast to other studies, Cheng et al. based their findings on genomic fingerprinting
by pulse-field gel electrophoresis (PFGE) and flagellar polymorphisms, which
provided concordant evidence for spread of a single clone. Subsequent studies in the
UK, Australia and Brazil, have confirmed that P. aeruginosa is capable of epidemic
spread within and between CF centres (Anthony et al. 2002, Armstrong et al. 2003,
Armstrong et al. 2002, Denton et al. 2002, Jones et al. 2002, McCallum et al. 2001,
Pallegrino et al. 2002). It would appear that some P. aeruginosa strains are more
"transmissible" than others, are associated with increased morbidity and can
superinfect patients already colonised with P. aeruginosa (Al-Aloul et al. 2004,
McCallum et al. 2001).
In summary, the clinical implications of highly transmissible multiresistant P.
aeruginosa are four-fold: 1. Acquisition of a multiresistant P. aeruginosa as the
primary pathogen reduces or prevents the opportunity for early therapy to eradicate
P. aeruginosa. 2. The patient requires prolonged and more frequent periods of
hospitalisation. 3. There tends to be a significant decrease in lung function. 4.
Prompt and strict isolation of the patient is required to limit spread.
1.4 Emerging CF Pathogens
With aggressive antibiotic therapy increasing life expectancy and hence an
increasing population of CF adults, the microbiology of CF is evolving. One
development is the identification of novel bacterial species in CF sputum. Emerging
and potential CF pathogens include: S. maltophilia (Demko et al. 1998, Denton and
21
CHAPTER ONE INTRODUCTION
Kerr 2002, Denton et al. 1998), Pandoraea spp. (Coenye et al. 2001, Jones and
Webb 2003), Ralstonia spp. (Coenye et al. 2002), and A. xylosoxidans (Liu et al.
2002, Peltroche-Llacsahuanga et al. 1998). The pathogenic potential of these species
is unclear. However, common features are that they are usually soil organisms, have
the potential to infect immunocompromised patients and tend to be antibiotic
resistant. With reference to Pandoraea spp there may also be cross-infection issues
(Coenye et al. 2001, Jones and Webb 2003).
1.5. Burkholderia cepacia
Arguably the most feared CF pathogen to have emerged in recent decades is B.
cepacia. First isolated from a CF patient in the 1970s (Ederer and Matsen 1972), the
full impact of this organism on the CF community would not be recognised until the
1980s when potential virulence, inherent antimicrobial resistance and transmissibility
came to be realised.
1.5.1 Burkholderia - A Taxonomic History
Burkholderia cepacia (formerly Pseudomonas cepacia) was initially identified as the
causative agent of soft rot of onion bulbs (cepa = Latin onion) (Burkholder 1950).
Identification of other Pseudomonas species included isolation ofPseudomonas
multivorans from soil and water samples (Stainer et al. 1966), and Pseudomonas
kingii from clinical environments (Jonsson 1970, King 1964). However, it was soon
recognised that these novel species were in fact synonymous with P. cepacia
(Ballard et al. 1970, Sands et al. 1970, Snell et al. 1972).
At this time, taxonomic classification ofP. cepacia was based on rRNA-DNA
hybridisation, and P. cepacia was grouped in Pseudomonas RNA homology group II
(Palleroni et al. 1973). Subsequently, a new genus, Burkholderia, was proposed
(Yabuuchi et al. 1992) belonging to the P-subdivision of the phylum Proteohacteria
(Kersters et al. 1996). Consequently, the type species was joined by seven other
species from homology group II, including B. gladioli, B. pseudomallei, and B.
mallei. Of the seven, two were later reclassified into a new genus Ralstonia
22
CHAPTER ONE INTRODUCTION
(Yabuuchi et al. 1995). The complex identification and taxonomic classification of
these closely-related species continued with the addition ofB. cocovenenans (Zhao et
al. 1995), B. vandii, B. glumae and B. plantarii (Urakami et al. 1995). A subsequent
study has shown that B. cocovenenans and B. vandii are junior synonyms ofB.
gladioli and B. plantarii respectively (Coenye et al. 1999). An outline of the
phylogenetic relationship between the present 31 species in this genus and closely
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Fig 1.6 16S DNA based phylogenetic tree showing the positions of Burkholderia species and
representatives of related genera. Scale bar indicates 5% sequence dissimilarity
(Reproduced by kind permission: Coenye and Vandamme 2003).
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Historically, Burkholderia species were recognized as phytopathogens and soil
bacteria, with two important exceptions; these are the highly virulent human
pathogens B. mallei and B. pseudomallei. Thus, a simplistic approach to
Burkholderia species is no longer of relevance. Present studies of these highly
adaptable microbes must take account of their complex taxonomy and emerging role
as human and animal pathogens.
1.5.2 The Burkholderia cepacia complex (Bee): A Complex Complex
In a seminal study published in 1997 isolates previously identified as "B. cepacia"
were reclassified into five genomovars, termed the Burkholderia cepacia complex
(Bcc) (Vandamme et al. 1997). A genomovar is a group of genomically distinct
bacteria, which cannot be separated on phenotypic characteristics (Ursing et al.
1995). The Bcc has now been extended to at least nine genomovars (Coenye et al.
2001, Coenye et al. 2001, Vandamme et al. 2002, Vandamme etal. 2000). A tenth
genomovar, B. uhonensis, has been proposed but has yet to be confirmed within the
Bcc (Yabuuchi et al. 2000). Genomovar status is based on polyphasic taxonomic
studies, including: DNA-DNA, DNA-rRNA hybridisations, whole cell protein and
fatty acid analysis (Vandamme et al. 1997). At this time, all of the original
genomovar designations have been superseded by species names (Table 1.5).
Table 1.5 The B. cepacia complex
Genomovar Species Reference
1+ B. cepacia (Vandamme etal. 1997)).
II B. multivorans (Vandamme et al. 1997)).
III B. cenocepacia (Vandamme et al. 2003)).
IV B. stabilis (Vandamme et al. 2000)).
V B. vietnamiensis (Gillis etal. 1995)).
VI B. dolosa (Coenye et al. 2001, Vermis et al. 2003)).
VII B. ambifaria (Coenye et al. 2001)).
VIII B. anthina (Vandamme et al. 2002)).
IX B. pyrrocinia (Imanaka et a!. 1965, Vandamme etal. 2002))
X* B. ubonensis (Yabuuchi etal. 2000)).




By taxonomic convention, genomovar I contains the type species, and thus retains
the formal binomial name, B. cepacia (Vandamme et al. 1997). Genomovar II was
named B. multivorans on the basis of its unique biochemical characteristics
(Vandamme et al. 1997). Genomovar IV was named B. stabilis due to its low level
of genomic variability in comparison to other Bcc genomovars. Further distinctions
can be made by the lack of (3-galactosidase activity and an inability to utilise sucrose
(Vandamme et al. 2000). Genomovar V was recognised as a previously-identified
species B. vietnamiensis (Gillis et al. 1995). Genomovar VII was named as the novel
species B. ambifaria (Coenye et al. 2001). The differentiation of B. ambifaria from
other Bcc members is based on growth at 42°C, (3-galactosidase activity, lysine
decarboxylase and ornithine decarboxylase activity, acidification of sucrose and P-
haemolysis (Coenye et al. 2001). Genomovar VIII was identified as a novel species,
and termed B. anthina (Vandamme et al. 2002). Distinction of genomovar VIII from
I and III proved difficult, but was unequivocally achieved by rec/f-based restriction
fragment length polymorphisms (RFLP) analysis based on rRNA-PCR assays
(LiPuma et al. 1999). Genomovar IX was recognised as the previously described
species B. pyrrocinia (Imanaka et al. 1965, Vandamme et al. 2002). At present, B.
ubonesis (genomovar X) is included as a member of the Bcc due its taxonomic
similarity (Yabuuchi et al. 2000).
The differentiation of genomovars III and VI from B. cepacia (genomovar I) and B.
multivorans, respectively, proved to be problematic. However, genomovar III has
recently been named as the novel species B. cenocepacia ("new-cepacia")
(Vandamme et al. 2003). Within B. cenocepacia, four recA lineages have been
identified (IIIA-D). Genomovars I and III can also be distinguished using AFLP
analysis (Coenye et al. 1999) and recA -based restriction RFLP (Mahenthiralingam et
al. 2000). Most recently, genomovar VI has been classified as the novel species B.
dolosa on the basis of its inability to assimilate tryptamine, azelaic acid and salicin
(Vermis et al. 2004). Amongst present members of the Bcc, only B. dolosa fails to
grow on Bcc selective (PCAT) media.
25
CHAPTER ONE INTRODUCTION
Currently, the most accurate means to identify Bcc species in general, and B.
cenocepacia and B. multivorans specifically, is by species-specific rec/1-based PCR
assays (Vermis et al. 2002).
For the purpose of this thesis, the taxonomic nomenclature will be as follows: pre-
1996: "B. cepaciapost-1996: Bcc and individual species names.
Members of the Bcc are Gram-negative, non-sporing aerobic bacilli. Typically, they
are motile and both catalase and oxidase positive. Pigmentation is not uncommon,
but may require specific growth media, for example tyrosine agar, to enhance
melanin production (Ogunnariwo and Hamilton-Miller 1975). This dark brown
pigment is associated with some Bcc species, primarily, although not exclusively B.
cenocepacia. The nutritional and metabolic diversity of the Bcc is impressive, with
some strains able to utilise penicillin G as a sole carbon source (Beckman and Lessie
1979, Vermis et al. 2003). This high metabolic activity of the Bcc makes some
strains attractive candidates for biological control of plant fungal disease (Homma et
al. 1989) and bioremediation of contaminated soils (reviewed by Gerhardson 2002,
Parke and Gurian-Sherman 2001). The demand for such agents has led to a fierce
debate to determine if the use of Bcc species as biopesticides (King and Parke 1993)
poses a risk to human health (Govan et al. 2000, Holmes et al. 1998, Jones et al.
2001). Although the jury is still out, there is unequivocal evidence that clinical and
environmental Bcc species are indistinguishable and share common habitats
(Balandreau et al. 2001, LiPuma et al. 2002, Vandamme et al. 1997). The present
regulatory position is that all potential candidates for use as biopesticides must be
notified to the United States Environmental Protection Agency (USEPA) for
assessment under "New Use Rule" legislation. This system of regulation would




It is not the strongest ofthe species that survives nor the most intelligent, but the one
that is the most responsive to change.
- Darwin
All Bcc species have large genomes (mean size approximately 8 Mbp) and multiple
replicons that may contribute to genomic plasticity (Mahenthiralingam el al. 2002,
Parke and Gurian-Sherman 2001, Wigley and Burton 2000).
The genome of the B. cenocepacia isolate J2315 (electrophoresis type (ET)-12
lineage) (Govan et al. 1996, Mahenthiralingam et al. 2000b); has recently been fully
sequenced (www.sanger.ac.uk/proiects/B-cepaciaT The choice of J2315 as the
candidate strain was based on five key factors: 1. It is the dominant CF pathogen in
the Bcc, 2. It is transmissible, 3. It is associated with poor clinical outcome, 4. The
original isolate from the index patient was stored in two separate and established
collections (Govan et al. 1993), and 5. It is amenable to genetic manipulation. The
multireplicon genome of J2315 comprises three "chromosomes" (3.870, 3.212 &
0.876 Mbp respectively) and one large plasmid (92.7 Kbs). Thus, the total genome
size is 8.056 Mbp. This compares with a genome size of 6.8 Mbp for B. multivorans
(ATCC 17616) and 8.0 Mbp fori?, cepacia (ATCC 25416). With an estimated 7,300
genes and the genomic mass of some protozoa, Darwin himselfmay have been
surprised to note both the size and the potential genomic plasticity of this bacterial
genome.
1.5.4 Bcc: The Pathogen
"B. cepacia''' infections in humans tend to be severe, yet thankfully rare.
Historically, "5. cepacia''' was first associated with endocarditis in the 1950s (Schiff
et al. 1961, Sorrel and White 1953, Speller 1972). Most infections at this time were
nosocomial and/or associated with immunocompromised patients (Jarvis et al. 1987,
Martone et al. 1987). Patients who require intensive care are now known to be
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particularly at risk of Bcc infection (Holmes et al. 1999, Phillips et al. 1971). Other
Bcc nosocomial infections include: renal transplant-associated urinary tract
infections (Li et al.2003), iatrogenic-urinary tract infections (Keizur et al. 1993),
haemodialysis-associated bacteraemia (Kaitwatcharachai et al.2000, Magalhaes et
al.2003), bacteraemia (Huang et al.2001), lung abscesses (Poe et al.\911), ventilator-
associated respiratory infections (Loukil et al. 2003) and respiratory infections
(Bureau-Chalot et al. 2003). "B. cepacia" has also been implicated as the causative
organism in infections (wound, endocarditis and septicaemia) thought to have arisen
from contaminated medicines such as antibiotic/disinfectant solutions (Bassett et
al. 1970, Speller et al. 1971), distilled water (Rapkin.1976) and liquid/aerosol
preparations (Noriega et al. 1975, Ramsey et al.2001, Steere et al. 1911, Van Laer et
al. 1998).
"B. cepacia " infections in immunocompetent individuals are rare, but significant. It
has been identified as the causative agent of "foot rot" in soldiers serving in swamp
environments (Taplin et al. 1971) and to be the cause of community acquired
pneumonia in an immunocompetent host (Pujol et al. 1992). Contamination of an ear
drop preparation, by "B. cepacia", was responsible for multiple brain abscesses
secondary to otitis media, in an otherwise healthy individual (Hobson et a 1.1995).
One group of individuals who are particularly susceptible to life-threatening
respiratory infections with "B. cepacia" are patients with the inherited condition
known as chronic granulomatous disease (CGD) (Clegg et al. 1986, Govan et
al. 1996, Lacy et al. 1993, LiPuma.1998, O'Neil et al. 1986). The susceptibility of
CGD patients to "B. cepacia" infection is thought to arise due to the underlying
genetic defect in neutrophil-associated oxidative killing in conjunction with the
inherent resistance of "B. cepacia'''' to neutrophil-derived non-oxidative killing
mechanisms: antimicrobial peptides (Speert et al. 1994).
A recent study indicating the potential of the Bcc to cause animal infections was an
outbreak of sub-clinical mastitis in sheep (Berriatua et al.2001). This is the first
report of a natural Bcc infection in animals. Although Bcc species are not thought to
pose the same risk to animals as other zoonotic agents, difficulties in identification
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may lead to underreporting. Undoubtedly, the most important group of mammalian
hosts affected by Bee infections are CF patients.
1.5.5. The Bcc and CF
"B. cepacia" was initially identified in a CF patient in the early 1970s (Ederer and
Matsen 1972). Subsequently, the role of "5. cepacia'''' in the pathogenesis of CF lung
disease was recognised with the onset of pneumonia and septicaemia in an
adolescent CF patient (Rosenstein and Hall 1980). However, it was not until a
seminal retrospective study highlighted the increased prevalence of "B. cepacia"
colonisation in CF patients in Western Canada, that the variable clinical outcomes
were documented (Isles et al. 1984). "5. cepacia" infection in CF has three main
clinical outcomes: 1. The patient may be an asymptomatic chronic carrier, 2. There
may be a gradual deterioration in lung function resulting in increased morbidity,
similar to P. aeruginosa infection, and 3. The most severe outcome is a rapid and
fatal necrotising pneumonia accompanied by septicaemia (this is rarely observed in
other CF infections). This unexpected and life-threatening outcome, termed
"cepacia-syndrome", occurs in 20-30% of "5. cepacia" positive patients (Isles et al.
1984, LiPuma 1998). Importantly, clinical outcome cannot be predicted even when
patients within a single CF centre are infected by the same strain (Govan et al. 1993).
Host factors, including disease (CF) severity and immunological status, as well as
bacterial factors, including Bcc individual species and strains, appear to play
important roles in the end result of Bcc infection. Despite the variable outcomes,
significant clinical decline is expected in all "B. cepacia'" positive patients, with an
approximate 50% reduction in life expectancy.
The distribution ofBcc species in CF is disproportionate. In general, B.
cenocepacia, B. multivorans and B. vietnamiensis account for 95% of isolates
(LiPuma et al. 2001, Mahenthiralingam et al. 2002). Moreover, patient to patient
spread and acute pulmonary deterioration are primarily associated with B.
multivorans and B. cenocepacia (Govan et al. 1996, LiPuma 1998,
Mahenthiralingam et al. 2002).
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1.5.6 Bcc: Epidemiology, Transmission and Segregation Issues
In addition to the potential virulence and detrimental pulmonary effect ofBcc
infection, transmission of this organism between CF patients is a major issue in
patient management, in particular cross-infection control. Historically, transmission
of "5. cepacia" was thought to be restricted to spread amongst siblings or
hospitalised patients (Tablan et al. 1985, Tablan et al. 1987). Clustering of "5.
cepacia''' infections in some CF centres highlighted a possible risk ofpatient to
patient transmission (Goldman and Klinger 1986). In one study, Thomassen and
colleagues noted that the increasing prevalence of "B. cepacia" could be reduced if
stringent infection control and segregation procedures were introduced (Thomassen
et al. 1986). The risk of direct person to person spread within the clinic (Fisher et al.
1993, LiPuma et al. 1990, LiPuma et al. 1988) or indirect nosocomial transmission
from contact with contaminated equipment (Nelson et al. 1991) was only fully
elucidated with the development of genomic fingerprinting. The use of ribotyping,
PFGE and other techniques provided compelling evidence that "B. cepacia'''' was
transmissible both within the CF clinic (Doring et al. 1996, Smith et al. 1993, Taylor
et al. 1992) and via social contact (Govan et al. 1993, Pegues et al. 1994).
Despite initial evidence that epidemic strains of "B. cepacia" were unique to
individual clinics (LiPuma et al. 1988), it soon became apparent that within the "5.
cepacia" population, unique strains and lineages existed which were more capable of
inter-regional and inter-continental spread (Govan et al. 1996).
A seminal paper by Govan and co-workers identified a highly transmissible strain
that was present in both Edinburgh and Manchester CF clinics from 1989 (Govan et
al. 1993). Genotypic and phenotypic data was used in conjunction with
epidemiological evidence examining social contact between patients. Transmission
was linked to attendance at weekend CF camps and a weekly fitness class. Although
the authors found that 50% of patients that had died during the study were infected
with this epidemic strain, clinical outcome was unpredictable and not linked to initial




The importance of surveillance, with respect to the epidemiology of CF infections,
was fully recognised by the finding that the "Edinburgh epidemic strain" had spread
across continents. Later termed the Edinburgh/Toronto ET-12 lineage (Govan et al.
1996), it had been isolated in an ongoing epidemic in Toronto, Canada with
transmission linked to attendance at summer camps (Johnson et al. 1994).
Increased knowledge ofBcc epidemiology and taxonomy indicated that most
transmissible strains belong to B. cenocepacia (originally genomovar HI), including
the notorious ET-12 lineage. However, other Bcc species have been responsible for
outbreaks including B. multivorans (Mahenthiralingam et al. 2001, Segonds et al.
1999) and others (Agodi et al. 2001, Biddick et al. 2003, Petrucca et al. 2003).
Several studies have shown the ET-12 lineage possesses both the so-called B.
cepacia epidemic strain marker (BCESM) (Mahenthiralingam et al. 1997), and a
novel cable pilus gene (Sajjan et al. 1995, Sun et al. 1995). BCESM has recently
been shown to be part of a novel genomic island encoding genes associated with
virulence and metabolism (Baldwin et al. 2004). Important genes identified encode
and AHL synthase, a porin (Opel), and an amidase (Amil). Mutagenesis studies in a
chronic rat lung model demonstrated that Amil is important in persistence and the
AHL synthase and Opel are important in virulence. The authors conclude that the
correlation between BCESM and virulent CF strains is validated by their study,
although others argue that neither BCESM or the cable pilus are considered to be
frequent enough within the Bcc to be sufficient indicators of virulence or
transmissibility (LiPuma et al. 2001).
The impact of epidemiological studies on the Bcc have resulted in the publication of
national and frequently updated guidelines that focus on Bcc cross infection issues
(www.cftrust.org.uk & Saiman and Siegel 2004). As well as describing many high
risk factors associated with transmission, the document outlines current cross-
infection procedures and states that "B. cepacia" positive CF patients should be
segregated at both inpatient and outpatient clinics, and encouraged not to mix
socially. Not surprisingly, such Draconian measures have had a significant social
impact on the CF community (Duff 2002). The implications of such measures were
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also highlighted in an emotive article describing how two brothers with CF decided
to live apart when one became "B. cepacia" positive (Webb 2000). Although cross-
infection control measures have reduced the incidence of transmission significantly,
outstanding issues remain. The potential for transmission to non-CF individuals
(parents, non-CF siblings and partners) is slight, but has been highlighted as a risk
(Ledson et al. 1998). Environmental acquisition of "epidemic strains" is also
considered to be a risk factor (LiPuma et al. 2002). Furthermore, cohorting of Bcc
positive individuals may encourage "superinfection". Acquisition of a second, more
virulent, Bcc (ET-12) strain resulted in increased morbidity and mortality (Ledson et
al. 1998, Mahenthiralingam et al. 2001). At present, all Bcc species are considered
equal for the purpose of cross-infection control. Segregation based on species
identification within the Bcc has not been recommended. However, species
identification is important in patients being considered for lung transplantation (De
Soyza and Corris 2003). In these patients, infections with B. cenocepacia has been
found to carry a high risk and benefit from alternatives to peri-transplant procedures
(Aris et al. 2001, De Soyza and Corris 2003, De Soyza et al. 2001).
1.5.7 Bcc and Virulence
The fact that clinical outcome cannot be predicted in patients infected with the same
strain suggests that both bacterial and host factors are important. In contrast to P.
aeruginosa where alginate biosynthesis and biofilm production are key virulence
determinants, no such factors have been demonstrated within the Bcc, including B.
cenocepacia. The specific virulence determinants required for Bcc infection in CF
individuals remain largely unknown. Bacterial factors probably work in combination
and include adherence, siderophores, invasion, intracellular survival,
exopolysaccharide, type III (Tomich et al. 2003) & type IV secretion systems,
quorum sensing (and QS regulated genes (Aguilar et al. 2003)) and LPS (Hutchison
and Govan 1999), as well as several extracellular virulence factors (Table 1.6). The
importance of each factor in the ability to colonise and cause tissue damage is
unknown, and is probably dependent on the Bcc species, and indeed the strain
investigated. Furthermore, the inherent multiple resistance of the Bcc to
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antimicrobial agents, including natural defensins, provides another potential factor in
the pathogenicity ofBcc lung infections in CF.
Table 1.6 Bcc Virulence Factors (Reviewed by Gessner and Mortensen.1990, Hutchison and
Govan.1999, Mohr et al.2001, unless otherwise stated, Nelson eta/,1994)
Extracellular Virulence Factors
Haemolysin (both Phospholipase C and sphingomyelinase activities)
Catalase
Ornithine Decarboxylase






36 kDa proteinase (zinc metalloprotease)(Corbett et al.2003)




Adherence is considered to be the first stage ofbacterial colonisation and infection.
Pili or fimbriae are surface appendages that allow bacteria to interact with both each
other and the host. Type III cable pili and an associated adhesin have been described
in the ET-12 lineage and provide convincing candidates for adhesion to epithelial
cells and respiratorymucin (Sajjan et al. 1992, Sajjan and Forstner. 1992, Sajjan and
Forstner.1993, Sajjan et al. 1995). Possession of the cable pilus gene, cblA, has been
suggested as an epidemiological marker for transmissibility in Bcc isolates (Sun et
al. 1995). However, the cable pilus has not been observed in other epidemic strains
(Mahenthiralingam et al. 1997). Furthermore, the cblA gene has been identified in a
non-CF isolate and a phytopathogenic strain, indicating that the potential expression
of the cable pilus is not restricted to CF epidemic strains (Richardson et al.2001). As
a caveat, however, presence of the cblA in a "B. cepacia" isolate does not always
correlate with the expression of the cable pili (Sajjan et al. 2002).
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1.5.9 Quorum Sensing
A quorum-sensing system in the ET-12 B. cenocepacia isolate K56-2, has been
identified and consists of cepl and cepR genes. The expression ofA-acyl-HSL
appears to be conserved throughout the Bcc (Gotschlich et al. 2001). K56-2
synthesizes an TV-octanoyl HSL (Cr-HSL) and an A-hexanoyl-HSL (Lewenza et al.
1999, Lutter et al. 2001). The Cepl/R system has been implicated in the negative
regulation of siderophores and in the positive regulation of a secreted protease.
Likewise, the Cepl/R QS-system ofB. cenocepaciaHill has been shown to be
involved in swarming motility and biofilm formation (Huber et al. 2001). Similarly,
the QS-system in B. cepacia ATCC 25416 utilises C6- and C8-HSL molecules.
Mutant studies indicated that protease activity was significantly lower in the QS-
deficient mutants, and attenuated virulence was observed in an onion maceration
model (Aguilar et al. 2003).
As with P. aeruginosa, the regulation of virulence by QS-systems in the Bcc is
unlikely to provide a complete picture. Furthermore, the likelihood of a homologous
QS-system within the Bcc is low (Aguilar et al. 2003).
1.5.10 Siderophores
The ability to sequester iron from the mammalian host is fundamental to the success
ofbacteria as pathogens. Microbes acquire iron by the secreting ferric iron chelators,
known as siderophores. "B. cepacia" is known to produce at least four different
siderophores: ornibactins (Meyer et al. 1995), pyochelin (Sokol 1986), salicyclic acid
(SA) (Visca et al. 1993) and cepabactin (Meyer et al. 1989). The pathogenic
implications of each are unclear, although ornibactins and SA are the predominant




LPS (endotoxin), a membrane glycolipid ofGram-negative bacteria, is an important
bacterial virulence factor that has potent immuno-stimulatory activity on
mononuclear cells, granulocytes and B-lymphocytes with the induction of pro¬
inflammatory cytokines (Reitschel et al. 1993). The induction of pro-inflammatory
cytokines and LPS-mediated macrophage stimulation is thought to play an important
role in bacterial pathogenesis in CF (Greally et al. 1993). Prior to the current
taxonomic revision, in vitro studies showed that "2?. cepacia" LPS exhibited a higher
endotoxic activity and induced a greater cytokine response than P. aeruginosa and S.
maltophilia LPS (Shaw et al. 1995, Zughaier et al. 1999). In a subsequent study by
Hughes and co-workers, it was suggested that the inflammatory activity of "B.
cepacia" LPS may contribute to lung disease in CF by promoting increased
neutrophil recruitment and by priming neutrophil respiratory burst responses to
microbes and other stimuli (Hughes et al. 1997). Although LPS was not found to
trigger the respiratory burst directly, it was suggested that the increased potential for
release of tissue-damaging proteolytic enzymes and reactive oxygen species might
contribute to pathogenic sequelae seen in "B. cepacia" lung infections. Differences
in stimulatory activities of LPS, together with host factors, could also explain the
variable pathogenic sequelae seen in CF lung infections.
It has been suggested that differences in host inflammatory response to Bcc LPS may
be related to genomovar/species status of the patient (De Soyza et al. 2000).
However, a study by Kenna and colleagues investigating the relationship between O-
serotype and genomovar status, suggested the biological activity of LPS is likely to
be strain- rather than genomovar-specific (Kenna et al. 2003). Variation in the CD-
antigen, the immunodominant component of LPS, involves modification of sugar
moieties or changes in the length of the O-antigen sidechain, and is known to be a
significant virulence mechanism (Lerouge and Vanderleyden 2001). Individual
strain populations within the Bcc can exist as a mixture of smooth and rough LPS
chemotypes (Evans et al. 1999) and both can be highly endotoxic (Govan 2003,
Shaw et al. 1995, Zughaier et al. 1999). In contrast to environmental strains, clinical
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isolates tend to exhibit a rough chemotype (Evans et al. 1999). However, both rough
and smooth variants are capable of inducing the production of tumour necrosis
factor-alpha (TNF-a) to the same extent (Gronow et al. 2003). A recent report
examined LPS structures ofB. multivorans (LMG 14273) and B. cenocepacia (LMG
12614) (De Soyza et al. 2004). Interestingly, the authors suggest that effective
induction ofpro-inflammatory cytokines by B. cenocepacia LPS was due to the
presence of a P-hydroxymyristate (3-OH CI4:0), which was absent from the less
effective B. multivorans LPS.
1.5.12 Intracellular Survival and Growth
Several studies have suggested the potential intracellular survival of "5. cepacia".
Butler et al. demonstrated that epidemic CF strains exhibit a rough colonial
morphotype and are serum sensitive (Butler et al. 1994). In general bacterial strains
with rough LPS are more sensitive to serum, less virulent and rarely cause
bacteraemia (Crokaert et al. 1992). This is not the case with CF isolates of "B.
cepacia''' which frequently produce chronic lung infections and bacteraemia. This
apparent contradiction poses an interesting question regarding the mechanism ofBcc
survival in vivo. In 1996, a seminal study by Burns and co-workers described the
invasion of respiratory epithelial (A549) cells by "B. cepacia" (Burns et al. 1996).
Of particular importance, was the observation of intra-epithelial cell replication.
Further studies indicated that Bcc isolates were capable of: 1. Surviving in free living
amoebae (Landers et al. 2000, Marolda et al. 1999); 2. Resisting intracellular killing
by phagocytic cells and epithelial cells (Saini et al. 1999, Tipper et al. 1998), and 3.
Strain specific intracellular survival (Martin and Mohr 2000). The latter study
confirmed that the B. cenocepacia ET-12 strain J2315 was able to enter, survive and
replicate intracellularly in U937-derived macrophages and A549 pulmonary
epithelial cells. Moreover, other epidemic strains, irrespective of cable piliation,
were shown to be capable of attaching to and invading murine respiratory tract cells
(Chiu et al. 2001).
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Attachment is an important step in both the colonisation and the invasion of host
tissues. Recent work has focused on the role ofBcc flagella in host cell invasion
(Tomich et al. 2002). The authors noted that flagellar defective mutants exhibited
reduced invasion ofA549 cells and attributed this to impaired flagellum-mediated
motility rather than defective adherence.
Additional virulence determinants that may aid intracellular survival of Bcc include
the production of catalases which are found in 100% of "B. cepacia" isolates
(Gessner and Mortensen. 1990) and production ofmelanin-like pigments by some
epidemic strains (Zughaier et al. 1999). Catalase, and superoxide dismutase, are
important enzymes which neutralise the potential bactericidal effects of the host
defence molecules hydrogen peroxide and reactive oxygen species (Lefebre and
Valvano.2001). The melanin-like pigment, produced by ET-12 isolates, has been
shown to attenuate the respiratory burst activity by scavenging superoxide anions
(Zughaier et al. 1999).
Another potential argument in favour of the intracellularity of the Bcc relates to
antibiotic therapy. Even when in vitro antibiotic susceptibility can be demonstrated
(Nzula et al. 2002), this rarely translates into eradication or even reduction of bacteria
within sputum during antibiotic therapy (Gold et al. 1983).
1.5.13 Antibiotic Resistance and The Bcc
The term "multiresistant" is open to interpretation but usually describes organisms
that are resistant to at least three major classes of antibiotics; for example the P-
lactams, aminoglycosides, quinolones and tetracyclines. Most "B. cepacia" isolates
exhibit intrinsic resistance to many antimicrobial agents (Lewin et al. 1993, Nzula et
al. 2002, Pitt et al. 1996). In addition, resistance can develop during therapy. Not
unexpectedly, multiple resistance mechanisms have been observed in the Bcc. These
include: 1. Reduced outer membrane permeability; 2. Alteration of intracellular drug
targets or variation in extracellular drug binding sites; 3. Enzymatic degradation of
antimicrobials and, 4. Active removal of antibiotics by bacterial efflux pumps.
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Resistance can also result through several mechanisms acting simultaneously,
exemplified by the resistance to P-lactam based antibiotics.
1.5.14 P-Lactam Resistance
Bacterial resistance to the p-lactams can be due to the combination of inducible
chromosomal P-lactamases and low outer membrane permeability. The observation
that some "5. cepacia''' isolates can utilise penicillin G as a carbon source
exemplifies both resistance and a striking metabolic potential to both degrade and
utilise an antibiotic (Beckman and Lessie 1979). Isolates capable ofpenicillin
utilisation were found to possess a highly-inducible chromosomal penicillinase/p-
lactamase. One such strain, "B. cepacia" 249, has two separate P-lactamases that
vary in their activity (Beckman and Lessie 1979, Harai et al. 1980, Prince et al.
1988). The original penicillinase exhibits around 80% of the activity, and was later
found to be a chromosomally-encoded class A p-lactamase (Trepanier et al. 1997).
The second, is a cephalosporinase, and accounts for the remaining P-lactamase
activity found in "B. cepacia" 249 (Harai et al. 1980, Prince et al. 1988).
The P-lactamases of "B. cepacia" are also thought to exhibit carbapenemase activity
(Iaconis et al. 1994, Simpson et al. 1993). Interestingly, although the P-lactamase
activity extends to imipenem (Trepanier et al. 1997) it does not include meropenem
(Baxter and Lambert 1994, Iaconis et al. 1994). This observation could be clinically
important, as Bcc isolates tend to demonstrate in vitro susceptibility to meropenem,
and this agent is often the drug of choice in the treatment ofBcc infections (Lewin et
al. 1993, Nzula et al. 2002, Pitt et al. 1996).
Reduced outer membrane permeability is also a factor in resistance to P-lactam
antibiotics. The outer membrane of "B. cepacia" is characterised by unusually small
porins with low single channel conductance. Permeability studies with the P-lactam
nitrocefin, showed that the outer membrane permeability of "B. cepacia''' was
comparable to P. aeruginosa, but ten times lower than Escherichia coli (Parr et al.
1987). Further reductions in permeability, and thus increased resistance to P-
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lactams, are achieved by decreased expression of outer membrane proteins or
alterations in LPS. Aronoff (1988) described the reduced expression of two outer
membrane proteins, 36 kDa and 27 kDa respectively, which resulted in increased
resistance to p-lactams. The latter protein may be a major porin or an important
component of a major porin complex (Aronoff 1988, Gotoh et al. 1994).
1.5.15 Aminoglycoside & Polypeptide Antibiotic Resistance
Binding of aminoglycosides and cationic polypeptide antibiotics, such as polymyxin
B and colistin (polymyxin E), to LPS is considered to be the first stage in
antimicrobial action of these agents. Both compounds displace divalent cations that
stabilise and cross-link LPS in many Gram-negative bacteria. The effect of
destabilising the bacterial outer membrane is loss of integrity and stability. Once the
outer membrane is disrupted, positively charged polypeptide antibiotics can destroy
the cell by acting on the negatively-charged cytoplasmic membrane (Moore and
Hancock 1986). Aminoglycosides, on the other hand, act through an intracellular
target and inhibit protein synthesis. Most Bcc isolates are inherently resistant to both
aminoglycosides and the polymyxins (Nzula et al. 2002) and alteration in the initial
antibiotic binding site or cross-linking may account for such resistance.
LPS structure in "B cepacia" differs from many other Gram-negative bacteria.
Essentially, outer membrane stability is achieved by attaching 4-amino-4-
deoxyarabinose (Ara4N) to phosphate residues. Further substitution ofAra4N has
been observed on mainly the outer sugar (l->S)-D-glycero-D-talo-oct-2-u\sonic acid
(KO), and to a lesser extent, 3-deoxy-Z)-wa««o-oct-2-ulsonic acid (KDO) (Gronow
et al. 2003). Attachment ofAra4N residues to the phosphate groups of lipid A is
known to lead to polymyxin resistance (Helander et al. 1994). Ara4N contains a
positively-charged ammonium group, and thus reduces the negative charge of the
lipid A backbone induced by the phosphate groups (Vinion-Dubiel and Goldberg
2003). LPS stability is attained by the interaction ofpositively-charged arabinose
molecules with negatively-charged phosphate residues present in LPS (Cox and
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(Cox and Wilkinson. 1994, Vaara.1992), therefore, polymyxin resistance is achieved,
as divalent cross-linking is no longer required. The ability of "5. cepacia" LPS to
bind cationic molecules is low, due to low levels ofphosphate and KDO (Cox and
Wilkinson. 1994). Interestingly, "B. cepacia''' LPS has been shown to bind, with high
affinity, to polymyxin B, despite the presence ofAra4N (Shimomura et al.2003).
Despite the fact that polymyxin B is a potent antagonist of LPS-induced cytokine
release (Coyne and Fenwick.1993, Stokes et al. 1989), it was found to have an
unusual interaction with "B. cepacia''' LPS, in that, polymyxin B was unable to
antagonise the induction ofTNF-a and IL-6, and interaction was associated with
increased IL-ip inducing activity of "B. cepacia" LPS (Shimomura et al.2003).
With respect to aminoglycoside resistance, it is now assumed that because "B.
cepacia" LPS is not cross-linked by divalent cations, then the "self promoted" uptake
mechanism cannot function.
1.5.16 Resistance to Other Antimicrobial Agents
Plasmid-encoded resistance appears to be rare in Bee isolates, although one study has
reported tetracycline and ampicillin resistance determinants in a "B. cepacia" strain.
The presence of efflux systems in "B. cepacia" ensures that drugs entering the cell
could be actively exported. An important feature ofmany efflux systems is the
ability to act as "multi-drug resistant (MDR) efflux pumps" (Nikaido.1998). The
activity of a Bcc MDR efflux pump, homologous to the mexA-mexB-oprM efflux
operon in P. aeruginosa (Li et al. 1995), appears to be responsible for cross-
resistance to chloramphenicol, trimethoprim and ciprofloxacin (Burns et al. 1996).
Interestingly, the newer fluoroquinolones, such as gemifloxacin and moxifloxacin,
are also substrates for this MDR efflux system (Zhang et al.2001). Furthermore, the
recent cloning and characterisation of the norM gene, from B. vietnamiensis, which
encodes a multi-drug efflux protein, appears to confer some resistance to polymyxin
B (Fehlner-Gardiner and Valvano.2002). Wigfield et al. have described a Bcc
immunodominant efflux pump responsible for both nalidixic acid and tetracycline
resistance (Wigfield et al.2002). Cross-resistance in the Bcc, to
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trimethoprim/sulphamethoxazole, chloramphenicol and the quinolones, has also be
attributed to LPS structure and alteration in porin expression (Rajyaguru and
Muszynski 1997).
A novel mechanism of resistance observed in "B. cepacia''' is the dsbA-dsbB disulfide
bond formation system. Hayashi and co-workers demonstrated that a "B. cepacia'''
DsbA-DsbB mutant exhibits increased sensitivity to p-lactams, kanamycin,
erythromycin, novobiocin and ciprofloxacin (Hayashi et al. 2000).
Resistance of the Bee to antibiotics in vitro and in vivo may be influenced by the
environment and growth conditions. Interestingly, the antibiotic resistance observed
in P. aeruginosa biofdms is related to slow growth and anaerobiosis, not a barrier
effect. Planktonic and biofilm cultures were found to be more resistant to
ciprofloxacin and ceftazidime (Desai et al. 1998). Growth in an atmosphere of 5%
carbon dioxide (CO2) reduces the susceptibility of "5. cepacia" to p-lactam
antibiotics (Corkhill et al. 1994). Likewise, ciprofloxacin and tobramycin resistance
is increased if oxygen (O2) is depleted during growth (McKenney and Allison 1997).
Interestingly, the role of "B. cepacia" as a plant pathogen may partly explain the
inducible nature of certain resistance mechanisms. Salicylic acid is an important
signalling molecule in plant defence responses after pathogen attack (Klessig et al.
2000). Signalling cascades result in an acute disease response that acts systemically
throughout the plant. Early responses include an increase in reactive oxygen species,
cross-linking of cell wall proteins and increased expression of plant defence genes
(Baker and Orlandi 1995, Hammond-Kosack and Jones 1996, Lamb and Dixon 1997,
Yang et al. 1997). Some of these defence genes encode biosynthetic enzymes, such
as phenylalanine ammonia lyase (PAL). PAL is the first enzyme in the
phenylpropanoid pathway, which is involved in the synthesis of antimicrobial
compounds: the phytoalexins (Klessig et al. 2000).
In "B. cepacia" salicylate-inducible antibiotic resistance mechanisms have been
observed (Burns and Clark 1992). The authors reported that, in the presence of a
weak acid, salicylate, an outer membrane pore-forming protein was absent. This lack
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of expression conferred resistance. Thus, in its role as a phytopathogen, an adaptive
response of the Bcc may be to reduce outer membrane permeability in the presence
of a weak acid, such as salicylic acid, since low pH-mediated signalling results in the
production of antimicrobial compounds by the plant. Interestingly, a recent study
has shown that salicylate induces an efflux pump in B. cenocepacia (Nair et al.
2004). The authors state that salicylate is an important siderophore and a natural
substrate for the B. cenocepacia efflux system; therefore efflux-mediated resistance
may be upregulated in low iron concentrations, in the absence of antibiotic selective
pressure.
In conclusion, although there are a number of resistance mechanisms utilised within
the Bcc, in particular, reduced outer membrane permeability and MDR efflux pumps,
resistance varies significantly between isolates and within species (Nzula et al.
2002). This variability highlights the need for antibiotic susceptibility testing prior to
the administration of antibiotic therapy. However, susceptibility testing in relation to
CF lung infections is notoriously unreliable even with more susceptible pathogens
such as P. aeruginosa.
1.6 Novel Antimicrobial Therapies Against Bcc infections
With the immunological hurdles and physiological barriers facing gene therapy
becoming ever more complicated (Ferrari et al. 2003), present concerns of recurrent
microbial infection and inflammation have to be dealt with in the meantime. Novel
antimicrobial therapies do not offer a "cure" for CF, rather they offer a means of
disease management. As the major CF pathogens (S. aureus, P. aeruginosa and the
Bcc) are known to have increased virulence, be capable of epidemic spread and
multiply antibiotic resistant, novel antimicrobial agents are urgently required to stem
this considerable threat. Throughout this thesis, the focus will be on novel agents
with activity against the Bcc, since conventional antibiotic therapies are ineffective.
Such agents may also act against other CF and non-CF pathogens.
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1.7 Medicinal Use ofHoney
From within the bee's bodies
A drink ofvarying colours,
Wherein is healingfor men.
Holy Qu 'ran
Honey has been used as part of "folk medicine" for centuries but is now gaining a
renewed reputation as a possible answer to the growing problem ofmultiresistant
bacterial infections. As with other natural plant-derived compounds, such as allicin,
thyme oil, tea-tree extracts and St John's wort, much of the medicinal benefits of
honey are hidden in non-scientific literature or simply ignored. Since the
antimicrobial activity of honey was first described by Dold et al. in 1937, several
investigators have attempted to elucidate its antimicrobial components (Dold et al.
1937, cited by Wahden 1998.).
1.7.1 Antibacterial Components of Honey
The obvious explanation for the antimicrobial properties of honey is high osmolarity.
Honey is a supersaturated solution of sugars with a very low volume of free-water.
Free-water is measured as the water activity (aw). Many bacterial species are
inhibited by an aw value in the range 0.94-0.99: mean values for honey range from
0.5-0.6. However, the significance of inhibition by osmotic effects must take in
account the dilution ofhoneys prior to use (reviewed by Molan 1992a). The main
component sugars are the monosaccharides, fructose and glucose, and to a lesser
degree sucrose and maltose. The sugar/water composition of different types of
honey is variable and directly affected by both the season they are produced (Varis et
al. 1983), and whether the bees are wild or "domesticated" (Chou et al. 1994). The
high osmotic effect of these saturated sugar solutions on the bacterial cell, results in
the diffusion ofwater across the membrane and a lethal loss of osmotic pressure.
Interestingly, the osmotic effect appears to be only partially responsible for the
antibacterial activity, as studies using "artificial" honey solutions have concluded




Much of the early work on the antibacterial properties of honey described an
antibacterial factor, termed inhibine. Activity extended to both Gram-positive and
Gram-negative bacteria, was heat-labile and somewhat sensitive to light (Dold et al.
1937). The first attempt to clarify the chemical nature of inhibine described
hydrogen peroxide as the likely source of the antibacterial activity in a fall-flower
honey (White et al. 1963). Hydrogen peroxide was produced by glucose oxidase, an
acid-producing enzyme that catalyses production of gluconic acid and hydrogen
peroxide from glucose. The oxidase originates from the hypopharyngeal glands of
honey bees (Gauhe 1941, in French cited by Weston 2000). Hydrogen peroxide
levels can also be influenced by the amount of flower pollen-derived catalase present
in honey and by dilution of the honey during sample preparation (Bang et al. 2003).
A recent comprehensive review by Weston (2000) discounted the contribution of
other antibacterial factors present in honey, and indicated that antibacterial action is
due solely to pollen-derived catalase and its direct causative effect on the level of
hydrogen peroxide (Weston 2000, White 1966). However, an earlier study by
Wahden (1998) identified the presence of two antimicrobial phenolic acids (caffeic
acid and ferulic acid) as well as flavanoids in trefoil honey (Wahdan 1998). Many of
the phenolic compounds present in honey are derived from propolis (Amiot et al.
1989, Ferreres et al. 1992), a resinous material collected by bees and reputedly used
as an antibacterial agent within the hive (Marcucci 1995). A recent study has
demonstrated the antimicrobial activity ofpropolis in vitro, against Streptococcus
pneumoniae, H. influenza and S. aureus (Drago et al. 2000, Miorin et al. 2003).
Collected from the gum exudates of trees (mainly Poplar), propolis contains several
potential antimicrobial components including benzoic and cinnamic acids and
flavanoids. Although the concentration of these molecules is considerably less in
honey than in propolis (Bogdanov 1989), it is conceivable that they may act
synergistically and contribute to overall antibacterial activity. Furthermore, the
reaction of hydrogen peroxide with benzoic acid can create peroxyacids; these are
more stable than hydrogen peroxide and unaffected by catalase (Weston 2000). The
presence ofperoxyacids in honey has yet to be established.
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The pH of honey may also affect its antibacterial activity. Honey is generally acidic,
with a pH between 3.2 and 4.5 (Molan. 1992a). This acidity is primarily due to the
content of gluconic acid. Despite the fact that neutralised honey still has significant
antibacterial activity, pH may play a role in unbuffered or undiluted honey.
Other antimicrobial factors may include insect-derived peptides such as lysozyme
(Molan. 1992a), apidaecins (Casteels et al. 1989), abaecin (Casteels et al. 1990),
hymenoptaecin (Casteels et al. 1993) and royalisin (Fujiwara et al. 1990). These
enzymes are strongly induced when an insect becomes infected. The role of these
peptides in the antibacterial activity of honey has yet to be fully established, although
a study by Weston et al. (2000) indicated that their antibacterial role is likely to be
minimal (Weston et al.2000).
1.7.2 New Zealand Manuka (Leptospermum scoparium) Honey (NZMh)
New Zealand manuka honey (NZMh), which has received particular interest for its
antimicrobial activity, is derived from the nectar of the manuka tree (Leptospermum
scoparium: Myrtaceae), a species endemic to New Zealand. Several types of
manuka honey exist, but the level of non-peroxide killing is dependent on the region
in which the honey is produced (Molan. 1995). This variation in bioactivity was
explained by the presence of a plant-derived product present in manuka honeys,
which is yet to be identified (Molan et zz/. 1988). NZMh is presently marketed as a
natural antimicrobial product containing a "unique manuka factor" (UMF). The
nature of this "UMF" is unlikely to be a unique phenolic compound, as levels do not
vary between active and non-active manuka honeys (Weston et al. 1999). Nor is
UMF likely to be two abundant extractable organic components, syringic acid and
phenyllactic acid, found in many European honeys (Wilkins et al. 1993).
Furthermore, there is little variation in the oligosaccharide composition of active and
non-active manuka honeys (Weston and Brocklebank.1999).
Many potential antimicrobial compounds that have been identified in honey are
unique to the preparation used, and dependent on flower source. Furthermore,
45
CHAPTER ONE INTRODUCTION
because of the natural synthesis of honey, the level of the antimicrobial components
may vary between "batches".
1.7.3 Antimicrobial Spectrum ofNZMh and Other Honeys
The antimicrobial spectrum of honey is impressive and extends to both Gram-
positive and Gram-negative bacteria, as well as to fungi and yeasts. A report by
Willix et al. (1992), which described the sensitivity ofwound-infecting bacterial
species to manuka and an alternative monofloral honey, indicated that the activity of
both honeys extended to E. coli, Proteus mirabilis, Salmonella typhimurium, P.
aeruginosa, Serratia marcecens, S. aureus and S. pneumoniae (Willix et al. 1992).
Two further studies described potent antibacterial activity ofmanuka and pasture
honey against clinical isolates of S. aureus (Cooper et al. 1999a) and P. aeruginosa
(Cooper and Molan. 1999b). P. aeruginosa burn infections pose an important clinical
problem both in their management and treatment. Cooper et al. recently described
the sensitivity ofP. aeruginosa isolated from burns, to both manuka and pasture
honey (Cooper et al.2003).
Honey has been used traditionally to treat dyspepsia in many cultures. Somal and
co-workers examined the susceptibility ofHelicobacter pylori to manuka honey
(Somal et al. 1994). H. pylori is known to be an important cause of gastritis and
duodenal ulceration, thus the authors hypothesised that manuka honey may be an
alternative therapy in eradicating this organism from the stomach. In vitro sensitivity
studies indicated that H. pylori is inhibited by manuka honey, but in vivo efficacy
was not assessed.
Interestingly, the antibacterial activity ofmanuka honey extends to antibiotic
resistant pathogens including; MRSA, vancomycin-resistant Enterococcus faecium




1.7.4 Practical Applications of Honey and its Clinical Effect
The main therapeutic use of honey is in the treatment ofwounds that fail to heal with
conventional therapies. Bergam et al. reported that honey accelerated wound
healing in mice (Bergam et al. 1983). Human studies, which followed, have focused
on the effectiveness of topically applied honey-impregnated dressings (Wood et al.
1997). An initial study reported the efficacy of topically applied honey onto wounds
and ulcers in 58 of 59 patients following one week of honey therapy (Efem 1988).
The clinical effects reported were: 1. Gradual separation of necrotic and gangrenous
tissue from wall of ulcer; 2. Reduction in surrounding oedema; 3. Dehydration of
weeping ulcers; 4. Deodorizing of foul-smelling wounds, and 5. Sterilisation of the
infected lesion. In addition, wound healing and epithelialisation were also described.
Further studies have highlighted the wound-healing potential of honey with the
successful treatment ofburns (Subrahmanyam 1978), recalcitrant surgical wounds
(Cooper et al. 2001) and in the management ofpressure ulcers (Van der Weyden
2003). The latter study used a honey/alginate combination, and noted that as well as
the well-documented antibacterial activity, there appeared to be significant anti¬
inflammatory effects associated with the therapy.
A recent report examined the effect ofmanuka, pasture and artificial honeys on
macrophage function (Tonks et al. 2001). Macrophages play an important role in
regulating wound repair and are primed and activated by the pro-inflammatory
cytokine, TNF-a. The authors observed that both pasture and manuka honey caused
spontaneous release ofTNF-a from a human monocytic (MM6) cell line.
Furthermore, pasture, and to a lesser extent manuka honey, reduced production of
reactive oxygen intermediates (ROIs) signifying a potential antioxidant effect.
Additionally, both manuka and pasture honey have been shown to increase
production of other inflammatory cytokines, IL-1 (3 and IL-6, from MM6 cells (Tonks
et al. 2003), and in some cases to act as a mitogen for B- and T-lymphocytes
(Abuharfeil et al. 1999). Thus, in therapeutic terms, honey may play an important
immunological role in vivo.
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One problem connected with the therapeutic use of honey, is that it may contain
spores of Clostridium and Bacillus spp. increasing the risk ofwound botulism or
gangrene (Midura et al. 1979). However, sterilisation can be achieved by gamma
irradiation without compromising antibacterial activity (Molan and Allen 1996).
Aerosolisation may be an effective method of administering honey for treatment of
respiratory infections. Aerosolisation of 50% (vol/vol) acacia honey has been
described in the treatment of chronic and exudative bronchitis (Bejan et al. 1978 in
French) and Kirienko et al. advised the inhalation of honey and propolis to
supplement conventional therapy in treatment of chronic bronchitis (Kirienko et al.
1989, cited by Cooper et al. 2000). Other potential therapeutic applications include
the synergistic use of honey with conventional antibiotics (Karayil 1998).
In summary, the full implications of the medicinal use of honey are yet to be realised,
and this most natural and useful product may yet provide cheap and novel
alternatives to conventional therapies.
1.8 Bacteriophage (Phage)
So, naturalists observe, a flea
Hath smallerfleas that on him prey;
And these have smaller still to bite 'em,
And so proceed ad infinitum.
- Johnathan Swift
The independent discovery ofbacteriophage by Fredrick W. Twort and Felix
d'Herelle in 1915 and 1917 respectively, was the first indication that these bacterial
viruses might have a role in the treatment ofbacterial infections (d'Herelle 1917,
Twort 1915). Described initially as "filterable particles", bacteriophages were used
therapeutically until the antibiotic era began in the 1950s. At this time, the role of
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bacteriophage as therapeutic agents was no longer ofmajor concern and instead, they
became important tools of the molecular biology revolution. Ironically, it is
primarily as a result of increasing bacterial resistance to conventional antimicrobial
agents, that the therapeutic use ofbacteriophage has once again attracted attention:
on this occasion, supported by the molecular technology that these agents helped to
create.
1.8.1 Bacteriophage Life Cycle
The global population of phage (or bacterial viruses) is estimated to be more than
3010 (Brussow and Hendrix 2002). Bacteriophages infect bacteria by attachment to
specific receptors and injection ofphage nucleic acid into the cell (reviewed by Stent
1963). Phage particles or virions, exist as a protein capsid surrounding nucleic acid,
DNA or RNA. The nucleic acid can be double- or single-stranded, in a linear or
circular conformation. The specificity of phage for specific strains within species
has resulted in their use as a bacterial typing system.
Two types ofphage have been defined: virulent/lytic and lysogenic/temperate phage.
Virulent phages propagate through a lytic cycle. Upon infection, lytic phage DNA
enters a replicative cycle resulting in the production of new phage particles. The
production of a large number of daughter phage particles, and an associated lytic
enzyme, leads to lysis of the host. In contrast, temperate bacteriophages are able to
form lysogens; in this form phage exist in a latent or quiescent state known as a
prophage. In lysogenic bacteria, DNA is integrated into the bacterial chromosome
and exists as a prophage. Prophage DNA remains integrated into the bacterial
chromosome until induced, whereby the host cell expresses phage genes and lytic
growth is initiated.
Some temperate phages can act as vectors for horizontal gene transfer (transduction,
and are termed transducing phage. Two types of transduction have been described;
generalised and specialised. Generalised transduction is the process by which the
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transducing phage, through packaging of bacterial rather than phage DNA during
phage replication, can transfer a variety of loci of the bacterial genome from donor to
recipient cell, exemplified by the Salmonella phage P22. In contrast, specialised
transduction is the process by which the transducing phage, having integrated at
specific genomic loci, can transfer loci on either side of the integrated site, as is the
case with the E. coli phage X. Ofparticular interest is the ability of phage to transfer
antibiotic resistance genes within and between different host species. In P.
aeruginosa, transduction of imipenem resistance (Blahova et al. 1998), as well as
ceftazidime (Seginkova et al. 1986) and amikacin, gentamicin and tobramycin
(Knothe et al. 1981) has been well documented. The latter study demonstrated the
antibiotic resistance transducing potential of the well-characterised P. aeruginosa
phage F116.
Lysogenic phage may also play an important role in the evolution of bacteria as
pathogens including an intrinsic role in pathogen-host interactions (Miao and Miller
1999). Since the seminal study that demonstrated the essential role played by phage
in regulation and biosynthesis of diphtheria toxin (Freeman 1951), many phage-
encoded virulence genes have been found (Table 1.7).
Table 1.7 Bacteriophage encoded virulence factors (Adapted from Boyd et al. 2001, Miao
and Miller 1999)
Virulence Determinant Bacteria Bacteriophage
SopE S. typhimurium SopEO
SodC S. typhimurium Gifsy-2
Cholera toxin V. choierae CTXO
Toxin-coregulated pilus & CTX O receptor V. choierae VPI<J>
Diphtheria toxin Corynebacterium diphtheriae Converting p-phage
Shiga-like toxin-l and -II Enterotoxigenic E. coli Shiga-like toxin converting phage
Serum resistance E. coii Lambda (X)
Enterotoxin A & Staphylokinase S. aureus ct> 13
Toxic shock syndrome toxin-1 (TSST-1) S. aureus TSST-1
Streptococcal pyrogenic exotoxins A & C Group A Streptococci T12 & 3GL16
Neurotoxin Clostridium botulinum Phage C1
O-antigen acetylase Shigella flexneri Sf6
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The expansion in sequencing whole bacterial genomes has ensured that the
importance of phage and their role in bacterial virulence will remain the focus of
investigation.
1.8.2 Bacteriophage of the B. cepacia complex
Little is known of the phages of the Bcc. Early reports on the "B. cepacia" phages
CP1 (Cihlar et al. 1978) and CP75 (Matsumoto et al. 1986) predate revision ofBcc
taxonomy. Briefly, Cihlar et al. (1978) characterised an organic solvent-sensitive
phage, CP1, present in the lysogenic "R. cepacia" strain 249. Phage morphology
appeared to be T-even-like comprising a hexagonal head and contractile tail. The
authors were unable to demonstrate transduction of auxotrophic "5. cepacia" by
CP1. Matsumoto and co-workers described a generalised transducing phage, CP75,
derived from the lysogenic "B. cepacia" strain PCT1. CP75 was insensitive to
organic solvents, and had similar morphology to CP1. The CP75 genome was
estimated to be approximately 52 Kbp, and generalised transduction was
demonstrated by the use of three auxotrophic mutants requiring histidine, leucine or
methionine.
More recently, a study characterised two generalised transducing phages (NS1 and
NS2) from Bcc strains ATCC 29424 (B. vietnamiensis) and ATCC 17616 (B.
multivorans) respectively (Nzula et al. 2000). Evidence suggested that the bacterial
receptor was LPS, and both phages were capable of transducing ceftazidime
resistance. The broad host range ofNS1 and NS2 within the Bcc was surprising, and
even extended to P. aeruginosa and B. pseudomallei (Langley et al. 2003).
Likewise, some Bcc isolates were found to be sensitive to well-characterised P.
aeruginosa transducing phages, B3, F116 and G101. These studies highlighted the
potential for exchange of genomic loci, both within the Bcc, and between the Bcc, P.
aeruginosa and other Burkholderia species. The broad host range ofBcc phage is
unusual and interesting. Lytic phages with interspecies host range within the Bcc
have also been reported in association with soil-borne strains ofB. cenocepacia
(LiPuma et al. 2000). A novel phage (<j)E125) that can propagate in B. mallei has
been isolated from B. thailandensis strain E125 (Woods et al. 2002). B.
51
CHAPTER ONE INTRODUCTION
thailandensis, a non-pathogenic soil saprophyte is closely related to B. mallei and B.
pseudomallei. Prior to this study, eight lysogenic B. pseudomallei strains produced
bacteriophages that were more active on B. mallei than on B. pseudomallei (Smith
and Cherry 1957). B. mallei and B. pseudomallei are the causative agents of glanders
and melioidosis respectively, and are considered potential agents for bioterrorism.
Additionally, B. pseudomallei shares insertion sequences with "B. ce/>acm"(Mack
and Titball 1998).
1.8.3 B. cepacia phage 781 (Bcep781: Accession number- NC 004333)
The first full genome sequence of a B. cepacia (genomovar I) phage (Bcep781) has
recently been published online (www.ncbi.nlm.nih.gov). Information regarding
Bcep781 is scant, however, it was recovered from soil, and was initially propagated
on a B. cepacia soil isolate. The nucleic acid content is double stranded (ds)DNA and
is approximately 48.5 Kbp in size. Bcep781 is classified into the Myoviridae family
due to its contractile tail morphology. Two other Bcc phages have been described:
Bcepl (genomovar III soil isolate, NC_005263) and Bcep43 (genomovar I soil
isolate, NC_005342). Both have similar genome sizes and are morphologically
similar to Bcep781. All three phages are believed to be representatives of a novel
family of Bcc bacteriophages.
Further work on the lysogeny and phage host range within the Bcc will be discussed
in subsequent sections.
1.8.4 Bacteriophage Therapy
The first clinical studies of the efficacy ofbacteriophages as therapeutic agents were
performed at the beginning of last century. In 1918, d'Herelle published his first
report describing the involvement ofphage in "immunity" to bacillary dysentery
(d'Herelle 1918, cited by Stent 1963). d'Herelle concluded that "the pathogenesis
and pathology of dysentery are dominated by two opposing factors: the dysentery
bacillus as pathogenic agent and the filterable bacteriophage as agent of immunity".
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As a result of this observation, many clinicians began to examine the potential of
phage in the treatment of other bacterial infections. Phage therapy was found to be
particularly effective in the treatment and control of cholera (Morrison 1932).
Following the advent of the antibiotic era in the 1950s, interest in phage therapy
declined with the exception ofEastern Europe. More recently, interest in phage
therapy has re-emerged as the threat ofwidespread antibiotic resistance has become a
reality (Pirisi 2000).
Bacteriophage therapy has five main advantages over conventional antibiotics: 1.
Phages tend to be species specific, and therefore the host commensal flora remains
unaffected, 2. Phage replication is localised to the site of infection, 3. No serious side
effects have been described, 4. Phage-resistant bacteria remain sensitive to other
species-specific bacteriophage and, 5. Novel phages are easily identified. However,
there are also disadvantages to phage therapy: 1. The limited host range may impede
the treatment of the infection, 2. Phage preparations may contain toxins and bacterial
debris that cause severe symptoms in patients and, 3. Phage are rapidly removed
from the circulation by the reticuloendothelial system (RES) (Geier et al. 1973). In
a seminal study, Merril et al. (1996), the authors address each of these disadvantages,
and show how phage therapy can be improved (Merril et al. 1996). First, the authors
examined a range of virulent phages for both E. coli and S. typhimurium in a murine
infection model. Use of virulent phage was important, to prevent phage- infected
bacteria surviving as lysogens. Second, they purified the phage preparations on a
caesium chloride density-gradient to reduce the levels of endotoxin, and thus adverse
effects. Third, they reported a novel technique to increase the capacity of the phage
to avoid the RES. After injecting the phage preparation into mice, blood samples
were obtained and surviving phage propagated onto a mutator strain ofE. coli to
increase the chance of random mutations in the daughter phage. Interestingly, after
the process was repeated several times, a 16,000-fold increase in phage survival was
noted in the circulation. Although there are several caveats to this approach,
(including the possible presence of phage genes encoding toxins, antibiotic
resistance, and lysogeny), the authors concluded that the use of long-circulating
phages may have important therapeutic applications.
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Two reports by Alisky et al. (1998) and Sulakvelidze et al. (2001) have
systematically reviewed numerous clinical studies carried out over the last 50 years,
with particular emphasis on papers published in Russian, Georgian and Polish
journals (Alisky et al. 1998, Sulakvelidze et al. 2001). Ofparticular interest is the
six-part study examining the effectiveness of phages against infections caused by
various bacterial pathogens, including multiresistant mutants (Summarised in Slopek
et al. 1987). In total, 550 cases of suppurative bacterial infections were treated by
phage therapy. The bacterial pathogens included Staphylococci, Klebsiella,
Escherichia, Proteus and Pseudomonas, and 94.2% of the cases were resistant to
antibiotics. Phage were administered orally, or applied directly to the pleural and
peritoneal cavities, or as eye, nose or ear drops. Moreover, phage resistance was
monitored and where appropriate the phage pool adjusted. The spectrum of
infections studied was widespread, and included the respiratory, gastrointestinal,
genitourinary and lymphatic systems. Overall, the authors reported a positive
therapeutic result in 92.4% of the cases examined. This extensive analysis of phage
therapy in human infections is one ofmany which recommend the use of virulent
phage against multiresistant infections. Further examples include the treatment of
urinary tract infections (Perepanova et al. 1995), Staphylococcal lung infections
(Reviewed by Sulakvelidze et al. 2001), postoperative skin infections (Cislo et al.
1987), neonatal sepsis (Pavelenish and Tsertsvadze 1993) and P. aeruginosa
infections in CF patients (Shabalova et al. 1995). It should be noted that a major
caveat in all of these studies is the lack of sufficient control groups.
The use of phage therapy in animal infection models has also been extensively
studied. Smith and Huggins compared the efficacy ofphage therapy with
conventional antibiotics in a mouse model E. coli 018:K1 infection (Smith and
Huggins 1982). The authors reported that a single intramuscular dose of a single
strain of anti-Kl phage was more effective then multiple doses of tetracycline,
ampicillin, chloramphenicol, or trimethoprim plus sulphamethoxazole (co-
trimoxazole). Furthermore, dissemination of bacteria to brain tissue was prevented
in phage-treated mice. The authors also attempted to treat diarrhoea caused by an
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enteropathogenic strain ofE. coli O9:K30,99 (B44) in calves, piglets and lambs
(Smith and Huggins 1983). In contrast to the previous study, a combination of two
phages were used, and were only successful if administered prior to the onset of
diarrhoea. However, although post-onset administration of phage did not affect
lethality, inoculation of healthy calves with a faecal sample from phage-treated
calves did not result in pathology, suggesting that virulence was attenuated in the
passaged strain. Smith et al. carried out further studies into the control of diarrhoea
in calves caused by virulent enteropathogenic E. coli and concluded that symptoms
could be prevented with a single dose of 10,000 phage particles or by prior phage-
treatment of feed (Smith et al. 1987a, Smith et al. 1987b). In view of the apparent
success of these studies, further work was undertaken into the efficacy of phage in
the treatment of other animal infections. The successful treatment ofP. aeruginosa
and Acinetobacter baumannii was achieved when bacteria and phage were
administered simultaneously (Soothill 1992). Later, Soothill described the
prevention of skin graft destruction by P. aeruginosa in a guinea pig model (Soothill
1994). The author concluded, that the prophylactic topical application of phage in
burns patients might prevent P. aeruginosa infection.
Phages can also be used as biocontrol agents. Bacterial infection caused by the fish
pathogen Pseudomonas plecoglossicida in Plecoglossus altivelis (Nishimori et al.
2000), a fresh water fish, was controlled by the oral administration of phage-
impregnated feed (Park et al. 2000). The bacterial population in fresh water was also
lower in the presence of phage. Studies have also highlighted the potential of phages
in the reduction ofE. coli growing as biofilms polyvinylchloride (Doolittle et al.
1995). The authors showed that phage could penetrate a biofilm through a phage-
encoded polysaccharide depolymerase specific for the exopolysaccharide produced
by the host bacterium (Hughes et al. 1998b, Hughes et al. 1998a). Hanlon et al. also
demonstrated that the molecular weight and viscosity of phage-treated P. aeruginosa
alginate was reduced up to 40% as a result ofphage-mediated enzymatic degradation
(Hanlon et al. 2001).
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1.8.5 Bacteriophage Lytic Enzymes as Antibacterial Agents
A new twist to phage therapy removes the problems of using intact phage particles
by exploiting the phage-encoded enzymes used to lyse and exit the bacterial cell.
These lytic enzymes, produced during the phage lytic cycle, enable phage progeny to
escape from the host cytoplasm. In general, large lytic phages (DNA genome greater
than 20 Kbp) encode at least two proteins involved in host cell lysis: a holin and an
endolysin. This tightly regulated two-component lysis system involves holin
accumulation and oligomerization in the bacterial cell membrane and endolysin
accumulation in the cytoplasm. At a genetically programmed point in the phage life
cycle, the holin oligomers form lesions in the inner cell membrane allowing the
endolysin to access and disrupt the peptidoglycan cell wall (Bernhardt et al. 2002,
Young et al. 2000). The substrate for phage endolysin is the bacterial murein layer.
In general, phage endolysins have a two-domain structure (Diaz et al. 1990, Garcia et
al. 1990), and exist as soluble proteins with the N-terminal domain containing the
catalytic activity of the enzyme. This catalytic activity is directed against the three
types of covalent bonds (glycosidic, amide and peptide) of the peptidoglycan
polymer ofbacterial cell walls (Loessner et al. 1999, Navarre et al. 1999, Young
1992). The activity may be an endo-P-A-acetylglucosaminidase or an N-
acetylmuramidase (lysozymes), acting on the sugar moiety; an endopeptidase that
acts on the peptide cross-linking bridge; or an A-acetylmuramyl-L-alanine amidase
(amidase) which hydrolyses the amide bond between the sugar and peptide moieties
(Reviewed by Fischetti 2003). The C-terminal domain is specific for the cell wall
(Garcia et al. 1988, Lopez et al. 1997, Lopez et al. 1992). The endolysins of
Streptococcal phages have been examined and characterised in some detail (Garcia et
al. 1987, Garcia et al. 1984). The specificity of the lytic enzyme to its substrate is
such that without the cell wall binding domain the catalytic domain will not cleave.
Resistance to phage lysins has rarely been observed. The specific binding site of the
CP-1 endolysin, from the pneumococcal phage CP-1, is choline, a molecule essential
for bacterial viability (Garcia et al. 1988, Garcia et al. 1983, Hermoso et al. 2003).
This may explain why endolysin resistance is rare since the intact endolysin binding
sites are essential for bacterial viability.
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The two-domain structure appears to be essential for endolysin activity. Morita et al.
used mutant peptides to demonstrate that the loss of antibacterial activity
corresponded to the loss of the C-terminus (Morita et al. 2001). Interestingly, this
study also demonstrated the decrease in viability of P. aeruginosa on the addition of
the endolysin. In a subsequent study, other mutant peptides based on a phage
endolysin from Bacillus amyloliquefaciens were found to increase the permeability
of the outer membrane ofP. aeruginosa (Orito et al. 2004).
The antimicrobial activity of phage lysins resembles a process termed "lysis from
without". Historically, this term relates to the phenomenon of immediate lysis of the
host bacteria at high phage multiplicity, but even then the presence of lytic enzymes
was thought to play a vital role (Stent 1963).
Recently, a seminal study by Nelson and co-workers described the prophylactic use
of the Ci phage lysin, from a Streptococcal phage, to control and prevent Group A
Streptococcal pharyngitis (Nelson et al. 2001). Ci phage lysin is a murein hydrolase
(7V-acetylmuramoyl-L-amidase). The authors also reported that the lysin activity was
specific to Group A, C and E Streptococci, whilst other commensal Streptococci
were unaffected. The efficacy of the lysin was tested in vitro and an in vivo mouse
infection model. In vitro, the authors demonstrate that as little as 10 nanograms (ng)
of lysin can sterilise a culture containing approximately 107 Group A Streptococci
within five seconds. The in vivo study highlighted the potential use of the lysin as
both a prophylactic treatment to prevent Streptococcal colonisation and as a
treatment for an active infection.
Other studies have focussed on other Streptococcal phage lytic enzymes. Loeffler
and colleagues described a pneumococcal phage-encoded 34 kDa amidase, termed
Pal, that can specifically digest the pneumococcal cell wall within seconds, resulting
in rapid cell death (Loeffler et al. 2001). In a follow up study, Loeffler and Fischetti
successfully used a synergistic combination of lytic enzymes (Cpl-1 & Pal) to kill
penicillin-sensitive and -resistant pneumococci (Loeffler and Fischetti 2003). A
recent report has confirmed the in vivo antimicrobial activity of Cpl-1 against
pneumococci. Cpl-1, a muramidase (Garcia et al. 1987), was found to be an
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effective agent in controlling bacteraemia in a mouse model (Loeffler et al. 2003).
This result was confirmed by a subsequent study that also found that a combination
of phage enzymes (Cpl-1 and Pal) could successfully control antibiotic-resistant
pneumococcal bacteremia in a murine sepsis model (Jado et al. 2003). The crystal
structure ofCp-1 has recently been published and should aid future studies on the
interaction of this enzyme with its substrate (Monterroso et al. 2002).
In addition to the growing concerns ofmultiresistant pathogens, the urgency to
develop novel antimicrobial agents was intensified after the terrorist attacks on the
tFi
USA on September the 11 2001. In a remarkable and timely report, Schuch and co¬
workers identified a lysin, PlyG, isolated from the y phage ofBacillus anthracis
(Schuch et al. 2002). Protein analysis suggested that this enzyme was homologous to
iV-acetylmuramoyl-L-alanine amidases. Homology was noted in the N-terminal, or
catalytic domain, but absent in the cell wall specific C-terminal binding domain.
Interestingly, the lysin was active against B. anthracis isolates and other members of
the B. anthracis "cluster" ofbacilli. The bactericidal activity ofPlyG was
demonstrated in vivo and in vitro, and extended to both vegetative cells and
germinating spores. Furthermore, the ability ofPlyG to kill germinating spores was
exploited to develop a rapid and specific identification system for B. anthracis, or as
it is euphemistically called "the white powder". The specificity ofphage lysins for
their bacterial host was further emphasised by Zimmer et al (2002) who described a
murein hydrolase, from bacteriophage (j)3626, which specifically killed Clostridium
perfringens isolates (Zimmer et al. 2002).
Finally, a novel study investigated the potential use of a bacteriolytic protein from
phage P4282, against wilt disease in tobacco, caused by Ralstonia solanacearum
(Ozawa et al. 2001). The authors cloned and overexpressed the lytic gene in E. coli,
and observed specific killing ofR. solanacearum. Interestingly, the authors
concluded that the production of transgenic plants containing the bacteriolytic gene
ofphage P4282 might enhance resistance to bacterial wilt in nature.
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1.9 Antimicrobial Peptides (AMPs)
Despite continuous exposure to potential pathogenic organisms, humans remain
relatively free from infection. This apparent paradox can, in part, be explained by a
highly efficient acquired immune system. Mediated by cellular responses, acquired
immunity requires highly specific antigen recognition to initiate both humoral and
cellular arms. However, the initial acquired response may take from several days to
a few weeks to reach maximum efficiency. The outcome may be immunological
memory, but the infection must be contained to ensure survival of the host.
The first line of defence against potential pathogens is the innate immune system,
which is inducible, and whose role is to recognise and eliminate microbial challenges
via effector molecules. The innate system is not autonomous and signalling
molecules allow communication with the acquired immune system. Effector
molecules in innate immunity include: reactive oxygen species, nutrient limiting
molecules, proteases and antimicrobial peptides (AMPs).
AMPs are part of an ancient group ofhighly conserved peptides that are found across
a diverse range of organisms including unicellular prokaryotes, plants, insects,
amphibians and mammals. These defence molecules form part of a multifaceted
defensive system that is under intensive selective evolutionary pressure.
AMPs are gene-encoded and are initially expressed as a pre-propeptide, containing a
N-terminal endoplasmic reticulum targeting sequence (signal pre-sequence), the
adjacent precursor sequence (propeptide sequence) and the mature peptide at the C-
terminus. The mature peptide is proteolytically cleaved and generally has broad-
spectrum antimicrobial activity. Structurally, AMPs are generally amphipathic and
cationic, but anionic peptides have been described. AMP expression can be both
constitutive and inducible.
The classification ofAMPs can be based on chemical structure, anatomical site of
expression or gene family. Mammalian AMPs are generally characterised by the
presence of intramolecular disulfide bonds. Protegrins, identified from porcine
neutrophils, contain two intramolecular disulfide bonds (Harwig et al. 1995). Bovine
dodecapeptide, purified from bovine neutrophils, has a single disulfide bond (Romeo
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et al. 1988). Defensins, the most studied mammalian AMP, generally contain three
disulfide bonds. At present, three groups of mammalian defensins have been
observed: alpha (a), beta ((3), and theta (0). The classification of defensins is
generally based on the position of the cysteine residues and the connectivity of the
disulfide pairings (Fig 1.7). In contrast, classification can also be based on the amino
acid composition, such as: proline-rich bactenecins, from bovine leukocytes (Frank
et al. 1990); histidine-rich histatins, from human parotid secretions (Oppenheim et
al. 1988); proline-rich prophenin, from porcine leukocytes (Elarwig et al. 1995);
proline-rich AMPs, from ovine and caprine leukocytes (Shamova et al. 1999); and
tryptophan-rich indolicidin, from bovine neutrophils (Selsted et al. 1992). Other
examples ofAMPs include: the linear cathelicidin LL-37, characterised by an alpha
(a)-helical structure, isolated from human neutrophils and epithelial cells
(Gudmundsson et al. 1996), and a number of anionic peptides (Brogden et al. 1997,
Brogden et al. 1996).
I 1 1
a-Defensin -C1 -C2—C3 C4 C5C6-
L
I I I I
£-Defensin -CI C2—C3 C4 C5C6-
I I
(9-Defensm
Fig 1.7 The disulfide bridging connectivity in a, |3, and u-defensins: a-defensins are
characterised by C1-C6, C2-C4 and C3-C5 disulfide bridging (Selsted and Harwig 1989). |3-
defensins are characterised by C1-C5, C2-C4 and C3-C6 disulfide connectivity (Tang and
Selsted 1993). 0-defensins are characterised by an amide-linked backbone that forms a
cyclic structure with three disulfide bonds (Tang et at. 1999).
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Grouping AMPs according to gene family provides a more simplistic approach than
classification based on structural relationship or disulfide bond connectivity. In this
respect, two families ofAMPs are recognised, the defensins and the cathelicidins.
For the purpose of this thesis, attention will be focussed on defensins.
1.9.1 Defensins
Defensins are a family of small, cationic antimicrobial peptides identified in both
mammals and plants. To date, the defensin family has been subdivided into three
main classes (a, P, and 0) on the basis of structural characteristics. The role of 0-
defensins will not be discussed. In humans, genes encoding a- and P-defensins are
clustered on chromosome 8p23 (Linzmeier et al. 1999, Sparkes et al. 1989). The
taxonomic nomenclature of defensins is complex: a-defensins can be referred to with
the prefix DEFA or HNP or HD; P-defensins can be referred to with the prefix DEFB
or hBD, and murine P-defensins are designated by the prefix defb. For recent and
extensive reviews of defensins see Ganz (2003) & Schutte and McCray (2002).
1.9.2 Alpha (a)-Defensins
a-Defensins are 29-35 amino acids in length, and are characterised by six highly-
conserved cysteine residues that form three disulfide bonds. In humans, a-defensins
are expressed in neutrophils (HNP-1-4: DEFA1, DEFA2, DEFA3, DEFA4) (Lehrer
et al. 1993), Paneth cells (HD-5 and -6: DEFA5/6) (Jones and Bevins 1993, Jones
and Bevins 1992) and other epithelia including the epithelium of the vagina,
endocervix and fallopian tubes (DEFA5, DEFA6) (Quayle et al. 1998, Schutte and
McCray 2002). In neutrophils, a-defensins make up to 50% of the protein content of
the azurophilic granules. During phagocytosis, a-defensins are released into the
phagolysosome where they exert antimicrobial effects. In Paneth cells, DEFA5 and
DEFA6 are present in cytoplasmic granules (Mallow et al. 1996).
A recent seminal study by Salzman et al. has described the potent in vivo activity of
FID-5 (DEFA5) in protecting mice from oral administration of virulent Salmonella
typhimurium (Salzman et al. 2003). Using transgenic mice expressing HD-5, the
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authors demonstrated that this defensin protected animals from an infection that was
fatal for wild-type mice. Protection was achieved quickly upon administration of
bacteria, and lower counts of S. typhimurium were observed in the intestinal lumen,
with less dissemination to other organs. Interestingly, protection was only observed
if the dose of S. typhimurium was given orally, not intraperitoneally, supporting the
hypothesis that defensins act as "locally secreted antibiotics".
1.9.3 Beta ((3) Defensins
The first P-defensin to be identified was tracheal antimicrobial peptide (TAP)
isolated from bovine trachea (Diamond et al. 1991). A subsequent study
characterised the primary structure and the antimicrobial activities of thirteen novel
bovine antimicrobial peptides that were also classified as P-defensins (Selsted et al.
1993). These peptides shared high sequence homology with TAP, and were
structurally different from a-defensins. P-defensins are of similar size to a-
defensins, and contain six highly conserved cysteine residues. However, P-defensins
differ from a-defensins in the pattern ofpairing of their three disulfide bonds. To
date, four human p-defensins have been characterised. The first human P-defensin
was identified in human plasma (Bensch et al. 1995). Human P-defensin-1 (hBD-1)
is a cationic antimicrobial peptide, which is expressed constitutively in: salivary
glands and epithelial cells (Sahasrebudhe et al. 2000, Zhao et al. 1996), gingiva
(Krishnaprakornkit et al. 1998), buccal mucosal (Mathews et al. 1999), respiratory
epithelia (Goldman et al. 1997, McCray and Bentley 1997) and urogenital tissues
(Valore et al. 1998). Human P-defensin-2 (hBD-2) was isolated from psoriatic scales
of human skin and in the lung (Bals et al. 1998, Harder et al. 1997a, Harder et al.
1997b). Human P-defensin-3 (hBD-3) was initially isolated from human lesional
psoriatic scales, but also shown to be expressed in keratinocytes and respiratory
epithelial cells (Harder et al. 2001). Unlike the other studies, identification of human
P-defensin-4 (hBD-4) was based on genomic sequence alignments (Garcia et al.
2001). In contrast to the constitutive expression of hBD-1, hBD2 and hBD3 are
inducible in response to pro-inflammatory stimuli, such as LPS, TNF-a and IL-ip
(Bals et al. 1998, Harder et al. 2001, Harder et al. 1997a, Singh et al. 1998). Within
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the promoter regions of both hBD-2 and hBD-3 there are binding sites for NF-kB, an
important inflammatory mediator (Tsutsumi-Ishii and Nagaoka 2002). Conversely,
hBD-4 does not contain such binding sites, and is unaffected by inflammatory stimuli
(King et al. 2003). It is, however, inducible upon stimulation by bacterial factors,
including heat inactivated P. aeruginosa (Garcia et al. 2001). In a recent report,
activation of Toll-like receptor 2 (TLR2) was shown to induce the expression of
hBD-2 (Hertz et al. 2003).
To date, the antimicrobial activity of all human (3-defensins extends to both Gram-
positive and Gram-negative bacteria. Human P-defensin-1 has been shown to kill E.
coli, P. aeruginosa and Listeria monocytogenes (Goldman et al. 1997, Singh et al.
1998, Valore et al. 1998). Interestingly, hBD-1 can be secreted in five different
forms (Valore et al. 1998), with three forms existing in the respiratory tract (Singh et
al. 1998). Human P-defensin-2 has bactericidal against P. aeruginosa (Singh et al.
1998), E. coli (Bals et al. 1998) and C. albicans (Harder et al. 1997a), but has lower
activity against Gram-positive bacteria, such as S. aureus (Harder et al. 1997a). The
bactericidal activity of hBD-3 extends to S. aureus, vancomycin-resistant E. faecium,
P. aeruginosa, C. albicans and Streptococcus pyogenes (Harder et al. 2001). An
early report claimed that hBD-3 was active against "B. cepacia''' (Garcia et al. 2001);
significantly, this unusual killing activity was contradicted in a later study (Sahly et
al. 2003). The killing ability of hBD-4 appears to be limited to Staphylococcus
carnosus and P. aeruginosa (Garcia et al. 2001).
In general, the microbicidal activity of hBD-1 and hBD-2 is directed against Gram-
negative bacteria, whereas hBD-3 has a broader spectrum of activity. It has been
suggested that this broad spectrum ofbactericidal activity may result from a greater
density of cationic residues in hBD-3 compared to hBD-1 and hBD-2 (Harder et al.
2001).
The antimicrobial action of hBD-1, -2 and -4 is affected by the concentration of salt
(NaCl) (Bals et al. 1998, Garcia et al. 2001, Goldman et al. 1997), and in the case of
hBD-1 appears to be dependent on the secreted form (Valore et al. 1998). hBD-3 is
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less salt sensitive in its activity against S. aureus, and high salt concentrations are
needed to reduce the antimicrobial activity (Harder et al. 2001).
In addition to human-P defensins, mouse homologs have also been described with
antimicrobial activity against E. coli, P. aeruginosa, and S. aureus (Bals et al. 1998,
Morrison et al. 1999, Morrison et al. 1998, Yamaguchi et al. 2001). Moreover, a
novel five cysteine defensin, termed Defrl, has been identified and characterised
(Morrison et al. 2002). Antimicrobial activity ofDefrl extends to S. aureus, E. coli,
P. aeruginosa and J2315, the type strain ofB. cenocepacia (Vandamme et al. 2003).
Activity against this highly-resistant isolate (Nzula et al. 2002) is of special interest
since previous reports indicate that "5. cepacia'''' are inherently resistant to AMPs
(Hancock and Chappie 1999).
1.9.4 Mechanism of Killing by Defensins
Interaction between host membranes and the defensin molecules is thought to be
derived from the amphipathic nature of the latter; the positively-charged amino acids
of the defensin molecule interact with the negatively-charged phospholipid residues
of the host membrane. As a result of electrostatic interactions, the defensin
molecules can be drawn towards the membrane and accumulate as a "carpet" on the
membrane surface. At a critical point, the defensin carpet aggregates and inserts into
the membrane, forming a pore and reducing membrane integrity, a-defensins are
known to permeabilise sequentially the outer and inner membranes of E. coli (Lehrer
et al. 1989), although the exact nature ofpore formation is still the subject of debate
(Ganz and Lehrer 1999, Hoover et al. 2000, Sawai et al. 2001).
1.9.5 Defensins: Alternative Functions
Human a-defensins play an important role as innate defence molecules but can also
interact with the acquired immune system. Evidence indicates that a-defensins
stimulate the release of cytokines from airway epithelial cells (Van Wetering et al.
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1997) and from T cells (Lillard et al. 1999), and act as chemoattractants for
immature dendritic and nai've T cells (Yang et al. 2000), monocytes (Territo et al.
1989) and for granulocytes and lymphocytes (Welling et al. 1998).
Human P-defensins have also been shown to be chemoattractants for monocytes
(Garcia et al. 2001), T cells and immature dendritic cells (Yang et al. 1999),
suggesting a link between innate and adaptive immunity. The latter study postulated
that the chemoattractant activity may be due to defensin binding to the chemokine
receptor CCR6 (Yang et al. 1999). Murine-P-defensin-2 has been shown to activate
immature dendritic cells via Toll-like receptor 4 (Biragyn et al. 2002). The authors
found that such binding results in the upregulation of costimulatory molecules and
dendritic cell maturation.
Defensins have also been shown to be active against some enveloped viruses (Daher
et al. 1986, Lehrer et al. 1985). In addition, two recent studies have highlighted the
importance of defensins during HIV-1 infection. Zhang et al. observed that human
a-defensins 1, 2 and 3 are amongst the molecules involved in the antiviral activity
secreted by CD8+ T cells ofHIV-non-progressors (Zhang et al. 2002). Moreover, a
recent report has described the induction of P-defensin expression in human oral
epithelial cells by HIV-1 (Quinones-Mateu et al. 2003). In addition, the authors
observed that HIV-1 replication was inhibited by hBD-2 and -3 through direct
interaction with virions and via modulation of the chemokine receptor CXCR4.
Some defensins can also bind glycoproteins, which may explain their antiviral




The aims of this study were to identify and investigate novel antimicrobial agents
whose activity extended to the Burkholderia cepacia complex and other
multiresistant CF pathogens. The project focused on three major themes: 1. The
antimicrobial activity ofNew Zealand manuka honey, 2. Novel Bcc bacteriophages
and their lytic enzymes and, 3. Novel antimicrobial peptides, in particular,
antimicrobial activity of a novel synthetic defensin, Defr1.
66
CHAPTER TWO MATERIALS AND METHODS
2.1 Materials
2.1.1 Bacterial Isolates
All bacterial isolates were provided by Prof. John Govan from the Edinburgh Cystic
Fibrosis Microbiology Laboratory and Strain Repository (ECFML), and by Prof.
Peter Vandamme of the Belgium National Repository, Gent. Bcc strains used are
listed (Table 2.1). Other bacterial strains used are listed (Table 2.2). Where
appropriate and possible, further information regarding each isolate is provided.
Table 2.1 B. cepacia complex isolates used.
Species Strain Gent Lab No. Description
B. cepacia ATCC 25416 LMG 1222 Onion isolate; type strain
C2970 LMG 17997 Urine; Gent
C3159 LMG 18821 CEP 509; CF; Australia
ATCC 17759 LMG 2161 Soil; Trinidad
B. multivorans C2775 Sputum (CF); Aberdeen
C3161 LMG 13010 CF; Belgium
C3162 LMG 18825 CF-A1-1; CF-e UK
C3163 LMG 18824 CGD; USA
C3164 LMG 18823 249-2, LAB USA
ATCC 17616 LMG 17588 Soil; Canada
C1962 LMG 16665 Cerebral abscess; Aberdeen
C1576 LMG 16660 Sputum (CF); Glasgow; CF-e
C3160 LMG 18822 C5393; CF; Canada
B. cenocepacia J415 LMG 16654 Sputum (CF); Edinburgh;
J2315 LMG 16656 Sputum (CF); Edin; ET12; index case
C1394 LMG 16659 Sputum (CF-e); Manchester
J2956 Sheep Mastitis; Spain
C2836 BC 226 Miss (CF-e); Mississippi
C517 CF, Edinburgh, UK
C3165 LMG 18826 BC7; CF-e; Canada
C3166 LMG 18863 K56-2; CF-e; Canada; ET12
C3167 LMG 18827 C5424; CF-e; Canada
C3168 LMG 18828 C6433; CF-e; Canada
C3169 LMG 18829 PC184; CF-e; USA
C3170 LMG 18830 CEP511; CF-e; Australia
ATCC 17765 LMG 18832 Urinary-tract infection
C1632 Sputum (CF); Newcastle, CF-e
C1773 Blood Culture; Papworth
C1511 Sputum (CF); Manchester
R2817 J2967 (Balandreau et al. 2001)
R2827 J2970 "
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B. stabilis C3171 LMG 14294 CF; Belgium
C3172 LMG 18870 C7322; CF; Canada
C3173 LMG 18888 Clinical; Belgium
C3174 LMG 14086 Respirator; UK
B. vietnamiensis C2978 LMG 16232 CF isolate; sputum
C3175 LMG 18835 PC259; CF USA
C3176 LMG 18836 FC441; CGD Canada
C3177 LMG 10929 Rice; Vietnam
J2962 Sheep Mastitis, Spain
B. dolosa E12
B. ambifaria J2742 LMG 19182 Biological control; AMMD; pea rhizosphere
B anthina J2552 LMG 16670 Soil; Royal botanic gardens; Edin
J2553 RBG; Samseveira leaf; Edin











J2862 Soil; Rhizosphere; Vine plant
C1658 LMG 20982 Environmental; Manchester hospital
C1765 LMG 20983 Sputum (CF); Blackpool
B. pyrrocinnia J2536 Soil; Royal botanic gardens; Edin
J2542 Soil; Royal botanic gardens; Edin














Gnvr Unclassified J2540 LMG 16672 Soil; Royal botanic gardens; Edin
CF-e: Strains involved in epidemic outbreaks. Edin; Edinburgh.
Table 2.2 Other bacterial strains used
Species Strain Description
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Edin: Edinburgh. Glas: Glasgow, WGi 1: Western General Hospital, Edinburgh
2.1.2 Media
Unless otherwise stated all media were provided by Oxoid Ltd., prepared according
to the manufacturer's instructions using distilled water, and sterilised at 121°C at 15
psi for 15 minutes.
Nutrient Agar (NA): Columbia agar base, 39 g/L.
"B. cepacia''' isolation agar (CIA): 32.5 g/L (MAST Diagnostics) plus one selectab
(MAST) per 100 ml of agar. The selectab is added post-autoclaving once the media
has cooled to approximately 50°C. The final antibiotic concentration is 100 jag/ml
ticarcillin and 300 units/ml of polymyxin B.
Blood Agar (BA): Columbia agar base plus 5% defibrinated horse blood added post
autoclaving, once the media has cooled to approximately 50°C.
Pseudomonas Isolation Agar (PIA): 45 g/L (Difco Laboratories, U.S.A) plus 2%
(v/v) glycerol (Sigma-Aldrich, UK) added prior to autoclaving.
Iso-sensitest Agar (ISA): 31.4 g/L.
Iso-sensitest Broth (ISB): 23.4 g/L.
Nutrient Broth Yeast Extract (NBYE): Nutrient broth (No. 2) (25g/L) plus 5%
yeast extract (Difco).
Luria-Bertani (LB) Broth: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v)
NaCl.
LB Agar: 1 x LB broth, 1.5% bacto-agar.
2YT Broth: 1.6% Bacto-tryptone, 1.0% Yeast Extract, 0.5% NaCl, pH 7.5.
SOC Medium: 2% Tryptone, 0.5% Yeast Extract, 0.05% NaCl, pH 7.0.
Soft Overlay Agar: 2.5% (w/v) Nutrient broth (No.2), 0.38% Bacteriological agar.
Tryptone Soy Agar (TSA): 40 g/L.
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Skimmed Milk: Skimmed milk powder 10% (w/v) sterilised at 121°C at 15 psi for 5
minutes.
Phosphate Buffered Saline (PBS): One PBS tablet per 100 ml of distilled water.
Saline: 0.85% sodium chloride (w/v) (Sigma).
Bacteriophage Buffer: lOmM Tris/HCl, pH 8.0; lOmM MgCE.
2.1.3 Chemicals
All chemicals used in the following sections were provided by Sigma-Aldrich, unless
otherwise stated. The details of all the companies used are provided in Appendix 1.
2.2 Bacteriological Methods
2.2.1 Storage and recovery of isolates
Bacteria were stored at -70°C in 1 ml of 10% w/v skimmed milk. Post-thawing, Bcc
isolates were inoculated onto NA and incubated at 37°C. Isolates were subcultured
onto CIA to ensure purity of stored cultures. Similarly, P. aeruginosa isolated were
initially inoculated onto NA and incubated at 37°C. For identification, P.
aeruginosa isolates were also subcultured onto PIA to enhance pigmentation
production. S. aureus, E. coli and Candida isolates were recovered and subcultured
weekly onto BA, grown at 37°C, and stored at 4"C for up to a fortnight. All other
isolates used were inoculated onto NA and grown at 37°C.
2.2.2 Standardisation of Bacterial Cultures
Bacteria were inoculated in 10 ml NBYE and incubated for 18 hours at 37°C in an
orbital incubator. 1 ml of the overnight bacterial suspension was added to 9 ml of
fresh NBYE, incubated at 37°C for a further 4-5 hours, and centrifuged (4,500 x g for
15 minutes). The pellet was resuspended in an appropriate buffer; the optical density
was measured (a=590 nm) and adjusted to 1. The approximate number of bacteria in
the culture was 1 x 108 colony-forming units (cfu)/ ml.
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2.2.3 Antibiotic Sensitivity Testing: Agar Dilution Method
Stock solutions of antibiotics were prepared and stored at concentrations of 1 mg/ml,
100 pg/ml, 10 pg/ml and 1 pg/ml, according to the manufacturer's instructions. The
stock solutions were then added to 20 ml of ISA (cooled to 60°C) to give final
concentrations of doubling dilutions from 0.06 pg/ml to 512 pg/ml. The antibiotics
were mixed gently, and plates were flamed to ensure sterility. A control plate
containing no antibiotic was also prepared.
Bacteria to be investigated were inoculated into 10 ml of ISB and incubated
overnight. The bacteria were then standardised as described (section 2.2.2) to give
approximately 108 cfu/ml. After diluting the bacteria to approximately 107 cfu/ml in
saline, 1 pi of the suspension was inoculated onto the pre-dried antibiotic agar plates
by a multipoint inoculator (Denley, Billingshurst, Sussex), to give a final inoculum
of approximately 104 cfu. The plates were incubated overnight at 37°C before the
MIC was determined. Some species required an additional 18 hours at room
temperature before the MIC could be verified. The MIC was defined as the lowest
concentration at which there was no visible growth. Resistance was defined as an
MIC greater than the BSAC breakpoints for Pseudomonas species (MacGowan and
Wise 2001, Nzula et al. 2002).
2.2.4 Antibiotic Sensitivity Testing: Broth Dilution Method
Bacteria and antibiotic stock solution were prepared as described for the agar dilution
method. Antibiotic stocks were added to 10 ml of ISB to a final concentration of
doubling dilutions between 512 pg/ml and 0.06 pg/ml. 100 pi of the bacterial
suspension was inoculated into broth/antibiotic solution to give a final inoculum of
105 cfu/ml. Tubes were incubated overnight at 37°C in an orbital incubator, prior to
the determination of the MIC. The definition of the MIC was as described
previously.
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2.2.5 Production of Catalase
Bacteria were grown overnight at 37°C on NA. A drop of 3% H2O2 was applied to a
colony and catalase production was assessed semi-quantitatively by production of
bubbles (+/+++).
2.3 Molecular Cloning
Cloning vectors are outlined in Appendix 3.
2.3.1 DNA Digestion with Restriction Endonucleases
Restriction endonucleases (Invitrogen or New England BioLabs) were used in
conjunction with the manufacturers buffers. Digests were normally prepared by 3
hours treatment in a 25-50pl reaction at a temperature suggested by the manufacturer
(usually 37°C).
2.3.2 Polymerase Chain Reaction (PCR)
Standard PCR reactions were typically performed in a 50 pi final volume using 2 x
Ready To Go PCR™ beads (Amersham Biosciences, UK), 1 pi of template DNA, 5
pi of each primer, and 39 pi of dH20. The final concentration ofMgCf in a 50 pi
reaction was 3.0 mM. All PCR primers were purchased from Sigma-Genosys
(Appendix 2), and kept at -20°C in 10 pM stocks. Reactions were overlayed with
mineral oil, and unless otherwise stated all PCR and sequencing reactions were
performed in a Perkin Elmer 480 thermal cycler.
2.3.3 Agarose Gel Electrophoresis
DNA was electrophoresed on gels consisting of 1-1.5% agarose. Gels were cast with
1 x TAE buffer containing 0.5 pg/ml (w/v) ethidium bromide. DNA samples were
mixed with 10 x loading dye, vortexed and loaded onto the gel. Electrophoresis was
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performed at 70 volts in horizontal electrophoresis apparatus containing TAE buffer.
DNA fragments sizes were estimated by comparison to DNA size markers
(HyperMarkers I & IV, Bioline). Following electrophoresis agarose gels were
visualised with a short wave UV transilluminator.
2.3.4 Agarose Gel Extraction of DNA Fragments with a QIAquick Gel
Extraction Kit (QIAGEN)
DNA fragments were extracted according to the manufacturer's instructions. In
brief, DNA fragments were marked in the gel using a sharp scalpel blade under UV-
light, and fully excised under normal room lighting. Depending on the weight of the
fragment (three volumes ofbuffer QG to one volume of gel fragment),
approximately 250 pi ofbuffer QG was added and, ensuring that the fragment was
fully immersed, incubated at 50°C for 10 minutes. During the incubation period the
sample was frequently vortexed to aid dissolving. Once the fragment had fully
dissolved, one gel volume of isopropanol was added and mixed thoroughly by
inverting. The mixture was then added to a QIAquick spin column, and centrifuged
at 15,000 x g for 1 minute. The flow through was discarded and the column-bound
DNA was washed (and centrifuged at 15, 000 x g for 1 minute) once with 500 pi of
buffer QG and once with 750 pi of buffer PE. Prior to the final elution step, the
column was centrifuged at 15,000 x g to ensure complete removal of buffer PE. 25
pi of sterile distilled water was added to the column, and incubated at room
temperature for 1 minute, before centrifugation at 15,000 x g for 1 minute to elute the
DNA. DNA samples were stored at -20°C.
2.3.5 DNA Fragment Ligation
Ligations were performed such that the insert to vector ratio was typically 7:1.
Reactions contained 10% ligase buffer (New England Biolabs, UK), 5% T4 DNA
Ligase (New England Biolabs, UK), and dH20 to a final volume of 20 pi. Ligation
reactions were incubated overnight at room temperature (16-23°C). Ligation
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reactions always incorporated negative controls, including a vector minus insert
control, to determine the contribution ofplasmid re-ligation to transformation
efficiency.
2.3.6 Purification of Plasmid DNA with a QIAprep Spin Miniprep Kit
(QIAGEN)
Plasmid DNA was purified according to the manufacturer's instructions. In brief, a
single transformant was inoculated into 10 ml of 2YT broth containing the
appropriate antibiotic (100 pg/ml of ampicillin or 50 pg/ml of kanamycin), and
incubated overnight at 37°C in an orbital incubator. The bacterial suspension was
centrifuged at 1,500 x g for 10 minutes, the pellet resuspended in 250 pi ofbuffer PI
and transferred to a microfuge tube. 250 pi ofbuffer P2 was added and mixed
thoroughly by inverting several times. 350 pi ofbuffer P3 was added and mixed
carefully, before the mixture was centrifuged at 15,000 xg for 15 minutes. The
supernatant was applied to a QIAprep spin column, and plasmid DNA was bound by
centrifugation at 15,000 x g for 1 minute. The DNA was washed by addition of 500
pi ofbuffer PB (15,000 x g for 1 minute) and 750 pi ofbuffer PE. After an
additional centrifugation step (15,000 x g for 1 minute), plasmid DNA was eluted by
the addition of 50 pi of sterile distilled water. Plasmid DNA was stored at -20°C.
2.3.7 Preparation ofGlycerol Stocks of Transformants
Glycerol stocks were prepared by the addition of 200 pi of sterile 60% glycerol to
800 pi of an overnight bacterial culture. After vortexing, the aliquot was stored at -
70°C. Recovery of the culture was achieved by spreading a loopful of the suspension
onto LB-agar containing the appropriate antibiotic and incubating overnight at 37°C.
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2.3.8 Automated DNA Sequencing
MATERIALS AND METHODS
Automated DNA sequencing was carried out on an ABI prism 377 DNA sequencer,
using the Sanger dideoxy chain termination method. Sequencing reactions were
performed in 0.5 ml PCR tubes with 2 pi of template DNA, 1 pi ofprimer, 13 pi of
dH20, and 4 pi of BigDye™ V. 3.0 (PE Biosystems, UK). Reactions were overlaid
with mineral oil and transferred to a thermal cycler; 95°C for 30 seconds, 54°C for 15
seconds and 72°C for 4 minutes, repeated for 30 cycles.
2.3.9 Cloning of PCR Products
PCR products containing restriction endonuclease sites at their 5' end were digested
with the appropriate restriction endonuclease prior to cloning into the desired vector.
However, ifno such sites were present, PCR products were cloned using a PCR 2.1-
TOPO TA cloning kit, (Invitrogen) (Appendix 3). Cloning reactions contained a lpl
aliquot of the PCR 2.1 vector, lpl of 200 mM NaCl and 3pl ofPCR product. The
mixture was mixed and incubated at room temperature for 30 minutes prior to
transformation ofOne Shot TOP 10 chemically competent E. coli (Invitrogen, UK).
2.3.10 Transformation of One Shot TOP10 Chemically Competent E. coli
One Shot chemically competent cells (Invitrogen, UK) were transformed according
to the manufacturer's instructions. Briefly, a 25 pi aliquot of competent cells was
thawed on ice, prior to the addition of 2 pi of the TOPO cloning reaction. The
sample was incubated on ice for 30 minutes, before heat shocking for 30 seconds at
42°C. The sample was then immediately incubated on ice for 2 minutes, after which
250 pi of SOC medium was added. The sample was incubated in an orbital
incubator for 1 hour at 37°C, spread onto an LB-ampicillin agar plate, and incubated
overnight at 37°C. Colonies were picked and analysed further by miniprep and
restriction endonuclease digestion.
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2.4 Protein Expression and Purification
2.4.1 Transformation of Chemically Competent E. coli (DH5a,HMS174, BL21
(DE3) & BL21 (PlysS) Novagen) with Vector DNA
The chemically competent cells were transformed according to the manufacturer's
instructions. Briefly, a 25 pi aliquot of competent cells was thawed on ice, prior to
the addition of 2 pi of expression plasmid containing the gene of interest. After
incubation on ice for 5 minutes, the sample was placed at 42°C for 30 seconds, and
immediately re-incubated on ice for 2 minutes prior to the addition of 250 pi of SOC
medium. The sample was incubated in an orbital incubator for 1 hour at 37°C. The
mix was spread onto an LB-agar plate containing the appropriate antibiotic and
incubated overnight at 37°C. Single colonies were used to inoculate fresh broth to
achieve overexpression of the gene.
2.4.2 Protein Over Expression
Overexpression was achieved by transforming chemically competent E. coli with the
desired expression plasmid containing the gene of choice. A single colony was used
to inoculate 500 ml of2YT broth supplemented with the appropriate antibiotic
(ampicillin 100 pg/ml; kanamycin 50 pg/ml) and grown overnight at 37°C, in an
orbital incubator (140 revs/min). This seed culture was then used to inoculate 5 litres
of2YT supplemented with the appropriate antibiotic, and grown at 37°C to OD = 1
(l=600nm) before induction with 10 mM isopropyl thio-P-D-galactoside (IPTG).
After a further 3 hours the cells were harvested by centrifugation (4000 x g for 15
minutes at 4°C) and washed in binding buffer (20 mM Tris/HCl, pH 7.5, 0.5 M
NaCl, 5 mM imidazole). The cells were resuspended in binding buffer (5 ml per
gram ofwet cell paste) and disrupted by sonication (15 pulses of 30 seconds at 30-
second intervals) at 4°C. The cell debris was removed by centrifugation at 27, 000 x
g for 20 minutes at 4°C, after which the supernatant was filtered through a 0.45 pm
membrane (Millipore, USA) prior to chromatography.
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2.4.3 Protein Purification
The filtered cell lysate was applied to a Hitrap® chelating affinity column
(Amersham Biosciences, UK) previously washed with 5 column volumes of dFEO,
loaded with 3 column volumes of charge buffer (100 mM NiSCL) and equilibrated
with binding buffer at room temperature. The column was then washed with 5
column volumes ofbinding buffer before bound material was eluted using a linear
gradient of 0-100% elution buffer (20 mM Tris/HCl, pH 7.5, 0.5 M NaCl, 1 M
imidazole). Fractions were analysed by SDS/PAGE.
2.4.4 Purification of Periplasmic Proteins
Periplasmic proteins were purified by a modification of the method by Berish et al.
(1992). Briefly, the cell pellet was resuspended in 50 ml of 1 M Tris (pH 8.0). 50
ml of 2% CTAB was prepared and stirred at 37°C until dissolved. After mixing, the
solution was slowly stirred overnight at 37°C. The white insoluble material was
removed by centrifugation (10,000 x g for 15 minutes at 4°C). The supernatant (cell-
free extract) was incubated overnight at 4°C to ensure that all the CTAB had
precipitated. After diluting to a final voume of 1 litre, the cell-free extract was
filtered using Whatman number 4 paper (Fischer). The cell free extract was applied
to a RESOURCE®S cation exchange column (Amersham Biosciences, UK) and
connected to a Fast Protein Liquid Chromatography (FPLC) system, washed to the
manufacturer's instructions, and equilibrated with 10 mM Tris buffer (pH 8.0). The
cell free extract was loaded onto the column at a flow rate of 4 ml/min. Unbound
protein was removed by extensive washing with low salt buffer. Proteins were
eluted with a linear NaCl gradient of low-to-high salt (0-1 M NaCl over 20 column
volumes in 10 mM Tris buffer). Fractions were collected and analysed by SDS-
PAGE.
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2.4.5 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
25 pi of each fraction was mixed with 25 pi of SDS Loading buffer, vortexed, and
boiled for 10 minutes in a 70°C water bath. 20 pi of each sample was then loaded
onto a 12% Nu-PAGE Bis/Tris gel (Invitrogen, UK). A low molecular weight
standard was also loaded. The gel was run in vertical electrophoresis apparatus
containing Nu-PAGE MES running buffer for 35 minutes at 200 volts, and stained
with comassie blue.
2.4.6 Mass Spectrometry
Mass spectrometry was performed on a MicroMass Platform II quadruple mass
spectrometer equipped with an electrospray ion source, under the supervision ofMr
Nick Tomczyk, School ofChemistry, University of Edinburgh. In brief, the
spectrometer cone voltage was ramped from 40 to 70 volts and the source
temperature was set to 140°C. Protein samples were separated with a Waters High
Performance Liquid Chromatography (HPLC) 2690 with a Phenomenex C5 reverse
phase column directly connected to the spectrometer. The proteins were eluted from
the column with a 5-95% acetonitrile (containing 0.01% trifluoroacetic acid) gradient
at a flow rate of 0.4 ml/min. The total ion count in the range of 500-2000 m/z was
scanned at 0.1 second intervals. The scans were accumulated and spectra combined
and the molecular mass determined by the Maxent and Transform algorithms of the
Mass Lynx software (MicroMass).
2.4.7 Sequence Analysis and Bioinformatics
DNA sequence analysis was performed using Vector NTI 6 software (Informax), and
BLASTn (http://www.ncbi.nlm.nih.gov:80/BLAST). In addition, protein sequence
analysis was performed using Vector NTI 6 software (Informax), BLASTp
(http://www.ncbi.nlm.nih.gov:80/BLAST) and www.expasy.com .
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2.5 Antimicrobial Activity of Honey
2.5.1 Preparation of Honey Samples
New Zealand manuka honey (NZMh) (Comvita, New Zealand) with an antibacterial
equivalent of 4% carbolic acid, an alternative NZMh (with a UMF level of 10), and a
traditional Scottish honey (Tweedside) were diluted to a final concentration range of
5-50% (v/v) with dH20. Samples were autoclaved and centrifuged at 3200 x g for 20
mins to remove debris. The supernatant was then passed through a 0.2 pm
membrane (Millipore). A sample of each solution was examined for potential
anaerobic organisms by inoculating an egg yolk agar plate (Oxoid), which had been
pre-reduced for 24 hours, and incubated anaerobically for 24-48 hours at 37°C. An
artificial honey solution (40.5% fructose, 33.5% glucose, 7.5% maltose, 1.5%
sucrose) was prepared as described previously (Wahdan.1998).
2.5.2 Antimicrobial Activity ofHoney
Test bacteria were grown to mid-logarithmic phase in ISB (Oxoid, UK) and then
diluted to 2xl06 cfu/ml. 100 pi of bacteria was added to 1 ml of test honey and the
minimum inhibitory concentration (MIC), based on turbidity, was assessed after
overnight incubation at 37°C. The minimum bactericidal concentration (MBC) was
determined by inoculating 100 pi of each non-turbid honey dilution onto ISA. The
MIC and MBC were deemed to be the first dilutions in which there was no turbidity
and no growth.
2.5.3 Killing Rate of Honey
To determine the rate ofbacterial killing by honey, the experiment described
previously was modified. Briefly, 10 ml of honey (33% v/v) was inoculated with 1
ml of 106 cfu/ml bacteria and incubated at 37°C for 24 hours. At 30-minute time
points, 100 pi was removed, serially diluted onto NA and bacterial viability
examined after incubation at 37°C for 18 hours.
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2.5.4 Effects of Catalase, Light, and pH on the Antimicrobial Effect of Honey
The assay described in section 2.5.2 was repeated with the following modification.
To determine the effect ofH2O2 on bacterial killing, catalase was added to the
reaction at a final concentration equivalent to ten times the estimated concentration
ofH2O2 (NZMh contains approximately 45 mM ofH2O2). To assess the effect of
light on antibacterial activity, honey samples were exposed to 24 hours of direct
sunlight prior to use. The pH of honey samples ranged from 3.6 to 4.5, this was
neutralised with 1 M NaOH prior to use.
2.5.5 Time-Lapse Light Microscopy
Test bacteria (106 log phase) were inoculated into 10 ml of a 33% (v/v) honey
solution and viewed under an inverted microscope (Olympus: 1X70) and recorded
using time-lapse video equipment. The morphological changes were monitored for
24 hours at room temperature.
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25/05/2001 +++B. cenocepacia
Nebuliser: Honey was nebulised using both a Ventstream nebuliser with
mouthpiece at a flow rate 71/min (air), and a sidestream
nebuliser.
Dose: Honey was administered at 33% (v/v) and 25% (v/v) with 35%
(02).
2.6 Bacteriophage Assays
Control bacteriophages used are listed (Table 2.3).
Table 2.3 Control Bacteriophage (Holloway and Krishnapillai 1975, Nzula etal. 2000)
BacteriophageHost Propagating Strain
E79 P. aeruginosa PA01
D3 P. aeruginosa PA01
F116L P. aeruginosa PA01
NS1 B. vietnamiensis ATCC 29424
NS2 B. multivorans ATCC 17616
2.6.1 Isolation of New Lysogenic Bacteriophages for the Bee
Temperate phage were identified and maintained as described (Nzula et al. 2000).
Lysogenised bacteria were investigated using the following method: 20 strains of the
Bee were prepared as saline suspensions (approximately 106 cfu ml"1), inoculated
onto TSA (Oxoid, UK) using a multipoint inoculator and incubated at 30°C for 6
hours. Bacterial growth was inverted over chloroform vapour for 15 minutes and
allowed to air-dry for 15 minutes. Soft agar overlays (2.5 ml), inoculated with 100
pi log-phase culture of each of the 20 strains, were layered over the original bacterial
growth and the plates incubated overnight at 37°C. Phage plaques, identified in the
overlay in the proximity of the original inoculum were used to prepare single-plaque
preparations as follows: an agar plug containing a single phage plaque was removed
using a sterile glass pipette, transferred to 10 ml phage buffer, vortexed for 30
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seconds, centrifuged at 3000 x g for 30 minutes and filtered (pore size 0.2 pm;
Millipore)
2.6.2 Isolation of Environmental Bacteriophages
Twenty samples of soil, river sediment and rhizosphere (soil plus root material) were
collected and the presence ofphage investigated using a modification of the phage
enrichment technique described previously (Weiss et al. 1994). Briefly,
approximately 10 g sample was suspended in 15 ml LB broth and dispersed by
shaking in an orbital incubator (140 rev/min) for 30 minutes at 30°C. After removal
of soil particles by centrifugation (4000 x g for 20 minutes), the supernatant was
filter-sterilized (pore size 0.2 pm; Millipore) and 1 ml aliquots added to 15 sterile
tubes. To each tube, was added 25 pi of exponential-phase cultures from one of 15
potential propagating strains chosen to represent genomovars I-V of the Bcc strain
panel (Mahenthiralingam et al. 2000b), and the contents incubated at 37°C overnight.
Bacterial cells were removed by centrifugation (4000 x g for 30 minutes), the
supernatant was membrane-filtered as before and 10 pi filtrate was spotted onto
lawns of the propagating strain. Phage plaques were identified after overnight
incubation at 37°C, and single-plaque stocks were prepared as described in section
2.6.1.
2.6.3 High-Titre Bacteriophage Preparations
High-titre phage preparations were prepared as follows: 100 pi single-plaque
preparation, containing approximately 105 pfu ml"1, was added to 2.5 ml soft nutrient
agar, previously seeded with 100 pi exponential-phase culture of the propagating
strain. The mixture was then overlaid on NA and allowed to set. After 18 hours at
37°C, overlays showing semi-confluent lysis were harvested into 10 ml phage buffer.
The lysate was vortexed and centrifuged at 3200 x g for 30 minutes and the
supernatant membrane-filtered. Phage titres were determined, as pfu ml"1, by
incorporating 100 pi host bacteria (exponential-phase NBYE culture) and 100 pi
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phage stock in 2.5 ml soft agar overlay, and counting lytic plaques after an 18 hour
incubation at 37°C. Stock preparations were maintained at 4°C.
2.6.4 Host Range of Bacteriophages
Stock phage preparations were diluted in phage buffer to approximately 108 pfu/ml
against the propagating strain, and 10 pi was spotted onto lawns (prepared from
exponential-phase NBYE cultures) of potential host bacteria. Lytic activity was
recorded after 24 hours at 37°C on a scale ranging from <10 plaques (+) to confluent
lysis (+++). In addition to a panel of 66 Bcc strains, 55 other strains were
investigated: P. aeruginosa (n=30); S. maltophilia (n=12); B. caledonica (n=l); B.
gladioli (n=2); Comamonas acidovorans (n=l); P. fluorescens (n=3); P. mendocina
(n=l); P. stutzeri (n=2); P. putida (n=l); P. testosteroni (n=l); P. syringae pv. tabaci
(n=l); R. pickettii (n=2).
2.6.5 Electron microscopy
Stock phage preparations (approximately 108 pfu ml"1) were centrifuged at 3,200 x g
to remove cell debris, and then at 100, 000 x g for 1 hour. Phage pellets were
resuspended in 1 M ammonium acetate, negatively stained with 2% (w/v) potassium
phosphotungstate solution (pH 7.0), and phage morphology examined with a Hitachi
model HU-12A transmission electron microscope.
2.6.6 Bacteriophage DNA Extraction and RFLP Profiling
In preparation for DNA extraction, high-titre phage stocks (containing at least 1010
pfu ml"1) were prepared using soft agar overlays, as described previously. DNA was
extracted from 10 ml phage stock using the Wizard Lambda preparation DNA
purification system in conjunction with the Vac-Man laboratory vacuum manifold
(Promega, UK). Briefly, 40 ul of nuclease mix was added to 10 ml ofphage lysate
and after incubation at 37°C for 15 minutes, 4 ml of phage precipitant was added and
the reaction was placed on ice for 30 minutes. The reaction was centrifuged (10,000
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x g for 10 minutes) and the pellet resuspended in 500 pi of phage buffer. Insoluble
particles were removed by centrifugation (10, 000 x g for 10 seconds), the
supernatant transferred to a clean microcentrifuge tube, 1 ml ofpurification resin was
added and thoroughly mixed. A Wizard® minicolumn was prepared and attached to
the vacuum manifold. The phage resin/lysate mix was applied to the syringe barrel
and a vacuum applied to draw the mix into the minicolumn. The column was
washed by adding 80% isopropanol and applying a vacuum to draw the solution
through the minicolumn. The vacuum was applied for a further 30 seconds after the
solution was removed to dry the resin. The syringe barrel was removed and the
minicolumn was transferred to a 1.5 ml microcentrifuge tube. Residual isopropanol
was removed by centrifugation (10, 000 x g for 2 minutes). The minicolumn was
transferred to a clean microcentrifuge tube, 100 pi of preheated (80°C) water was
applied, and the column centrifuged (10, 000 x g for 20 seconds). Extracted DNA
was eluted in sterile distilled water and stored at -20°C. DNA quality was assessed
on a pre-cast 0.8% agarose gel "E-gel" (Invitrogen, UK). In cases where DNA was
not pure enough for DNA restriction, purification was performed using the PCR
protocol from the QIAquick gel extraction kit (Qiagen, UK). In brief, 5 volumes of
buffer PB were added to 1 volume of DNA. The mix was transferred to a QIAquick
spin column and DNA was bound by centrifugation (15,000 x g for 1 minute). 750
pi of buffer PE was added to the spin column. After centrifugation (15,000 x g for 1
minute), the flow through was discarded and the column was centrifuged as before.
The spin filter was transferred to a clean microcentrifuge tube and purified DNA was
eluted in 30 pi of distilled water by centrifugation (15,000 x g for 1 minute).
Purified DNA was stored at -20°C. To determine genome size and to confirm that
the phages were different from one another, approximately 1 pg DNA was restricted
using 10 U HindUl (Promega, UK), incubated for 3 hours at 37°C and visualized on
0.3% TBE agarose gel alongside 1 pi Ready-Load Lambda DNA///z>zi/III fragments
(Invitrogen, UK).
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2.6.7 Alternative Method for Bacteriophage DNA Extraction
The alternative method is based on a protocol described by Sambrook et al. (1989).
Phages were prepared by infecting the host bacteria at high multiplicity. Briefly, 50
ml of bacteria were grown in NBYE overnight at 37°C in an orbital incubator (140
rev/min), prior to inoculating 4 x 500 ml ofNYBE. The bacterial cultures were
incubated for 3-4 hours before stock phages with 1010 plaque forming units (pfu)
were added (1:100). The culture was incubated for a further 3-5 hours, with vigorous
shaking, until lysis was visible. 10 ml of chloroform was added to each flask, and
incubated for a further 10 minutes at 37°C. Flasks were cooled to room temperature,
prior to the addition ofDnase I and Rnase, each to a final concentration of 1 pg/ml.
The reaction was incubated at room temperature for 30 minutes. NaCl was added
and dissolved to give a final concentration of 1 M, and incubated on ice for 1 hour.
Solid polyethylene glycol (PEG 8000) was added to a final concentration of 10%
(w/v). PEG was dissolved by stirring at room temperature then transferred to ice
water for approximately 1 hour to allow the precipitation of phage particles. Phage
particles were recovered by centrifugation at 11,000 x g for 10 minutes at 4°C.
Supernatants were discarded, and the pellet was resuspended in bacteriophage buffer
(8 ml for each 500 ml flask). PEG and bacterial cell debris was removed by adding
an equal volume of chloroform and vortexing for 30 seconds. The organic and
aqueous phases were separated by centrifugation at 3000 x g for 15 minutes at 4°C,
and latter retained. The aqueous phase was subjected to centrifugation (25, 000 rpm
for 2 hours at 4°C), and the supernatant discarded. The pellet was resuspended in 1-2
ml of phage buffer and incubated at 4°C overnight. Proteinase K (final concentration
of 50 pg/ml) and SDS (final concentration 0.5% w/v) were added, mixed and
incubated at 56°C for 1 hour. The digestion mix was cooled to room temperature,
prior to the addition ofphenol equilibrated with 50 mM Tris (pH 8.0). An emulsion
was formed by invert mixing, and separated into separate phases by centrifugation
(3000 x g for 5 minutes at room temperature). The aqueous phase was removed and
extracted with 50:50 mix of equilibrated phenol and chloroform. The aqueous phase
was recovered as before, and extracted with an equal volume of chloroform. Sodium
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acetate (to a final concentration of 0.3 M: pH 7.0) was added to the aqueous phase
and mixed thoroughly prior to the addition of 2 volumes of ethanol. The solution
was mixed and incubated at room temperature for 30 minutes. Thread-like DNA
precipitate was transferred, using a Pasteur pipette, to a DNA microfuge tube
containing 1 ml of 70% ethanol. DNA was recovered by centrifugation (12, 000 x g
for 2 minutes, at 4°C). The supernatant was removed and the DNA pellet allowed to
dry at room temperature. The DNA was dissolved in 250 pi of dTpO and stored at -
20°C. DNA was quantified on a 0.6% agarose gel.
2.6.8 Beep 781 Endolysin: Recursive (Gene Assembly) PCR
The Beep 781 bacteriophage genome was analysed and the hypothetical endolysin
gene was identified (Accession Number/Locus: NP_705653 [255 amino acids]; gene:
ORF25). The gene assembly technique was based on the Recursive PCR protocol as
described (Prodromou and Pearl 1992). Twenty-two oligonucleotides representing a
synthetic Beep 781 endolysin were synthesised (Sigma-Genosys) (Appendix 2). The
oligonucleotides were 37-46 bp long with overlapping regions of 7-15 bp in length.
Subsequent insertion of the synthesized gene into an expression vector was
facilitated by the incorporation, in the outermost oligonucleotides, of an Ncol site at
the 5' end and a BamHl site at the 3' end of the final gene. The recursive PCR (30
cycles of 2 minutes at 95°C, 2 minutes at 56°C and 1 minute at 72°C, with a final 10
minutes at 72°C) was performed in a Techgene (Techne) thermal cycler. The
reaction contained 20-30 pmol of the outermost 5' oligonucleotides of each strand, 2-
3 pmol of the internal primers, 10 pi of 10 x Herculase buffer, 5 units ofHerculase®
polymerase (Stratagene), 4 pi ofDimethyl-sulfoxide (DMSO), 4 pi of 100 pM of
each dinucleotide triphosphates (dNTPs: dATP, dCTP, dGTP, dTTP), and dH20
added to a final volume of 100 pi. The product was subjected to agarose gel
electrophoresis and DNA extracted from the gel as described previously. The
purified PCR product (10 pi) was then subjected to another round of recursive PCR,
using only the outermost oligonucleotides. After agarose gel electrophoresis,
extracted DNA was cloned into PCR 2.1 as described previously, and the integrity of
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the sequence was determined by automated sequencing. Mutations and mis-base
pairing was corrected using the standard PCR protocol, and a mega primer PCR
reaction using primer-pair specific temperatures (lysin fix primers outlined in
Appendix 2). hi brief, an internal primer with the fix sequence was coupled with the
reverse outermost primer in a PCR reaction using the standard protocol and the
original template DNA. The PCR product was purified using gel electrophoresis and
the product used as a reverse primer coupled with the forward outermost primer and
the initial template DNA. After purification, the product was cloned into PCR 2.1
and the integrity of the sequence assessed. Once the template sequence was correct,
the PCR product was cloned into an expression vector.
2.6.9 Bacteriophage D3 Endolysin Cloning
Bacteriophage DNA was extracted as described previously. Endolysin specific
primers were identified from the sequenced genome (ORF 31: 160 amino acids)
(Kropinski 2000), and synthesized with a 5' Ncol site and a 3' BamHl site to aid
latter cloning steps (Sigma-Genosys) (Appendix 2). The PCR reaction combined; 5
pi of both forward and reverse D3 lysin primers (Appendix 2), 5 pi ofD3 template
DNA, 5 pi of 10 x Herculase buffer, 5 units ofHerculase® polymerase (Stratagene),
2 pi ofDimethyl-sulfoxide (DMSO), 2 pi of 100 pM of each dinucleotide
triphosphates (dNTPs: dATP, dCTP, dGTP, dTTP), and dH20 added to a final
volume of 50 pi for 30 cycles (95°C for 1 minute, 56°C for 1 minutes and 72°C for 1
minute). The PCR product was extracted from an agarose gel, and used as the
template for a second round ofPCR (95°C for 1 minute, 56°C for 1 minutes and 72°C
for 45 seconds). The PCR product was then cloned into PCR 2.1 and subjected to
automated sequencing. Mutations were corrected using the Mega-primer PCR
protocol outlined previously. Once the template sequence was correct, the PCR
product was cloned into an expression vector.
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2.6.10 Antibacterial Activity of Bacteriophage Endolysins
The in vitro activity of the phage lysins was determined as outlined by (Schuch et al.
2002). 1 ml of log-phase bacteria were treated with lysin and plated after 3 hours
onto ISA, incubated overnight at 37°C at which time bacteria were enumerated.
2.6.11 Expression of a Bacteriophage Endolysin in a Bacterial Overlay
E. coli transformants containing an expression plasmid/bacteriophage lysin gene
were spread onto ISA containing the appropriate antibiotic and fPTG (final
concentration 1 mM) and grown overnight at 37°C. Control plates with E. coli
transformants containing the vector minus the lysin insert were also prepared.
Bacterial growth was inverted over chloroform vapour for 15 minutes and then
allowed to air-dry for 15 minutes. Soft agar overlays (2.5 ml), inoculated with 100
pi exponential-phase culture of the propagating bacteria were layered over the
original bacterial growth and allowed to set. Evidence of lysis was assessed after
overnight incubation at 37°C.
2.7 Cationic Antimicrobial Peptide (CAMP) Assays
Experiments involving CAMPs were carried out in collaboration with Mr David
Clarke, School of Chemistry, University of Edinburgh.
2.7.1 Preparation of peptide
The synthetic peptides (Albachem, Edinburgh) were lyophilised (in 250 pg aliquots)
and kept at -70°C. Prior to use, the peptide was dissolved in 250 pi of 0.01% acetic
acid to give a stock solution with a final concentration of 1 mg/ml. The peptide
preparations were held at 4°C during use and after which were stored at -70°C.
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2.7.2 Antimicrobial activity of CAMPs
Test bacteria were grown to mid-log phase in ISB (Oxoid) and then diluted to 2xl06
cfu/ml in 10 mM sodium phosphate containing 1% (v/v) ISB, pH 7.4. The bacterial
samples were washed three times in buffer to ensure removal of salt. Varying
concentrations of test peptide (peptide range 1.5 pg/ml to 100 pg/ml) were incubated
in 100 pi of the bacterial suspension at 37°C for 1 or 3 hours. 10-fold serial dilutions
of the incubation mixture were plated on ISA plates, incubated at 37°C, and the
number of cfu determined the following day. The MIC of the peptide was the
concentration required to fully inhibit bacterial growth. All assays were repeated at
least three times and experimental errors found generally to be within one doubling
dilution. Dose-response curves were determined from surviving cfu.
2.7.3 Salt Sensitivity of CAMP
The salt sensitivity of the CAMP was determined as follows. The assay was
conducted as described previously, but after the final washing step the bacteria were
resuspended in 10 mM sodium phosphate (1% v/v ISB, pH 7.4) containing varying
concentrations ofNaCl (range 25 mM to 300 mM).
2.7.4 Inhibition of Antimicrobial Activity with LPS
Briefly, peptide (final concentration equivalent to 4 x the MIC) was incubated with
varying concentrations of LPS (range 3.15 pg/ml to 200 pg/ml) from E. coli (Sigma-
Aldrich, UK), B. cenocepacia J2315 and P. aeruginosa PAOl for 1 hour at 37°C.
Bacterial suspensions were added as before and inhibition ascertained after overnight
incubation at 37°C.
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2.7.5 Inhibition of Antimicrobial Activity with Lipoteichoic Acid
The inhibition of antimicrobial activity by lipoteichoic acid (Sigma-Aldrich, UK)
from S. aureus was determined as described (section 2.7.4). In this case, LPS was
replaced with varying concentrations of lipoteichoic acid (range 1.5 pg/ml to 100
pg/ml).
2.7.6 Phase-Contrast Microscopy
At 30 minute intervals during the bacterial inhibition assay, a sample was observed
under phase contrast microscopy (Olympus, UK) and morphological changes in
bacteria observed.
2.7.7 Radial Diffusion Assay
This antimicrobial assay was performed using a well-established radial diffusion
method described by (Cole and Ganz 2000, Lehrer et al. 1991, Yount and Yeaman
2004). Test bacteria were grown to log-phase and diluted to a final concentration of
n
10 cfu/ml. 1 ml ofbacterial suspension was added to 9 ml of ISA, vortex mixed and
poured into a Petri-dish. The agar was allowed to set prior to the formation of 5 mm
holes by an Ouchterlony punch, to which 5 pi of test peptide was added (peptide
concentration range 0.5 pg/ml- 25 pg/ml). The plates were incubated at 37°C for 3
hours, before 10 ml of soft agar was overlayed, dried and incubated overnight at
37°C after which time the zone of killing was determined.
2.7.8 Time-Kill Assay
The assay described in section 2.7.2 was used but the reaction was carried out in a
200 pi volume with a final peptide concentration of 25 pg/ml. At 30 minute
intervals 10 pi of suspension was removed and serially diluted onto ISA. This
procedure was repeated for 3 hours. After the plates were incubated overnight at
37°C, bacterial viability was assessed and the cfu/ml determined.
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2.8 Statistical Analysis
Statistical analysis was carried out using Graphpad Prism software (Graphpad). A P
value of <0.05 was taken to indicate significance.
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Appendix 1. Commercial suppliers of reagents and equipment
Albachem UK, Ltd., Elvinston Science Centre, East Lothian, EH33 1EH, UK.
www,albachem.co.uk
Amersham Biosciences UK, Ltd., Amersham Place, Little Chalfont,
Buckinghamshire, HP7 9NA, UK. www.amershambiosciences.com
Bio-Rad Laboratories Ltd., Bio-Rad House, Maylands Avenue, Hemel Hempstead,
Hertfordshire, HP2 7TD, UK. www.bio-rad.com
Comvita, Bay of Plenty, New Zealand, www.comvita.com
Difco Laboratories, Detroit, Michigan, U.S.A. www.bd.com
Graphpad, San Diego, CA. www.graphpad.com
Invitrogen, Ltd., 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RE,
UK. www.invitrogen.com
MAST Diagnostics, Bootle, Merseyside, UK. www.mastgrp.com
Millipore, 80 Ashby Road, Bedford, Massachusetts, USA. www.millipore.com
New England Biolabs (UK) Ltd., 73 Rnowl Piece, Wilbury Way, Hitchin,
Hertordshire, SG4 OTY, UK. www.neb.com
Olympus UK Ltd., 2-8 Honduras Street, London EC1Y OTX, UK.
www.olympus.co.uk
Oxoid Ltd., Basingstoke, Hampshire, UK. www.oxoid.com
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PE Biosystems, Warrington, England, UK. www.appliedbiosystems.com
Promega UK, Ltd., Delta House, Chilworth Research Centre, Southampton, SO 16
7NS, UK. www.promega.com
Roche Diagnostics Ltd., Bell Lane, Lewes, East Sussex, BN7 1LG, UK.
www.roche.com
QIAGEN Ltd., Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX,
UK. www.qiagen.com
Sigma-Aldrich Ltd., Dorset, UK. www.sigmaaldrich.com
Sigma-Genosys, www.sigma-genosys.eu.com
Stratagene Europe, Gebouw California, Hogehilweg 15, 1101 CB Amsterdam,
Zuidoost, The Netherlands, www.stratagene.com
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Appendix 2. Oligonucleotides utilised during this study
























1 (For) AACTTGACGTGATGGTGCGC 68.5
2 (Rev) GCGCACCATCACGTCAAGTT 68.5
3 (For) CGAGCGCGCGCAACTTGACGTG 80.3
4 (For) CGAGCGCGCGCAACTTGACGTT 78.6
5 (Rev) TGCGGCAGCGCGAAGCGCACCATC 86.1
6 (For) CAACTTGACGTTATGGTTCGTTTCGCTCTG 74.8
D3 Lysin
1 (For) CCCATGGCAGTTGTTTCCGA 70.2
2 (Rev) GGATCCTCACGACAGCACCCCGCCCGCTGCAAG 89.7
D3 Lysin Fix
1 (Rev) GGATCCGTGGGGCGGGCGTCGATCA 86 0
_
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Appendix 3. Cloning vectors utilised in this study
tacZuMQ
M1 j P-micr \ Kpnl
Sac i tor*!. f
1 ' l
CAS CM AGA OCT AT& AC C ATG ATT ACS CCA AGC TIG OTA CCG AOG ICS GAT CCA OTA
err r-r? tot rn* Tt>r rr, ri T&r taa t<jc nryr aat pat nrr- 4177 rr& #77- qat
OTA A06 GCC GCC ACT GTG C?G GftA TTC GOC TTpfJpff
CAT TOC COG 030 TCA CAC OAC CTT AAO CCO •
Awi»
PwR7i
Faftv R',fxi mi xfe>i m\xt*\
AGA TAT CCA TCA CAC TOG 030 CCO CTC m CAT OCA,' 7CT AOA 000 OCC AAT TCQfOCC TAT
TCT ATA 03T AST CJTG ACC COS OCC CAC CTC GTA COT ATA TCT CCC 000 TTA AX |<X£ ATA
♦
a*#*!
JA QCC GAA TTC 7X
r r coo err wd acq
4,Ml
TT Pflyy^ IH3 f-JC'i Ptfrner
MS «& T08 TAT WiCMT tO CIS ®C GTC SIT ttA C Aft CST CGT SAC TUB OA AAC
\, ira rtr. ata .mirtta /,r.-r /af. ras ftuft caa i./,x rjTT «c* ft-A «m Aft": r.rt rr«
Vector pCR 2.1. Vector pCR 2.1, 3928bp in size, was obtained from
Invitrogen.
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pET Plasmids were obtained from Novagen.
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3.1 Aims
The aim of this section was to determine or confirm the antibiotic susceptibilities of a
panel ofBcc isolates derived from environmental and clinical sources. The extent of
resistance within some Bcc species has been recently investigated (Nzula et al.
2002), and concordance of this study was sought prior to examination of novel
therapies.
3.2 Results: Sensitivity Testing
The antibiotic susceptibility profiles ofBcc species have been previously
investigated to some degree (Lewin et al. 1993, Nzula et al. 2002, Pitt et al. 1996).
In the present study, susceptibility of a representative panel of Bcc strains was
determined by the agar dilution method. MIC values are presented in Table 3.1.
Sensitivity of the Bcc panel to the antibiotics investigated varied within and between
species. Strikingly, all Bcc species examined were resistant to polymyxin B (MICs >
512 pg/ml). No strains examined were sensitive to tobramycin; MICs ranged from 4
to 256 pg/ml. MICs of ceftazidime ranged from 0.12 to 256 pg/ml, with 81% (n=
39) of the isolates examined sensitive. Similarly, 85.4% (n= 41) of the strains
investigated were sensitive to meropenem, although the MIC range varied from
<0.06 to 8 pg/ml. Sensitivity to ciprofloxacin was moderate, with 64.6% (n= 31) of
the strains sensitive, and a MIC range of 0.12 to 128 pg/ml. Only a few Bcc strains
were sensitive to chloramphenicol (12.5%, n= 6) and trimethoprim (6.3%, n= 3),
with MICs between 4 to 128 pg/ml and 0.25 to 64 pg/ml respectively. These
findings indicate that meropenem, ceftazidime and ciprofloxacin exhibit the most
activity against members of the Bcc.
Clinical Bcc isolates (shown in black) were significantly more resistant to the
antibiotics studied than environmental Bcc isolates (shown in red) (P= 0.0001).
Resistance between Bcc species varied (Fig 3.1), but all Bcc strains examined were
resistant to at least 40% of the 7 antibiotics tested.
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Ofparticular interest are the epidemic strains CI 576 (fi. multivorans; Glasgow
epidemic) and J2315 (fi. cenocepacia; Edinburgh epidemic, ET-12). Both exhibit
high-level (100%) resistance to all of the conventional antibiotics examined, in
contrast to non-epidemic clinical isolates that show variable resistance.
3.3 Results: Multi-Resistance of.fi. cenocepacia
When attention was focussed on fi. cenocepacia, resistance was less in
environmental isolates than in clinical isolates (Table 3.2). The mean percentage
resistance is 67.83 (Standard Deviation, SD± 14.3) and 51.9 (SD± 7.215) for clinical
and environmental strains respectively. Clinical isolates of fi. cenocepacia are also
significantlymore resistant to the antibiotics examined than environmental isolates
(P = 0.0023). However, the data also indicate that resistance is strain dependant,
irrespective of origin. Interestingly, 100% of environmental fi. cenocepacia isolates
(n= 11) were sensitive to the ciprofloxacin and meropenem. In contrast, clinical
isolates show 50% (n=8) sensitivity to ciprofloxacin, with 81.3% sensitive to
meropenem.
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Table 3.1 MICs of conventional antibiotics against members of the Bcc
Species Strain Description Ceftaz Chlor Cipro Trimeth Tobra Poly Mero
B. cepacia ATCC 25416 Onion isolate 4 16 4 2 64 >512 1
C2970 Urine; Gent 2 8 2 2 16 >512 2
C3159 CF; Australia 8 16 4 4 128 >512 1
ATCC 17759 Soil, Trinidad 4 8 0.12 4 32 >512 1
B. multivorans C3161 CF; Belgium 2 32 2 2 16 >512 4
C3162 CF-e UK 4 16 4 4 64 >512 1
C3163 CGD; USA 4 16 2 2 64 >512 0.5
C3164 LAB USA 2 8 0.12 0.5 16 >512 4
ATCC 17616 Soil; Canada 4 8 0.5 2 32 >512 4
C1962 Cerebral abscess 1 8 8 4 32 >512 0.5
C1576 CF; Glasgow 256 32 16 4 64 >512 8
C3160 CF; Canada 8 128 4 32 32 >512 1
B. cenocepacia J415 CF; Edinburgh 4 64 2 4 64 >512 0.5
J2315 CF; ET12 16 32 8 32 256 >512 8
C1394 CF; Manchester 1 16 2 64 128 >512 0.12
C3165 CF; Canada 2 16 0.12 0.25 8 >512 8
C3166 CF; Canada 4 16 4 32 128 >512 1
C3167 CF; Canada 2 8 0.12 0.25 8 >512 16
C3168 CF; Canada 2 16 32 32 32 >512 1
C3169 CF; USA 0.12 4 16 0.5 8 >512 0.5
C3170 CF; Australia 2 16 32 32 128 >512 2
ATCC 17765 Urinary-tract 4 16 2 4 32 >512 1
C1632 CF; Newcastle 8 32 16 8 64 >512 0.5
C1773 Blood Culture 32 8 64 1 32 512 0.5
C1511 CF; Manchester 4 32 8 32 32 >512 2
C2374 CF; Edinburgh 8 16 128 32 64 >512 0.5
R2817 Env; Philippines 2 4 0.25 1 4 >512 0.25
R2827 Env; Philippines 4 16 0.25 16 16 >512 0.5
R8351 Env; Philippines 1 8 0.25 1 8 >512 0.25
R8571 Env; Philippines 4 4 0.25 4 8 >512 0.25
R8574 Env; Philippines 4 8 0.25 1 16 >512 0.5
R8580 Env; Philippines 4 8 0.25 1 16 >512 0.5
R8605 Env; Philippines 4 16 0.25 1 16 >512 0.5
R9239 Env; Philippines 2 8 0.25 1 8 >512 0.5
R9243 Env; Philippines 2 8 0.25 4 8 >512 0.5
R9235 Env; Philippines 2 8 0.25 1 16 >512 0.5
R9342 Env; Philippines 2 8 0.25 2 16 >512 0.5
B. stabilis C3171 CF; Belgium 8 4 64 32 8 >512 <0.06
C3172 CF; Canada 2 16 4 32 64 >512 0.5
C3173 Clinical; Belgium 2 16 0.12 0.25 8 >512 <0.06
C3174 Respirator; UK 8 16 0.12 2 8 >512 1
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B. vietnamiensis C2978 CF isolate 2 8 1 4 16 >512 0.25
Species Strain Description Ceftaz Chlor Cipro Trimeth Tobra Poly Mero
B. vietnamiensis C3175 CF USA 2 8 0.12 32 16 >512 0.5
C3176 CGD Canada 2 8 0.12 2 16 >512 0.12
C3177 Rice; Vietnam 2 4 0.12 32 16 >512 0.25
B. ambifaria J2742 AMMD 0.5 8 0.25 0.5 4 >512 1
B anthina J2552 Soil; RBG; Edin 1 8 1 1 8 512 1
Gnvr Unclass J2540 Soil; RBG; Edin 0.12 4 0.25 0.5 8 >512 <0.06
P. aeruginosa NCTC 10662 Antibio Contol 2 128 0.5 32 0.12 1 1
Break Point
Values 8 8 4 0.5 4 4 4
Ceftz, ceftazidime; Chlor, chloramphenicol; Cipro, ciprofloxacin; Trimeth, Trimethoprim;
Tobra, tobramycin ; Poly, polymyxin; Mero, meropenem. Gnvr unclass, genomovar/species
unclassified. Antibio control, antibiotic control P. aeruginosa NCTC 10662. RBG Edin, Royal
botanical gardens, Edinburgh. Environmental (Env) isolates are highlighted in red. Clinical


















Fig 3.1 The resistance of the S. cepacia complex to antibiotics, ine figure shows the
percentage antibiotic resistance of each isolate, of each species, within the Bcc.
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Table 3.2 Antibiotic Resistance in B. cenocepacia
CF/Non CF/ ENV Ceftaz Chlor Cipro Trimeth Tobra Poly Mero % Resistance
C3165 S R S S R R R 57.1
C3170 S R R R R R S 71.4
C1394 S R S R R R S 57.1
C3167 S R S S R R R 57.1
C3168 S R R R R R S 71.4
C3166 S R R R R R S 57.1
C3169 S S R R R R S 57.1
J415 S R S R R R S 57.1
C517 S R S R R R S 57.1
C1335 S R S R R R S 57.1
J2315 R R R R R R R 100
C2374 R R R R R R S 85.7
C1632 R R R R R R S 85.7
C1511 S R R R R R S 71.4
C1773 R R R R R R S 85.7
ATCC17765 S R S R R R S 57.1
R2817 S S S R R R S 42.8
R2827 S R s R R R S 57.1
R8351 S R s R R R S 57.1
R8571 S S s R R R s 42.8
R8574 S R s R R R s 42.8
R8580 S R s R R R s 57.1
R8805 S R 3 R R R 3 57.1
R9239 s R S R R R S 42.8
R9243 s R S R R R S 57.1
R9235 s R S R R R s 57.1
R9342 s R S R R R s 57.1
Break Point 8 8 4 0.5 4 4 4
CF isolates are shown in black. Non-CF clinical isolates are shown in blue. Environmental
isolates are shown in red. Ceftz, ceftazidime; Chlor, chloramphenicol; Cipro, ciprofloxacin;
Trimeth, Trimethoprim; Tobra, tobramycin ; Poly, polymyxin B; Mero, meropenem. %
Resistance is defined as the number of antibiotics each strain is resistant to (based on the
MIC breakpoint) in relation to the number of antibiotics used (n=7). R; Resistance, S;
Sensitive.
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3.4 Discussion:
"5. cepacia" is often described as a pan-resistant organism. This is not supported by
these data, which demonstrate considerable variation in resistance between and
within Bcc species. As with some other bacterial pathogens, the concept of
describing the antibiotic sensitivity of an individual species in general terms is of
little use in the case of the Bcc.
With few exceptions, the data obtained with this extended Bcc panel correlated with
the findings ofNzula et al. (2002). The data support the hypothesis that the grouping
of species into antibiograms does not provide relevant information on individual-
strain resistance profiles. Thus, clinical relevance of conventional antibiotic therapy
can only be established if individual strains are examined to determine the full extent
of their resistance. The variation within species may result in less effective therapy,
and antibiotics that are successful against one strain may be ineffective against
another isolate of the same species and from the same environment.
B. cenocepacia is arguably the most important Bcc species in CF lung disease. The
observation that clinical isolates ofB. cenocepacia tended to be more resistant than
environmental isolates could be explained by prior exposure to antibiotics.
Investigation of a greater number of environmental isolates from B. cenocepacia and
other Bcc species is necessary to confirm this trend. Unfortunately, environmental
examples ofBcc species are not readily available. In particular, despite the
significant prevalence ofB. multivorans amongst CF isolates, this species is seldom
identified in natural environments.
Despite the well-established clonality of three B. cenocepacia isolates (ET-12
isolates; C3165, C3166 and J2315), the MIC data and extent of resistance against
individual antibiotics varied. The data highlight two important facts recently
confirmed in outbreaks ofP. aeruginosa infections (Jones et al. 2002). First, when
cross-infection is suspected or investigated routinely, antibiograms are an unreliable
marker of clonality. Antibiograms are useful, however, in monitoring resistance
patterns within clinics. Second, variability in MIC data for individual strains and
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antibiotics emphasises the need to base therapy on individual isolates (Hobson et al.
1995, Pitt et al. 1996). This is strikingly evident for the most active agent
meropenem (C3165 and J2315: MIC 8 jag/ml; C3166: MIC 1 pg/ml).
Only two Bcc strains investigated were resistant to all antibiotics; CI 576, a Glasgow
epidemic strain, and J2315, the Edinburgh representative of the ET-12 lineage. Both
epidemic strains highlight the characteristics most feared of the Bcc: high virulence,
transmissibility and multi-resistance. Interestingly, the high resistance of the
Edinburgh isolate was noted and commented on in one of the earliest antibiotic
studies (Lewin et al. 1993) which predated its epidemic spread and the clinical use of
meropenem.
A major caveat in current definitions of antibiotic resistance is the reliance on MIC
breakpoints. At present, breakpoints are based on a concentration of antibiotic that
can be achieved by intra venous (IV) administration, and that has been shown to
inhibit bacterial growth. Thus, breakpoints may not be relevant to infections at
specific sites, such as the lung. In CF, antibiotics may be delivered to the lung by
aerosol, a process that may achieve a concentration of the drug approximately 1000-
fold higher than IV. In such cases as CF, present definitions of resistance are
probably unreliable and need redefined. To compound these difficulties, clinical
improvement and bacterial reduction in sputum is rarely observed in the treatment of
Bcc infections (Isles et al. 1984). Furthermore, this study has demonstrated that all
the Bcc isolates are resistant to at least 40% of the 7 most relevant antibiotics
investigated emphasising the need for novel and effective therapeutic agents against
the Bcc.
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4.1 Aims
As the results from Chapter three indicate, many Bcc isolates exhibit extensive
resistance to multiple groups of antibiotics fulfilling the criteria to be termed
multiresistant b acteria. T hese d ata also emphasize that novel antimicrobial agents
are required to provide therapeutic options against life-threatening Bcc infections.
Plant products, including honey, are traditional remedies which have created
renewed interest as broad spectrum antimicrobial agents (Cooper et al. 1999a, Somal
et al. 1994) and as a wound dressings (Van der Weyden 2003). Significantly, this
antimicrobial activity has been shown to extend to multiresistant pathogens (Karayil
1998). The aim of this section was to investigate the antimicrobial activity of NZMh
against Bcc and other problematic CF pathogens.
4.2 Results: Antibacterial Activity of Honey
The potential antibacterial activity ofNZMh was investigated against a panel ofBcc
isolates chosen to represent a variety of clinical isolates, plus epidemic and
biopesticide strains. Two strains were included from a recent outbreak of untreatable
ovine mastitis. NZMh was sterilised as described and the absence of anaerobic
organisms confirmed. The MIC and MBC were determined for each strain (Table
4.1). MICs ranged from 9 to 17% (v/v), and MBCs from 9 to 20% (v/v). Catalase
production was determined for each strain used. All Bcc strains produced catalase
with the exception ofATCC 25416, C3159 and C3175. To investigate the spectrum
of activity against multiresistant strains, a selection of such strains were selected and
tested for susceptibility to 33% (v/v) NZMh. The panel of resistant bacteria included
S. aureus (n= 3), Acinetobacter baumannii (n= 5), E. coli (n= 3), Klebsiella
pneumoniae (n= 3), Enterococcus faecium (n= 3), E.faecalis (n= 3) and S.
maltophilia (n =1). Interestingly, all strains were completely inhibited by the
concentration ofNZMh used, with the exception of one strain ofE. faecium, which
produced a small number of CFUs post-exposure to NZMh. Inoculation of these
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surviving colonies in 33 % (v/v) NZMh resulted in confluent growth, consistent with
resistance.
4.3 Results: Killing Curves
Log phase bacteria were challenged with 33% (v/v) NZMh (approximately 3 x MIC)
and monitored for growth for 24 hours. Kill curves for NZMh against: P. aeruginosa
PAOl, E. coli ATCC 25922, B. cenocepacia J2315 and B. cepacia ATCC 25416, are
shown in Fig 4.1. Experiments were carried out in triplicate and repeated twice. The
kill curves show that bacterial killing becomes obvious at 5 hours, with 100% killing
achieved by 24 hours. After 24 hours exposure all strains showed 100% killing with
the exception ofE. coli. No E. coli was recovered after 36 hours.
4.4 Results: Antibacterial Components ofHoney
The antibacterial components of honey have been discussed in detail and include:
osmolarity, H2O2, pH and phytochemicals (Molan 1992a, 1992b, 1995). For the
purpose of the present study each of these putative killing agents was assessed and its
importance determined.
Log-phase cultures of bacterial strains outlined in Table 4.1 were inoculated into
100% artificial honey, which comprised high concentrations of sugars with low
water content. All strains showed growth in 100% artificial honey suggesting that
osmolarity is not solely responsible for the antibacterial activity of honey.
The importance ofH2O2 in the antibacterial activity ofboth NZMh and Scottish
honey (NH) was determined by attempting to remove all traces of both H2O2 and the
H2O2 generating enzyme glucose oxidase. Diluting honey, to a concentration of 33%
(v/v) has been shown to increase H2O2. Thus it was important to ensure that this
phenomenon did not affect the antibacterial activity (Bang et al. 2003). Prior to the
assay, all honey preparations were autoclaved to destroy glucose oxidase, and
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catalase was added to neutralise any H2C>2 present. The data suggest that H2O2 is
important in the antibacterial activity ofNH. All strains were killed by a 33%
solution, however, killing was inhibited on the addition of catalase (Table 4.2). In
contrast, catalase did not affect the antibacterial activity ofNZMh against J2315,
PAOl and NCTC 10662. Interestingly, however, ATCC 25416 was able to grow in
33% NZMh in the presence of catalase. Catalase production did not seem to
correlate with resistance to NZMh; C1576 and ATCC 25416 exhibit different levels
of catalase production but shared identical NZMh MICs (Table 4.1). Exposure to 24
hours of sunlight did not alter killing potential of either honey sample. Light has
been previously reported to reduce the antibacterial effect of honey; this was not
observed in this study (Table 4.3). Likewise, neutralisation ofpH did not alter
antibacterial activity (Table 4.3)
Various components of honey were extracted using organic solvents and high
performance liquid chromatography (HPLC). Disappointingly, however, individual
fractions did not exert antibacterial activity (data not shown) and thus further
investigation was discontinued.
4.5 Results: Time-Lapse Phase Contrast Microscopy
Bacteria were observed for 24 hours under phase contrast microscopy in the presence
ofNZMh at room temperature and in NBYE. Initially, no obvious morphological
changes, such as blebbing or filamentation, were observed. However, motility was
disrupted and ceased within 6 hours. At 24 hours few intact cells remained and the
preparation had been reduced to bacterial debris. In contrast, control cells cultured in
NBYE remained intact and motile at 24 hours incubation.
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Table 4.1 Catalase production and sensitivity of the Bcc and P. aeruginosa isolates to NZMh
(% v/v)
Strain Catalase MIC for NZMh (% v/v) MBC for NZMh (% v/v)
J 2315f +++ 10 11
J 2962f + 11 12.5
J 2742f ++ 11 12.5
J 2956t +/- 12.5 14
C 3159f - 12.5 14
C3173f +/- 11 12.5
C 3175f - 10 12.5
C1576f +++ 17 20
ATCC 25416f - 17 17
PA01* +++ 9 10
NCTC 10662* +++ 12.5 14
Catalase production was scored according to severity of reaction with H202 with +++; high,
++; intermediate, +; low, +/-; very low & no production. fBcc Strains; *P. aeruginosa
strains.
Table 4.2 The effects of catalase on the antibacterial activity of honey
Strain NZMh NH NBYE NZMh + C NH + C NBYE + C
ATCC 25416f - - +++ +++ +++ +++
J2315f - +++ - ++ +++
PA01* - +++ - + +++
NCTC 10662* - - +++ - ++ +++
NZMh, 33% (v/v) New Zealand manuka honey; NH, 33% (v/v) Scottish honey; NBYE,
nutrient broth-yeast extract; C, catalase. +++, 500-1000 colonies; ++, 200-500 colonies; + 5-
200 colonies; -, no growth. fBcc Strains; *P. aeruginosa strains.
Table 4.3 The effects of light and neutral pH on the antibacterial activity of honey
Strain NZMh +JL NH + L NZMh (pH 7) NH (pH 7) NBYE (control)
ATCC 25416t - . +++
J 2315f - - - +++
PA01* - - - . +++
NCTC 10662* - : - - +++
NZMh, 33% (v/v) New Zealand manuka honey; NH, 33% (v/v) Scottish honey; NBYE,
nutrient broth-yeast extract. L, exposure to 24 hours of sunlight prior to use. +++, 500-1000
colonies; ++, 200-500 colonies; + 5-200 colonies; -, no growth. fBcc Strains; *P. aeruginosa
strains.
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Fig 4.1 Killing Curves. Bactericidal activity of NZMh against: A, P. aeruginosa
PA01; B, E. coli ATCC 25922; C, B. cenocepacia J2315; D, B. cepacia ATCC
25416. Bacterial cultures were grown to log-phase and inoculated into honey
preparations (33% v/v). At time points; designated samples were removed and
CFUs determined. Whole lines and closed symbols represent control growth in
NBYE. Dotted lines and open symbols represent viability in 33% NZMh.
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4.6 Results: In vivo Use of NZMh in a CF Patient
A patient infected with the multiresistant, virulent and transmissible B. cenocepacia
ET-12 lineage was admitted with a respiratory exacerbation. Since the patient had
shown little response to conventional antibiotic therapy it was decided to administer
NZMh as a last resort.
The initial dose was 4 ml of 33% (v/v) NZMh, nebulised using a ventstream
nebuliser and mouthpiece. This is a breath-enhanced nebuliser with a one-valve
system and is commonly used for nebulised antibiotics. Despite concomitant
administration of bronchodilators, the patient's spirometry fell and he felt short of
breath. In addition, the NZMh appeared to be crystallising on the respiratory filter of
the nebuliser (Fig 4.3). The second dose ofNZMh was at a reduced concentration
(25% v/v) and was administered using a sidestream nebuliser (4 ml, once daily).
This valveless system reduces the labour of breathing for the patient. On this
occasion, the patient reported feeling fine, and no oxygen desaturation was noted. At
this point, it was decided to continue with a dose of 25% (v/v) although the
mechanism of nebulisation was modified. NZMh was delivered via a mouthpiece as
before, but the mouthpiece was inserted into a mask to allow the simultaneous
administration of 35% oxygen. After three doses it became apparent that the patient
had to work particularly hard to inhale the NZMh, in contrast to the relative ease at
which antibiotics, Dnase and bronchodilators were tolerated. However, the latter
mechanism of administration appeared to be the most comfortable and the patient
was willing to double the daily dose. The patient's temperature appeared to stabilise
from day 9 (Fig 4.2), and thus NZMh therapy was continued for a further five days.
NZMh appeared to have little effect on sputum production and oxygen saturation
(Table 4.4). After several days significant oxygen desaturation was observed (even
with the administration of oxygen) and all therapies were stopped. The patient died
comfortably three days later.
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Fig 4.2 Temperature variation in CF patient being treated with NZMh. The error bars denote
the range of temperatures noted at daily time points. * denotes the start of NZMh
nebulisation.
Table 4.4 Patient details post admission to hospital
Days Post Admission Honey Concentration (% w/v) Sputum (g/d) Oxygen Saturation (%)
6 0 175 95
7 0 265 93
8 33 100 93
9 25 194 91
10 25 200 93
11 25 199 93
12 25 87 90
13 25 138 96
14 25 175 NM
15 25 109 NM
Oxygen saturation highlighted in red denotes use of air, blue denoted use of oxygen, g/d;
grams/day. NM: not measured.
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A
Fig 4.3 Honey crystal formation on respiratory filter during nebulisation.
The arrows indicate the honey crystals. A, respiratory filter with crystallised honey residue;
B, respiratory filter x 10.
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4.7 Discussion
These data demonstrate the broad antimicrobial spectrum ofNZMh, which covers
Gram-positive and Gram-negative bacteria and individual isolates exhibiting
multiresistance to conventional antibiotics. This activity has considerable
implications for therapy as multiresistant infections become more widespread. It is
interesting to note that resistance to conventional antibiotics does not confer
resistance to NZMh. Indeed, B. cenocepacia J2315, arguably the most resistant
member of the Bcc to conventional antibiotics, was amongst the most sensitive
strains to NZMh. In contrast, the B. multivorans epidemic strain CI576 and B.
cepacia type strain ATCC 25416 were the most resistant to NZMh. These data
suggest that conventional resistance mechanisms, including MDR efflux systems, do
not play a significant role in resistance to NZMh. This hypothesis is supported by
the fact that although resistance was observed, it is a rare event. Resistance ofE.
faecium strain was observed and appeared to be stable. Inherent resistance was not
identified in other Enterococci spp., and so does not appear to be widespread even in
this species.
The antibacterial components of honey have been well studied, but no definitive
antibacterial factor has been identified. Weston et al. (2000) discounted the effects
of osmolarity, pH and phytochemicals, and stated that activity was due solely to
H2O2. In some respect, the data presented in this thesis support these findings. The
effect of osmolarity was reduced by autoclaving, and removing much of the
caramelised sugars from honey samples. A control artificial honey had little effect
on bacterial growth. Likewise, neutralising the pH did not affect the killing potential
of honey. However, the role ofH2O2 is more complex. For example, the data show
that resistance does not correlate with high level of bacterial catalase production.
Furthermore, glucose oxidase is sensitive to heat, thus autoclaving will destroy the
enzyme. Cumulatively, addition of catalase and the destruction of glucose oxidase
did not inhibit the antibacterial activity ofNZMh against B. cenocepacia .12315, P.
aeruginosa PAOl and NCTC 10662. In contrast, NH was unable to exert
bactericidal activity. This finding suggests that either H2O2 levels are higher in
NZMh than in NH and therefore the treatments did not reduce it significantly, or that
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important factor in NH samples. Furthermore, the retention of antimicrobial activity
after autoclaving offers a safe alternative to the use of gamma irradiation in
sterilisation of honey preparations for therapeutic purposes (Molan and Allen 1996).
HPLC was unable to provide a suitable candidate for the "UMF" as antibacterial
activity was not observed for individual fractions. Since no antibacterial activity was
noted in any of the 20 fractions attempts to isolate an antimicrobial factor in this way
were discontinued. Other extensive investigations described in the literature have
attempted to elucidate the unique antibacterial factor in honey by a number of
chemical techniques. To date, no study has provided a definitive antibacterial factor
(Mato et al. 2003, Suarez-Luque et al. 2002, Suarez-Luque et al. 2002).
From the data presented in this thesis, it appears that the antibacterial activity of
NZMh involves a complex synergism between H2O2 and plant derived chemicals.
This is supported to some extent by batch variation- a fundamental problem in
studies of the antibacterial activity ofNZMh is batch-to-batch variation. Despite
attempts to over come this problem, clinical efficacy may be difficult to predict.
Explanations for variation in potency include flower source, season of harvest and
the position of the hive in the farm (Molan 1992b). Certain NZMhs are marketed as
having standardised potency: this was not supported by the data in this thesis.
The use ofNZMh in an in vivo model was a unique opportunity to contribute to the
treatment of a CF patient. The patient presented with a respiratory exacerbation and
late stage "cepacia-syndrome" was suspected. Response to conventional treatments
was also minimal. Although the patient eventually succumbed to B. cenocepacia
infection, valuable lessons can be learned from this compassionate use ofNZMh,
including optimal dose and drug delivery
Interestingly, the patient showed an improvement during treatment with honey in
combination with antibiotics and bronchodilators, including reduction in pyrexia.
Honey has been shown to exert effects on the immune system and influence cytokine
levels (Abuharfeil et al. 1999, Tonks et al. 2001). Therefore, it has been speculated
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that NZMh may have a positive clinical effect by reducing the inflammatory
response, and hence fever.
The patient was at end stage disease, pre-organisation of treatment was minimal, and
valuable data including sputum microbiology and inflammatorymarkers were not
observable. Earlier intervention may have prompted a more significant improvement
and allowed more in-depth pre-planning and analysis before initiation of therapy.
Nevertheless, the study was challenging and provided a unique insight into the
application of a novel therapy in a clinical setting.
During this study, a paper was published reporting the susceptibility ofmultiresistant
strains of "B. cepacia" to honey (Cooper et al. 2000). Despite reporting significant
sensitivity among 20 "B. cepacia'" strains isolated from CF sputa, the authors failed
to take account of the diversity and strain variation within the Bee. No distinction
was made between individual Bee genomovars or strains. The authors also failed to
mention possible clonality between the clinical isolates used. Thus, although the
study was encouraging, it is difficult to draw any firm conclusions. Cooper et al.
(2000) also compared data from a previous publication (Cooper and Molan 1999b)
and concluded that "B. cepacia" was more sensitive to honey than P. aeruginosa.
Unfortunately, the authors fail to take in account batch variation of honey samples.
The potential use of a honey as a therapeutic agent in CF can be considered to be
two-fold. Not only are CF-associated bacteria, including multiresistant epidemic
strains, sensitive to the antibacterial activity ofhoney but also high osmotic solutions
may alter local physiological conditions within the upper airway. It is hypothesised
that in CF airways, isotonic hyperabsorption of ASL, in the absence ofCFTR, results
in diminished ASL volume, low mucus transport and mucus plug accumulation to
which bacteria can adhere (Boucher 1999, Matsui et al. 1998). An alternative
hypothesis suggests that an increase in salt concentration in ASL inhibits
antimicrobial defensins resulting in defective bacterial killing (Goldman et al. 1997,
Smith et al. 1996). In either case, osmolytes which would draw water into the
airway lumen may offer an alternative therapy (Tarran et al. 2001). The use of
hyperosmotic agents has recently been reviewed (Hirsh 2002). Several studies have
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highlighted the potential use of non-ionic osmolytes. The carbohydrate, mannitol, is
an osmotic agent that has been used to increase mucociliary clearance in several
respiratory conditions including: asthma (Daviskas et al. 1997), bronchiectasis
(Daviskas et al. 1999, Daviskas et al. 2001), mucociliary dysfunction (Daviskas et al.
2002) and CF (Robinson et al. 1999). Administered as a dry powder, mannitol is
well tolerated and appears to be as effective as hypertonic saline (HS) (Robinson et
al. 1997). Mannitol may also be retained in the lung for longer as it is less permeable
than Na+ and CI" (Yankaskas et al. 1987). The therapeutic use ofHS is disputed and
appears to be less effective than recombinant human deoxyribonuclease (rhDNase)
(Suri et al. 2001). Furthermore, HS is ionic and may inhibit the action of salt-
sensitive defensins. Interestingly, although use ofmannitol in CF improved
mucociliary clearance, the authors observed a fall in forced expiratory volume in one
second (FEVi) immediately after administration of both HS and mannitol despite
premedication with a bronchodilator. Data presented in this thesis also highlighted a
fall in FEVi during and after administration ofNZMh. Mucociliary clearance may
be assisted by the fact that mannitol has been shown to stimulate mucus secretion in
an in vivo animal model (Kishioka et al. 2003). Alternatively, amiloride, which
blocks uptake of salt and water across the airway epithelium, has been used as a
strategy to enhance the degree of hydration and dilute the composition ofCF ASL
(Tomkiewicz et al. 1993). A five-carbon sugar, xylitol, has been shown to have low
transepithelial permeability, be poorlymetabolised by bacteria, lower the
concentration of salt in CF ASL, and increase the volume ofASL (Zabner et al.
2000). The main problem of aerosolised osmolyte therapy concerns the difficult in
achieving a uniform distribution of aerosol, particularly in the lung periphery
(Daviskas et al. 1999).
Irrespective of the outcome of the pathophysiological debate that surrounds CFTR
and the CF lung, the use of honey and osmolytes may have therapeutic benefits
(Zabner et al. 2000). A potential osmolyte would require five important
characteristics. First, it must be non-ionic. Second, the compound must have low
transepithelial permeability. Third, the osmolyte must not be readily metabolised by
bacteria. Fourth, the compound must well-tolerated in humans. Fifth, because
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defensins kill rapidly, the osmolyte does not have to be retained in the lung for long
periods as transient exposure may reduce salt significantly. Interesting, honey in
general and NZMh in particular, fulfils these criteria providing a high osmolar
solution capable of rehydrating the airway with broad-spectrum antibacterial activity.
In future, NZMh may prove to be an important therapeutic agent either individually
or in combination with conventional therapies.
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5.1 Aims
The aim of this study was to investigate the bacteriophages of the Bee, in terms of
lysogeny and the presence of lytic phages in natural environments. Bcc phages have
received little attention, although lysogeny had been reported previously (Cihlar et
al. 1978, Matsumoto et al. 1986, Nzula et al. 2000). Lytic Bcc phages, from soil and
the plant rhizosphere, had not been described previously. The aim was to isolate a
panel ofBcc phages and determine their host range against the Bcc, Burkholderia
and Pseudomonas species.
A further aim was to clone, recombinantly express, purify, characterise and
determine the antibacterial activity of an endolysin from the Bcc bacteriophage
(Bcep781), and from the P. aeruginosa serotype converting phage D3, using DNA
sequence data from the published genomes.
The work in the next three sections was carried out in collaboration with Dr Dervla
Kenna (Medical Microbiology, University of Edinburgh).
5.2 Results: Lysogeny Within the B. cepacia Complex
Of the 21 Bcc strains that were investigated, 10 strains (B. cepacia: ATCC 25416,
ATCC 17759; B. multivorans: C3161, C1576, C1962 and C3163; B. cenocepacia:
J2315, C3166, and C3170; B. stabilis: C3174) were found to be lysogenized. These
provided 14 temperate phages (DK1-4 and MM1-10) (Table 5.1). The P. aeruginosa
temperate bacteriophages D3 and F116L were used as turbid plaque positive
controls. Polylysogeny was noted for four strains J2315, J673, J675 and C3170.
5.3 Results: Isolation of Environmental Bacteriophage
Samples were collected from a variety of natural environments, and retained at room
temperature until they could be investigated further. Five virulent phages (JB1, JB3,
JB5, RLlc and RL2) were isolated from soils and from the rhizosphere of various
plants. Most positive samples included decayed plant material collected from moist
environments, but phages were also isolated from dry soils.
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5.4 Results: Host Range of B. cepacia Complex Bacteriophage
The host range of the newly-isolated phages identified in both the lysogeny
experiments and the environmental screen was determined. Individual phages were
tested against a preliminary host panel comprising the 21 Bcc isolates used in the
lysogeny screen. This information was then used in conjunction with Hindlll RFLP
profiles of each phage to confirm that distinct phages were accumulated. The RFLP
profiles also provided approximate genome sizes (Table 5.2). If two or more shared
the same host range, or RFLP pattern, only one was used for further study. An
exception was made for phages RLlc and RLlt, which shared the same host range
and RFLP pattern but produced different plaque morphologies: clear plaques in the
case of the virulent phage (RLlc) and turbid plaques in the case of the RLlt (Fig 5.1
& Table 5.2). Interestingly, a similar host range and RFLP profile was observed for
both temperate phages DK2 and DK3, which had been isolated from B. cenocepacia
C3166 and B. stabilis C3174 respectively. As previously observed for other "5.
cepacia''' phage, none of the newly identified phages were inactivated by treatment
with the organic solvent chloroform.
The host range of phages NS1, NS2 (Nzula et al. 2000) and eight novel phages (JB1,
JB3, JB5, DK1, DK3, RLlc, RLlt and RL2) was determined against an enlarged
bacterial host panel comprising 66 Bcc isolates and 55 isolates representing other
pseudomonads. The Bcc host panel included examples of each Bcc species,
however, only 1 strain ofB. dolosa and B. ambifaria was available for study.
Additionally, in collaboration with Dr Ty Pitt (Health Protection Agency, Colindale,
London, UK), the Bcc phages were tested against 40 B. pseudomallei strains.
The host range of individual phages included multiple Bcc species (Table 5.3).
Interestingly, no phage activity was detected against the single representatives ofB.
dolosa and B. ambifaria. However, within each Bcc species, there was wide
variation in susceptibility to an individual phage. The following paragraph describes
the species and number of strains within a species fnat acted as hosts for each phage.
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Phage JB1: B. cepacia (n=l); B. cenocepacia (n=3); B. stabilis (n=l); B.
vietnamiensis (n=l); B. anthina (n=3); B. pyrrocinia (n=6); B. ubonensis (n=l).
Phage JB3: B. multivorans (n=l); B. cenocepacia (n=2); B. anthina (n=2); B.
pyrrocinia (n=l); B. ubonensis (n=l). Phage JB5: B. cepacia (n=l); B. cenocepacia
(n=4); B. vietnamiensis (n=2); B. anthina (n=3); B. pyrrocinia (n=5). Phage DK1: B.
multivorans (n=l); B. cenocepacia (n=3); B. vietnamiensis (n=l); B. pyrrocinia
(n=l). Phage DK3: B. cepacia (n=l); B. multivorans (n=l); B. cenocepacia (n=3);
B. stabilis (n=l); B. vietnamiensis (n=l). Phage NS1: B. cepacia (n=l); B.
multivorans (n=l); B. cenocepacia (n=4); B. stabilis (n=l); B. vietnamiensis (n=l);
B. anthina (n=2); B. pyrrocinia (n=2); Genomovar unclassified (n=l). Phage NS2:
B. cepacia (n=l); B. multivorans (n=l); B. cenocepacia (n=9); B. vietnamiensis
(n=2); Genomovar unclassified (n=l). Phages RLlc/RLlt: B. cepacia (n=l); B.
multivorans (n=l); B. cenocepacia (n=2); B. stabilis (n=l); B. vietnamiensis (n=2);
B. anthina (n=l). Phage RL2: B. cenocepacia (n=6); B. vietnamiensis (n=l); B.
anthina (n=2); B. pyrrocinia (n=4); B. ubonensis (n=l).
Amongst the Bcc species used as potential hosts B. multivorans appeared to be least
susceptible to the phages investigated: of the nine B. multivorans strains examined,
only strain C2775 showed susceptibility. As has been previously observed for
phages NS1 and NS2, the host range of some phages was not restricted to the Bcc.
P. aeruginosa strains CI546 and J2852 were susceptible to phage JB3, and B.
gladioli strain C3654 was susceptible to phages NS2, DK1, RLlc/RLlt and JB5.
Interestingly, NS2 was found to be the only phage active against B. cenocepacia
J2315. NS2 was also active against 13 of the 40 B. pseudomallei strains tested. All
other pseudomonads investigated were not able to act as hosts for Bcc phages.
Although there may be species bias with respect to environmental and clinical
isolates investigated, there does not appear to be a significant correlation between the
environment of isolation and bacteriophage sensitivity.
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Table 5.1 Lysogenic Bcc and their associated bacteriophage
Species Lysogenic Bcc Strain Temperate Phage
B. cepacia ATCC 17759/J675 MM1
B. multivorans C3161 MM2
B. cenocepacia C3170 MM3
B. cepacia ATCC 25416/J673 MM4
B. multivorans C3163 MM5
B. cenocepacia C3170 MM6
B. cepacia ATCC 17759/J675 MM7
B. cenocepacia J2315 MM8
B. multivorans C1576 MM9
B. multivorans C1962 MM10
B. cepacia ATCC 25416/J673 DK 1
B. cenocepacia C3166 DK2
B. stabilis C3174 DK 3
B. cenocepacia J2315 DK4
Polylysogenic strains are indicated in red
Table 5.2 Bacteriophage genome size, plaque morphology and source
Phage Phage genome size (bp) Source Plaque Morphology
JB1 40,000 Soil, The Caribbean. Turbid Plaques, variable size
(0.5-1 mm in diameter)
JB3 34, 000 Plant rhizosphere, U.K. Clear Plaques (1 mm in
diameter)
JB5 40,000 Plant rhizosphere, U.K. Turbid Plaques, variable size
(0.5-1 mm in diameter)
DK1 45,900 Lysogeny Turbid Plaques, variable size
(0.5-1 mm in diameter)
DK2/DK3 25,800 Lysogeny Turbid Plaques (1 mm in
diameter)
NS1 48,000* Lysogeny Turbid Plaques, variable size
(0.5-1 mm in diameter)
NS2 48,000* Lysogeny Semi-clear plaques, variable
size (0.5-1 mm in diameter)
RL1c/RL1t 44,300 Plant rhizosphere, U.K. RL1c, clear, lytic plaques (1
mm in diameter) RL1t, turbid
plaques (1 mm in diameter)
RL2 40,000 Pond sediment, U.K. Semi-clear plaques, variable
size (0.5-1 mm in diameter)
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Table 5.3 Host range of bacteriophages within the B. cepacia complex
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C3176§ + -
C31775 + .+ + + ..+ +
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E12
+ - +..+ + +
+
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B. ambifaria
J2742 - - - - ■ - -
B. anthina
J2552 - - - - . - -
J2553 - - - - . - -
J2863 - - - - . - -
J2927 - - - - . - -
J2928 - - - - . - -
J2941 - - - - - - -
J2943 - - - - - - -
J2944 - - - - . - -
J2945 - - - - - - -
J2946 - - - - - - -
J2949 - - - - - - -
J2950 - - - - - - -
J2951 + - + - + - +
J2862 - - - - - - +
CI658 + + + - - - -
C1765 + + + - + + -
B. pyrrocinia
J2536 - - - - - - -
J2542 - - - - - - -
CI469 - - - - - - -
C3909 + - + - - - -
C3918 + - + + + - +
C3928 - - - - - - -
C3930 + - + - + - +
C3993 + - + - - - +
C3995 + - + - - - +
C3997 + + - - - - -
B. ubonensis
E26 - - - - - - +
E27 - - - - - - -
E571 - - - - - - -
E551 + + . _ _ _ -
Genomovar unclassifiable
J2540 + + -
lack of sensitivity to phage; +, < 10 plaques at phage inoculum site; ++, >10 plaques at
phage inoculum site; +++, confluent lysis at phage inoculum site
^Strains used in lysogeny experiments. * Lysogenic strains
¥ (Nzuia ei ai. 2000)
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Fig 5.1 Plaque morphology of RL1c and RL1t. RL1c (wild-type phage) clear plaques
indicated by red arrows. RLit (mutant phage) turbid plaques indicated by black arrows.
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5.5 Results: Electron Microscopy
Electron microscopy was used to identify the structural morphology of the Bcc
phages. In accordance with phage taxonomy (Ackermann 2001, Ackermann and
Krisch 1997); phages JB1, JB5, DK2/DK3, DK4, RLlc/RLlt and RL2 could be
described as possessing hexagonal heads and contractile tails of variable length,
characteristic of T-even-like phages (Fig 5.2). Such phages remain unclassified but
can be placed in the type genus of the Myoviridae family. In contrast, phages JB3
and DK1 were revealed to have the hexagonal heads and flexuous, non- contractile
tails characteristic of lambda-like phages (Fig 5.2). Such phages remain unclassified
but can be placed in the type genus of the Siphoviridae family.
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Fig 5.2 Electron-micrographs of Bcc bacteriophages. A. JB1B. JB3, C. JEM, D.
JB5, E. RL1c, F. RL1t, G. RL2, H. DK1,1. DK2, J. DK3, K. DK4
(Magnification x 200,000).
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5.6 Discussion
The data presented show that lysogeny is relatively common in Bcc isolates and
demonstrate that virulent Bcc bacteriophages are present in the natural habitats of
these bacteria. Interestingly, the host range of the Bcc phages was not species-
specific and, in some cases (for example phage JB1), included the majority ofBcc
species presently known. These data are in agreement with the earlier study by
Nzula et al. (2000) on the Bcc phages NS1 and NS2. This broad host range, which
in some cases extended to the related pseudomonads P. aeruginosa and B. gladioli, is
unusual. With the exception of unusual phages such as the plasmid-like 'phasmid'
P4 (Gutmann et al. 1990), the host range ofmost phages is species specific. In terms
ofbiodiversity of the Bcc and scope for horizontal gene transfer it is also potentially
important.
The method for detecting lysogeny can also be utilised to identify bacteriocin
production. There was however, no apparent bacteriocin production and activity in
the panel ofBcc investigated. This finding is in agreement with previous studies
which highlight the low prevalence ofbacteriocinogeny in "B. cepacia''' (Govan and
Harris. 1985).
A broad host range for Bcc bacteriophages could contribute to genomic plasticity and
biodiversity of these bacteria, and their evolution from highlymetabolically active
soil saprophytes to plant, human and animal pathogens. The data show that there is
little correlation between phage sensitivity and whether isolates were isolated
clinically or from the natural environment suggesting that prophages did not
contribute significantly to virulence. Of particular interest was the finding that the
biopesticide strain B. ambifaria (J2742: AMMD) was not susceptible to any of the
Bcc bacteriophages investigated, a factor which could support its commercial use
(Parke and Gurian-Sherman.2001).
Lysogenic conversion and transduction are important processes by which
chromosomal host genes can be acquired and exchanged between bacteria (Canchaya
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et al. 2004). In vitro studies have shown that antibiotic resistance genes can be
transferred between B. vietnamiensis strains by phages NS1 and NS2 (Nzula et al.
2000). hi relation to the therapeutic use of Bee phages, their broad host range poses
a potential problem. The MIC data presented previously highlight the variation in
antibiotic resistance within the Bee. Bee phages appear to be promiscuous and thus
the potential for horizontal gene transfer within and between Bcc species needs to be
considered. This applies in particular to the data showing that Bcc phages can use P.
aeruginosa and B. pseudomallei as bacterial hosts. The fact that Bcc phages can use
the highly virulent B. pseudomallei as hosts is perhaps not surprising given their
close taxonomic relationship within the Palleroni 'RNA II' group. The role of P.
aeruginosa as hosts is more surprising given the taxonomic 'distance' between Bcc
and P. aeruginosa. Any therapeutic benefit for the Bcc phages may be lost by the
potential spread of resistance genes between pseudomonad species. Furthermore, as
reported for Shigella flexneri (Allison and Verma 2000), P. aeruginosa (Kropinski
2000) and the B. cepacia complex (Kenna et al. 2003), phages can modulate
bacterial virulence by contributing to O-antigen modification pointing to a potential
role for Bcc LPS as a potent virulence determinant. This possibility is even more
significant following recent evidence for the important role ofBcc LPS in cytokine
induction and its unique biological and structural properties (Hughes et al. 1997,
Shaw et al. 1995, Shimomura et al. 2003, Zughaier et al. 1999). The potential for
Bcc phages to encode pathogenic factors has recently been confirmed (Summer et al.
2004). The authors describe a B. cenocepacia phage BcepMu, which carries
amongst other factors, a LPS modification acyltransferase.
Opportunities for transduction and lysogenic conversion within the Bcc would not
only exist in natural environments shared by various Bcc species and related bacteria,
but also in CF airway secretions, where mixed infections ofP. aeruginosa and Bcc
are frequent and bacterial populations can reach densities in excess of 109 cfu/ml.
Additionally, the presence of bacteriophages in sputum has been reported (Ojeniyi et
al. 1991, Tejedor et al. 1982).
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Based on the close taxonomic relationship and shared insertion sequences and
environmental habitats, the observation that NS2 can utilise B. pseudomallei, the
causative agent ofmelioidosis and a potential agent for bioterrorism (Mack and
Titball 1998), as a propagating host is particularly significant. The potential
importance ofbroad-host-range phages such as NS2 is also highlighted by recent
reports ofB. pseudomallei infection in CF patients (including coinfection with Bcc
species) following travel to Thailand where melioidosis is endemic (Schulin and
Steinmetz 2001, Visca et al. 2001).
The shared host range ofDK2 and DK3 isolated from B. cenocepacia and B. stabilis
respectively, supports the host range studies and suggests that integration of the same
phage can occur in different species within the Bcc. While the presence ofmultiple
prophages within a single strain is common in P. aeruginosa (Holloway et al. 1960),
polylysogeny appeared relatively rare for Bcc species.
The turbid and lytic plaque morphology exhibited by the otherwise similar (host
range and restriction profile), environmental phages RLlc and RLlt was not
observed during the initial sample screen, and has not been reported previously for
Bcc phages. This variable plaque morphology was observed in early phage studies
and explained by the development ofhost range mutants (Luria 1947). These mutant
phages are able to overcome phage resistance because of changes in the structure of
the adsorption 'adhesin' on the phage. This structural alteration allows the phage to
re-adsorb to bacteria resistant to the wild type phage. Normally, such mutant phages
demonstrate an extended or curtailed host range, but this was not observed for
bacteriophage RL1. The co-existence ofRLlc (wild-type) and RLlt (mutant)
bacteriophage in the same population illustrates the ongoing mutational equilibrium
between Bcc phage and host, a phenomenon first recognised for the classic E. coli
phage T2 (Delbruck 1945, Hershey 1946).
All "B. cepacia" bacteriophages identified to date [Beep 1, 43, 781, Mu; CP1 (Cihlar
et al. 1978) and CP75 (Matsumoto et al. 1986); NS1 and NS2 (Nzula et al. 2000);
phage-42 (Ackermann and Krisch 1997)] have been shown to be morphologically
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similar to T-even like bacteriophages. Likewise, the majority ofBee phages
identified in this study were morphologically similar to previously identified Bee
phages. However, lambda-like Bee phages were also observed in this study.
The relative lack of susceptibility shown by B. multivorans to any of the phage panel
is interesting. Together, B. multivorans and B. cenocepacia account for over 90% of
clinical isolates of the Bcc (LiPuma et al. 2001); however, in contrast to B.
cenocepacia, B. multivorans is rarely isolated from natural environments (Bevivino
et al. 2002). The data presented here show that of the nine B. multivorans strains
tested (including the Glasgow epidemic strain CI576), only one strain (C2775)
exhibited phage susceptibility. However, further studies have tentatively identified a
novel Bcc phage from soil (RU2) which plates on B. multivorans C3164, as well as
three other strains (J2552 and J2553, both B. anthina & E571, B. ubonensis). Each
of these strains was resistant to the phage panel tested in this thesis.
Whole-genome sequencing of bacteria provides increasing evidence ofwidespread
exchange of chromosomal genes and other extrachromosomal elements mediated by
phages. The genome ofB. cenocepacia isolate J2315 has recently been fully
sequenced (http://www.sanger.ac.uk/Projects/B_cenocepacia/) and an initial BLAST
search of the provisional genome sequence identified a single prophage, supporting
the scarcity of polylysogeny in the studies for this thesis. However, these studies
tentatively identified two temperate bacteriophages, DK4 and MM8, from J2315.
Interestingly, four phage-related islands have been identified on chromosome one,
with another identified on chromosome three (Personal communication;
Mahenthiralingam, 2003). Further genomic analysis is necessary to elucidate the
importance of prophage in the evolution and genomic plasticity of this well
characterised epidemic lineage.
A characteristic feature of the Bcc phages identified in this study was that they were
not the easiest of phages to work with. Despite rigorous attention to protocols
including storage buffers and bacterial growth conditions, in some cases results were
difficult to repeat. These difficulties were not encountered with the classic P.
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aeruginosa phages E79, D3 and F116L suggesting that, like their bacterial hosts, Bee
phages have idiosyncrasies. This applied in particular to an apparent variability in
host range. Attempts to explain these discrepancies by attention to the depth of agar
overlays and the influence of anaerobiosis were unsuccessful. A possible
explanation is that variability in the host range may be, in part, due to a propensity
for Bcc phages to undergo mutations affecting host range.
In recent years, the major disadvantage of phage therapy, namely bacterial and/or
mammalian host resistance, has been addressed by identifying novel phages or by
selecting long circulating phage mutants resistant to clearance by the human reticulo¬
endothelial system (RES) (Merril et al. 1996). In the case ofBcc, the risk of gene
transfer between and within species of the Bcc and related pathogens, as a
consequence of phage therapy, adds an additional risk to their widespread clinical
use in CF. A novel twist to these problems would be to utilise the phage enzyme that
is required to exit, lyse and destroy the bacterial host cell: namely the phage
endolysin.
5.7 Bacteriophage Lytic Enzymes as Antibacterial Agents
Aims
The aim of this study was to investigate the antimicrobial potential of two phage-
derived endolysins. The first endolysin was derived from the Bcc phage Bcep781,
which has been fully sequenced. The second investigation focused on the endolysin
derived from the P. aeruginosa phage D3. Unlike the latter, the Bcep781 genomic
DNA was unavailable.
5.8 Results: Proteomic Analyses of the Bacteriophage Endolysins Bcep781 & D3
The protein sequences of the phage endolysins were obtained from a protein database
(www.pubmed.com) and, using a BLASTn search, were compared with other
proteins in the database. Sequences of high similarity were aligned using AlignX
software (Informax). Bcep781 endolysin was almost identical to two other
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endolysins in the database identified in Bcc phages Bcepl and Bcep43 (Fig 5.3).
The data highlight similarities and note amino acid differences, although all
sequences used were based on bioinformatics, and thus protein functionality has yet
to be determined. Furthermore, the endolysin identified in the Bcc phage
BcepNazgul (127 aa in length) shared no similarity with the Beep lysins. Further
protein analysis of the Bcep781 endolysin is provided (Table 5.4). The protein
sequence ofphage D3 lysin was subjected to a similar study described above.
Interestingly, it appeared to show protein sequence homology to an endolysin
described in P. putida KT22 440, although to a lesser extent than the Beep phage
lysins (Fig 5.4). Further protein analysis of the D3 endolysin is provided (Table 5.5).
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Fig 5.3 Proteomic alignment of Bcc bacteriophage endolysins. Three protein sequences of
Beep endolysins (Beep 1, 43 and 781) were aligned using AlignX software (Informax).
Sequence homology is shown in red, partial homology is shown in blue, no homology is
shown in green. The consensus sequence is also provided.





Charge at pH 7 0.01
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Endolysin P. putida KT2 440
Translation of D3 Endolysin
Consensus
Endolysin P. putida KT2 440
Translation of D3 Endolysin
Consensus
Endolysin P. putida KT2 440
Translation of D3 Endolysin
Consensus
Endolysin P. putida KT2 440
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Fig 5.4 Proteomic alignment of the bacteriophage D3 phage endolysin. The protein
sequences of the D3 endolysin were aligned with an endolysin from P. putida KT22 440
using AlignX software (Informax). Sequence homology is shown in red, unique sequence is
shown in black. The consensus sequence is also provided.
Table 5.5 Bacteriophage D3 endolysin analysis
Analysis Entire Protein
Length 160 aa
Molecular Weight 17310.84 m.w.
Isoelectric Point 9.02
Charge at pH 7 3.02
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5.9 Results: Recombinant Synthesis of the Bacteriophage Bcep781 Endolysin
Gene by PCR
Since neither intact Bcep781 phage particles nor genomic DNA were available, we
had to rely on the phage genomic sequence for gene synthesis. Twenty-two primers
were designed and synthesized, with restriction endonuclease sites engineered to the
5' and 3' ends to aid later cloning steps. Each primer was designed to overlap at the
3' end, as represented in Fig 5.5. The one-step recursive PCR method was used to
synthesize the 776 bp Bcep781 endolysin gene (Ncol/Bamlll) (Fig 5.6). Herculase®
Hotstart DNA polymerase was chosen in preference to Taq polymerase because of its
high fidelity amplification. This was required to reduce the occurrence ofpoint
mutations. The most critical aspects of this technique are the relative concentrations
of the internal and outer (amplifying) oligonucleotides and the design of overlapping
ends. The initial round ofPCR did not appear to be successful and the extracted
DNA fragment was subjected to another round ofPCR with the outermost
oligonucleotides, prior to being cloned into PCR 2.1 (Fig 5.7). Automated DNA
sequencing highlighted sequence error at two specific sites. The 5' Ncol site
contained errors and a deletion of a guanine base at position 614 was also observed.
The 5' Ncol site was fixed by repeating the PCR protocol, using the outermost
primers (1 and 22) and the synthesised gene as the template. The base pair deletion
at position 614 proved to be problematic, and required several "fix" primers to be
tried before the integrity of the gene was assured. The fix method was based on a
mega-primer PCR and used a Taq polymerase with a lower fidelity than the proof¬
reading polymerase used in the gene synthesis step. The Bcep781 endolysin gene
was finally completed by a mega-primer PCR and site-directed mutagenesis to
reduce the GC content of the region in which the base pair deletion was present.
Four base pair changes (G—>T) were made, although each mutation was silent to
retain the amino-acid sequence integrity.
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Fig 5.5 The design of primers for the synthesis of the bacteriophage Bcep781 endolysin
gene. Twenty-two primers were designed to encode the entire genomic sequence of the
hypothetical endolysin gene. The even numbered primers overlapped the odd number
primers to ensure integrity of the synthesized fragment.
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5' Ncol
1
1 CCATGGCCGCGC CGCTGATCGT CGGCGCGTCG GGTCGCGCCG TGGTGTTTCT GCAGGCGCGG
■4
2 ► 2
61 CTCGGCCTCG CGCAGTCGGG CCAATTCGAC GCGAGCGTCG CAACGGCGCT GCGCCAGTGG
^
121 CAGGAGGCGC ACGGGATGAC GCCGGATGGC GTGTACGGAT CGCAGACGAA TGCGGTGATG
4
4 7
181 ACGGCGCGCG CGCTGCCGGA CATCGCCGAC GCGGCTGCGC GCCTGAACGT CGACACGCCT
6 9
241 GCGCTCCAAG CCATTATCCA GGTCGAGACA ACGGGTAGCG GCTTCCTGCC CGACGGGCGG
•4
8
301 CCGCGCATCC TGCTCGAACG CCACAAGGTA TGGGCGGCGA CGAGCCCGGC GCAGCGCGTG
11 _ 10




421 AACGCGCGCG GCGCGGGCGA GTGGGTGCGT TTCGAGCGCG TGGCAGCCGT CACGGGCGAC
■4
J5 14
481 GAAGTGGCCG CGCAGTGCTG CTCCTGGGGA CTCGGGCAGG TTATGGGCGC CAACTATGCG
^
17
541 ACGTGCGGCT TCACGAACGC CGTCGGTCTG ATGTTCGCGA GCGCCCTGAA CGAGCGCGCG
16 19
601 CAACTTGACG TGATGGTGCG CTTCGCGCTG CCGCAGGCCG GCCTGCTCGG GGCATTACGT
18




721 TACGACACGA AGCTGTCCGA TGCGTACACC ACATTGACGT CGCGATAAGGATCC
«4
22 Bamffl 3'
Fig 5.6 Gene synthesis of bacteriophage Bcep781 endolysin gene using recursive PCR.
The figure shows the 22 primers used in the synthesis of the Beep 781 endolysin gene
(Appendix 2), their positions across the gene, and the location of the engineered A/col and
Bam'rii sites. Black arrows represent forward primers (5' - 3'). Red arrows represent
reverse primers (3'-5').
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Fig 5.7 Bacteriophage gene synthesis and subsequent cloning steps. The 22 Bcep781 lysin
primers were added together with dNTPs and Herculase polymerase. The external primers
(1 & 22) were added at 10 x the concentration of the internal primers (2-21). A. The initial
round of PCR produced a smear of DNA and a band between 500 and 900 bp was extracted
and the DNA content was purified. B. The second round of PCR used the extracted band
from A in conjunction with the external primers (1 & 2). This round of PCR resulted in a DNA
band of 776 bp, consistent with the expected number of base pairs for the Bcep781
endolysin gene. The band was excised, and the DNA was extracted and purified. C. The
excised band from B was subjected to another round of PCR using the external primers (1 &
22). The last round of PCR was utilised to increase the integrity of the synthesized gene,
prior to cloning into PCR 2.1. Lane 1: DNA Hyperladder I; Lane 2: DNA Hyperladder IV;
Lane 3: Gene synthesis product.
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5.10 Results: Cloning, Expression and Purification of the Bacteriophage
Bcep781 Endolysin
The phage Bcep781 endolysin gene was cloned into pCR 2.1. DNA sequencing
confirmed the presence of four point mutations at positions 614, 620, 623 and 629.
Subsequently, the endolysin gene was cloned into a pET expression vector with a N-
terminal His6-tag (pET 6-His), for expression in various E. coli strains (DE3
lysogens); optimum recovery ofprotein was achieved with E. coli strain BL21 (DE3)
strain. The Bcep781 endolysin gene was also cloned into pET 28a to enable
purification of the native protein; unfortunately protein expression was not
successful. Cells were grown in shake flasks at 37°C and expression induced with 1
mM IPTG. The endolysin cell lysate was first purified by nickel-affinity
chromatography (FPLC). The protein was eluted with 200 mM imidazole and
twenty-five 5 ml fractions were collected. Absorbance was measured at 280 nm for
each (Fig 5.8). All fractions were subjected to SDS-PAGE on a 4-12% gel and
Coomassie staining highlighted a protein band with a molecular weight of
approximately 27-28 kDa (Fig 5.9). The molecular weight of Bcep781 lysin was
based on protein analysis software, Vector NTI (Table 5.6). Sample fractions were
pooled and concentrated using a spin filter of a molecular weight cut off (MWCO) of
10 kDa. The concentrated sample was then dialysed against 50 mM phosphate
buffer (pFI 8.0) with 100 mM NaCl and concentrated as before. The dialysed sample
was then subjected to platform mass spectrometry and its antimicrobial activity
investigated.
5.11 Results: Mass Spectrometry of the Bacteriophage Bcep781 Endolysin
The mass spectrum of the endolysin sample revealed the presence of a distinct
species ofmass 27917.0 Da (Fig 5.10). This figure did not correspond to the primary
structure analysis of the 6-His-Bcep781 endolysin, and differed by +37.12 mass
units.
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Fig 5.8 The absorbance values of FPLC fractions following Nickel affinity purification. The
fractions that demonstrated a significant absorbance value were subjected to SDS-PAGE
analysis.
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Fig 5.9 Purification of 6-His Bcep781 endolysin. The extract was purified using Nickel affinity
chromatography. The sample fractions were run on a 4-12% Bis/Tris SDS-PAGE gel and
stained with Commassie blue. Lane 1: Low molecular weight marker. Lane 2: fraction 8.
Lane 3: fraction 9. Lane 4: fraction 10. Lane 5: fraction 11. Lanes 2,3,4 show a band at





1 microgram = 35.868 pMoles
1 A[280] corr. to 0.68 mg/ml
Isoelectric Point 7.27
Charge at pH 7 0.53
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Fig 5.10 Mass spectrum of 6-His-Bcep781 endolysin. The data show that the predominant
mass (indicated by A) was 27916.65 ± 6.80.
147
5.12 Results: Antibacterial Activity of the Bcep781 Endolysin
The antimicrobial potential of the recombinant- purified 6-His-Bcep781 endolysin
was assessed using ten Bee isolates: two B. cepacia isolates (ATCC 25416 & ATCC
17759), three B. multivorans isolates (C1576, C1962 & ATCC 17616), four B.
cenocepacia isolates (C517, J2315, R9239, R2817), and one B. ambifaria isolate
(J2742-AMMD). The recombinant protein did not appear to have any activity
against the panel ofBcc isolates examined. Unfortunately, the propagating host
strain, now known to be a B. cepacia (genomovar 1) isolate, was unavailable as a
positive control.
5.13 Results: PCR of the Bacteriophage D3 Lysin Gene
The D3 endolysin gene was identified and specific primers were designed to amplify
the lysin (492 bp) gene from D3 genomic DNA (Fig 5.11). A 5' Ncol restriction
endonuclease site, and a 3' BamHl site had been engineered into the gene. The PCR
product was then cloned into pCR 2.1. DNA sequencing showed that the 3' BamHl
site had not been correctly inserted, although the consensus gene sequence was
correct. The absence of the restriction endonuclease made subsequent cloning steps
difficult. Therefore, a fix primer was designed and, by using a mega primer PCR the
restriction endonuclease site was corrected.
5.14 Results: Cloning, Expression and Purification of the Bacteriophage D3
Endolysin
The endolysin gene was cloned into a pET expression vector with a N-terminal His6-
tag (pET 6-His), for expression in various E. coli strains (DE3 lysogens); the
optimum recovery of protein was achieved using E. coli strain BL21(DE3). Cells
were grown in shake flasks at 37°C and expression induced with 1 mM IPTG. The
endolysin cell lysate was first purified by nickel-affinity chromatography (FPLC),
the protein was eluted with 200 mM imidazole and twenty-five 5 ml fractions were
collected. Each fraction was subjected to SDS-PAGE and run on a 4-12% gel.
Commassie staining highlighted a protein band with a molecular weight of
approximately 19-21 kDa (Fig 5.12). The molecular weight ofD3 endolysin was
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based on protein analysis software, Vector NTI (Table 5.7). However, the D3
endolysin appeared to be in the initial fractions (fractions 1 & 2) indicative ofnon-
binding to the Nickel affinity column. Sample fractions 1 and 2 were pooled and
dialysed (MWCO 18, 000) for 18 hours against 25 mM Tris buffer (pH 7.5). The pH
of the buffer was important, as this would enable latter purification steps. Due to its
PI, the D3 lysin would have an overall positive net charge, and thus could be purified
on a Resource S® (Sulfonic acid) column. It is very unlikely that E. coli proteins
would bind during Resource S® purification steps as they tend to have Pis of 3-7,
and be negatively charged at pH 7.5.
The dialysed (and desalted) sample was subjected to Resource S® purification and
the protein was eluted with 1 M NaCl and twenty-five 5 ml fractions were collected.
The absorbance at 280 nm was measured for each fraction (Fig 5.13). All fractions
were subjected to SDS-PAGE on a 4-12% gel and Coomassie staining highlighted a
protein band with a molecular weight of approximately 18-19 kDa (Fig 5.14).
The dialysed sample was then subjected to MALDI-TOF mass spectrometry and its
antimicrobial activity investigated.
5.15 Results: Mass Spectrometry of the Bacteriophage D3 Endolysin
The sample was subjected to MALDI-TOF mass spectrometry (Fig 5.15). The data
showed that the predominant mass in the sample was 16927.72 ± 6.49. The mass of
6His-D3 endolysin was predicted to be 18335.94, thus a mass discrepancy of
1408.22 ± 6.49 was noted. Further analysis did not provide an exact mass for the
expressed protein in the initial sample.
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Figure 5.11 The Bacteriophage D3 lysin gene amplified by PCR. Lane 1: DNA hyper ladder
1. Lane 2: D3 lysin gene. The data show the amplification of the D3 lysin gene (492 bp)
from extracted and purified D3 genomic DNA, using lysin specific primers.




1 microgram = 54.538 pMoles
1 A[280] corr. to 0.61 mg/ml
Isoelectric Point 9.02
Charge at pH 7 3.54
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Figure 5.12 SDS-PAGE analysis of Nickel affinity purification 6-His D3 lysin. The cell free
extract was purified on a Nickel affinity column and collected fractions were subjected to
SDS-PAGE (4-12% gel). Lane 1: multiplex marker. Lane 2: cell free extract. Lane 3: flow
through. Lane 4: fraction 1 & 2 from Ni-affinity purification step. The data show that an over-
expressed protein is present in fractions 1 and 2, which is indicative of no binding to the
affinity column.
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Fig 5.13 Resource-S purification. The D3 lysin recombinant protein was dialysed into 25
mM Tris buffer (pH 7.5) to ensure that the protein had an overall positive charge. The
extract was then purified using a Resource S purification step, and 25 fractions were
collected. The absorbance of each fraction at 280 nm was measured and this analysis
provided a number of peaks. The corresponding fraction was then subjected to SDS-PAGE
analyses.
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Fig 5.14 SDS-PAGE results after Resource S purification of 6-His D3 lysin. The purified
fractions from the Resource S purification that had previously been shown to have a
significant absorbance at 280 nm were subjected to SDS-PAGE (4-12% gel). Lane 1:
Multiplex marker. Lane 2: flow through loading. Lane 3: flow through wash. Lane 4: fraction
1. Lane 5: fraction 4. Lane 6: fraction 6. Lane 7: fraction 8. Lane 8: fraction 10. The
results indicate that fraction 4 and fraction 6 contained a protein with a molecular weight
consistent with the 6-His D3 lysin protein.
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Figure 5.15 Mass spectrometry of recombinant 6-His D3 lysin. The data show that the
predominant mass (indicated by A) was 16927.72 ± 6.49.
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5.16 Results: Antibacterial Activity of the Bacteriophage D3 Endolysin
The antimicrobial potential of the recombinant- purified 6-His-D3 endolysin was
assessed using three P. aeruginosa isolates: PAOl (positive control), HI 83
(Liverpool epidemic strain) & C3425 (Manchester epidemic strain). The
recombinant protein did not show any antimicrobial activity against the small panel
ofP. aeruginosa isolates examined, including the propagating strain used as a
positive control.
5.17 Results: Expression of Bacteriophage D3-6-His Lysin Fusion Protein in E.
coli HMS-174
The endolysin gene cloned into a pET expression vector with a N-terminal His6-tag
(pET 6-His) was expressed in E. coli cells HMS 174. Cells were grown in shake
flasks at 37°C and expression induced with 1 mM EPTG. During the mini-induction,
expression appeared to be consistent with expression in BL21 (DE3) cells (Fig 5.16).
Subsequently, large-scale induction of a 2-litre culture was prepared and purified
using nickel-affinity chromatography (FPLC). The protein was eluted with 200 mM
imidazole and twenty-five 5 ml fractions were collected. The absorbance at 280 nm
was determined for each fraction prior to SDS-PAGE. It was noted that the
recombinant protein had not bound to the affinity column (Fig 5.17). In addition, the
protein appeared to be completely insoluble, as highlighted by the large amount of
expressed protein in the cell pellet fraction (Fig 5.18).
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Fig 5.16 Bacteriophage D3 lysin expressed in E. coli HMS 174 mini induction. The HMS-
174 E. coli strain, transformed with the 6His-D3 lysin expression plasmid, was grown in 1 ml
of 2YT broth and induced with 1 mM for 3 hours. Lane 1: LMW marker. Lane 2: cell free
extract with no IPTG induction. Lane 3: cell free extract from cells induced with 1 mM IPTG.
The band in Lane 3 is approximately 18-19 kDa, as was the predicted molecular weight of
the 6His-D3 protein.
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Fig 5.17 Bacteriophage D3 lysin HMS-174 nickel affinity purification. The cell free extract
from the large scale induction of HMS-174 E. coli transformed with the 6His-D3 expression
plasmid was subjected to purification on a nickel affinity column, and 25 protein fractions
were collected. The data show that no significant level of protein was eluted by the
imidazole concentration gradient, and thus the over-expression did not result in soluble
recombinant D3 lysin.
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Fig 5.18 Insoluble D3 lysin expressed in HMS 174. The fractions collected from the Nickel
purification step were subjected to SDS-PAGE and run on a 4-12% gel. Lane 1: LMW
marker. Lane 2: Cell pellet. Lane 3: Cell free extract. Lane 4: Flow through. The results
show that the over-expression of the recombinant D3 lysin was successful. However, the
resultant protein was insoluble as indicated by its presence in the cell pellet.
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5.18 Discussion
Unlike other microbial-derived antibiotics (with the exception ofbacteriocins), the
activity of phage endolysins typically remains specific to the bacterial species acting
as the phage host. With the exception of one study by Ozawa et al. that investigated
the phage encoded bacteriolytic protein of phage P4282 and its lytic activity against
R. solanacearum (Ozawa et al. 2001), the available literature on phage endolysins
has focused on Gram-positive organisms. Thus, to the author's knowledge, this is
the first study to investigate the potential use ofbacteriophage enzymes against P.
aeruginosa and the Bcc.
The 776 bp Bcep781 endolysin gene was synthesized using 22 overlapping
oligonucleotides in a single reaction. Importantly, the success of this process was
dependant on the relative concentration of the internal and outer (amplifying)
oligonucleotides. Likewise, the choice ofDNA polymerase was fundamental to
successful gene synthesis. The synthesis was not without its problems, and several
attempts were required to correct a one base pair deletion. However, the technique
allows both optimisation of codon usage for E. coli, and the easy creation ofmutants
as novel primers can be introduced at any stage during synthesis to alter genomic
integrity. This makes the technique useful in situations where template DNA is
unavailable, mutant genes are desired, or the optimisation of codons is required to
increase protein yield.
Disappointingly, neither recombinant endolysin created and purified in this study
exhibited antibacterial activity. Explanations to account for this result include: First,
the function ofboth genes identified as endolysins, is based solely on bioinformatics
and full proteomic characterisation is required to identify their role in the phage life
cycle. Second, both endolysins were expressed with a N-terminal His6-tag that may
inhibit activity by altering the tertiary structure of the endolysin, thus stearically
altering its ability to bind to its target. The difficulty in the purification of the 6-His
D3 lysin supports this hypothesis, as the recombinant protein did not bind to a Nickel
affinity column, suggesting that the His-tag may have been buried within the tertiary
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structure. To avoid problems associated with His-tagging, attempts were made to
express the native endolysins in another pET system (pET 28a). However, although
both genes were successfully cloned into the pET 28a expression system, gene
expression was not achieved. The use of different E. coli strains was also
investigated. Interestingly, over-expression in E. coli HMS-174 may have been too
high and may explain why the resultant protein was insoluble. High-level over-
expression can reduce the fidelity of protein folding and therefore affect solubility.
Third, mass spectrometry indicated that neither endolysin possessed the expected
molecular weight despite the evidence of SDS-PAGE analysis. Thus, both
endolysins may have been subjected to modification or have been affected by E. coli
proteases and their structure altered during the purification steps. Fourth, to be fully
functional, phage lytic enzymes may require the presence of a holin, an enzyme
which is important during phage release from the host cell. Holins are small peptides
that are required for endolysins to gain access to bacterial peptidoglycan (Young and
Blasi 1995) and to lyse the host cell during "timed" lysis (Grundling et al. 2001).
The membrane lesions formed by holin/endolysin activity, are stable and non¬
specific and may be essential for the activity of endolysins in Gram-negative
organisms. Further studies are required to explore the roles of both holins and
endolysins as potential, and possibly synergistic, antibacterial agents. Fifth, the
ability of endolysins to kill Gram-negative cells from the outside-in remains to be
clarified. Furthermore, in this study, no positive host control strain for phage
Bcep781 was available and thus potential antibacterial activity may have been
missed.
The use ofphages as therapeutic agents has been the topic of extensive research for
over a century; however, only recently has the novel use ofphage derived-enzymes
as antibacterial agents received attention in the microbiological community.
Although recent focus has been on those phage-encoded enzymes that are
responsible for the exit ofphage progeny from the bacterial host, other essential
cellular functions, such as host DNA replication and transcription machineries, can
also be disrupted by phage-encoded peptides (Liu et al. 2004). Liu and co-workers
utilised a phage genomics approach to obtain information from the whole genome
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sequencing of26 S. aureus phages, and identified several polypeptides with
antibacterial activity. Such studies will become more commonplace as data from
genomic sequencing becomes more accessible.
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6.1 Aims
The aim of this study was to investigate the antimicrobial activity of a newly
characterised five-cysteine murine p-defensin (Defrl) against multiresistant
pathogens, including members of the Bee, epidemic P. aeruginosa and S.
maltophilia. Both Defrl and the 6-cysteine analog (Def-cys) were produced
synthetically (Albachem: Edinburgh) to enable further investigations. The 6-cysteine
analog, in conjunction with two conventional cationic antimicrobial peptides
polymyxin B sulfate and colistin sulfate (polymyxin E), were included in the study to
enable structural and functional comparisons, as well as to determine possible
mechanisms of action. Chemical synthesis of peptides with intra-molecular disulfide
bridging was incredibly expensive; therefore an alternative means of production,
namely recombinant expression, was also an aim of this project.
6.2 Results: Peptide Characterisation of Synthetic Defrl
The isolation and functional characterisation of the novel murine P-defensin, Defrl -
a polymorphism ofDefb8, which codes for only 5 cysteines was previously
described (Morrison et al. 2002). The structural characteristics ofDefb8 resemble a
normal P-defensin in disulfide connectivity and amphipathicity (Fig 6.1). The
synthetic Defrl peptide displayed antimicrobial activity against both Gram-positive
and Gram-negative bacteria, demonstrating that the 3-disulfide bonds that
characterise P-defensins are not a prerequisite for activity. Furthermore, Defrl was
reported as being active against the ET-12 isolate Burkholderia cenocepacia J2315.
The activity against B. cenocepacia strain J2315 was worthy of further investigation,
as no previously described CAMP has been shown to be active against the Bcc. In
addition, synthetic Defrl appeared to be structurally novel in that it exists as
covalently bound dimer (Fig 6.2 & Fig 6.3), suggesting a possible structure/function
relationship. Protein analyses ofDefrl and Def-cys are shown in Table 6.1 and 6.2.
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Fig 6.1 Peptide characterisation of Defb8 and its polymorphism Defrl. A: The 3D NMR
structure of Defb8 demonstrates the characteristic disulfide bond connectivity in a p-defensin
(Bauer et al. 2001). B: The electrostatic surface plot of murine Defb8 demonstrates the
cationic nature of the peptide. Acidic and basic residues are represented in red and blue
respectively. C: A primary sequence alignment of the p-defensin Defb8 and the
polymorphism Defrl. The characteristic cysteines are highlighted in green and the
intramolecular disulfide bridge connectivity is shown below. Notice the loss of C1 in Defrl
(C1 is replaced by a tyrosine residue). Mass spectrometry analysis of synthetic Defrl
indicates it dimerises via an intermolecular disulfide bridge through two free C5 cysteines.
COOH
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Fig 6.2 Electrospray Mass Spectrum (ESI-MS) of synthetic Defrl (A:
Oxidised & B: Reduced). The deconvoluted data represent the mass of the
peptide. For Defrl (A) the mass is given as 7565.59±0.29. This is consistent
with a dimer containing intermolecular disulfide bridging when one examines
Defrl reduced. For Defrl reduced (B) the mass is given as 3787.87±0.16,
which is consistent with the predicted mass. (Masses are in the top right
hand corner of each spectrum). For each disulfide formed there is a loss of 2
Flydrogen atoms (therefore a mass loss of 2 x 1.008 Da). So mass is
consistent with a dimer containing 5 disulfide bonds, ie 2 x (Mass of red
peptide) - 5 (2 x 1.008 Da): 2 x 3787.87 - 10.08 = 7565.66 Da. NB: This data
does not show how many disulfides are intermolecular or intramolecular.
This data was compiled with the help of David Clarke (School of Chemistry,
University of Edinburgh).
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Defrl Monomer 1
Intermolecular cystine bridge
(Dirtier forms through free cysteine)
Fig 6.3 Model-ribbon structure of synthetic Defrl. The model illustrates two Defrl
monomers, with two intramolecular disulfide bonds, linked by an intermolecular disulfide
bridge between the free cysteines. Disulfide bonds are shown in yellow. Reprinted by kind
permission of Dr Perdita Barran (School of Chemistry, University of Edinburgh).
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6.3 Results: Antimicrobial Activity ofDefrl & Other CAMPs
The initial MIC and dose response assays of the CAMPs focussed on two Bee
isolates, B. cepacia ATCC 25416 and B. cenocepacia J2315. It became apparent that
both were highly resistant to Defrl (MIC >100 pg/ml) and other CAMPs
investigated, including Def-cys (MIC >100 pg/ml), polymyxin B (MIC >512 pg/ml)
and colistin (MIC >512 pg/ml) (Table 6.3). The dose response data confirmed that
both Bcc isolates are resistant to Defrl and Def-cys (Fig 6.4 & Fig 6.5). The study
was therefore expanded to include other resistant and problematic CF organisms
including: four multiresistant epidemic P. aeruginosa isolates from Manchester
(C3425), Liverpool (HI83), Brisbane (C4269) and Melbourne (C3781) as well as a
PAOl mutant (PA0579) that secretes copious amounts of a positively charged
polysaccharide (alginate) and a rough LPS CF isolate (P235); five CF S. maltophilia
isolates (CI980, C3625, C3626, C3627, C3642); two strains from the genus
Ralstonia sp. (C3019 and C3081); one S. aureus strain (ATCC 25923), and an
MRSA isolate (SI 13); one C. albicans strain (J2922). Other bacterial pathogens
investigated included!?, coli (ATCC 25922), E.faecalis (ATCC 29212), Bordetella
bronchoseptica (J3083) and Acinetobacter baumannii (U45). The MICs for each
peptide were determined by aliquoting the peptide at concentrations ranging from
0.75-100 pg/ml in phosphate buffer containing log-phase bacteria. The combination
was incubated for 3 hours; the incubation time was predetermined by the result of the
time-kill assay using PAOl and Defrl at five times the MIC (25 pg/ml) (Fig 6.6).
Under normal circumstances, lyophilised Defrl and Def-cys were dissolved in 0.01%
acetic acid as this helps to stabilise cysteine formation and inter-bridging (acetic acid
provides a source ofH+); however, when investigating the activity of reduced Defrl,
the peptide was re-suspended in phosphate buffer and the assay was incubated for 1
hour to limit the level ofoxidation which may lead to intermolecular disulfide bridge
formation (Fig 6.7). Excluding the Bcc isolates examined, the MIC ranges were:
polymyxin B; 0.12- >512 pg/ml, colistin; 0.5- >512 pg/ml, Defrl; 3-25 pg/ml, Def-
cys; <12.5-100 pg/ml, Defl reduced; 25-100 pg/ml (Table 6.3). Interestingly,
resistance to conventional cationic antimicrobial peptides did not confer resistance to
Defrl. All S. maltophilia, Ralstonia sp., E.faecalis, S. aureus, MRSA and C.
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albicans strains examined were highly resistant to both polymyxin B (MIC range 4-
>512 pg/ml) and colistin (MIC range 8- >512 pg/ml), but remained as sensitive to
Defrl (3-25 pg) as P. aeruginosa strains which were all sensitive to polymyxin B
(MIC range 0.5-1 pg/ml) and colistin (MIC range 1-2 pg/ml). The converse was
also true. Sensitivity to both polymyxin and colistin did not confer sensitivity to
Defrl. Two strains demonstrated this phenomenon: P. aeruginosa PA0579 and S.
maltophilia C3642. The data suggest that different CAMPs may have different
modes of action. Furthermore, in contrast to polymyxin B and colistin, Deft 1 is
active against both Gram-negative and -positive bacteria.
The data show that, with respect to P. aeruginosa PAOl, reduced Defrl and Def-cys
are ten times less active than oxidised Defrl. This lends support to the hypothesis
that dimerised Defrl is more active as a result of disulfide bonds, and in particular an
inter-molecular disulfide. Def-cys may dimerise, but not covalently.
6.4 Results: Killing Curve
The rate ofkilling of P. aeruginosa PAOl with Defrl was studied. The period
required to reduce bacterial viability (initial inoculum 105 cfu/ml) to almost zero was
found to be between 0 and 30 mins post Defrl challenge (Fig 6.6).
6.5 Results: Dose Response Curves
The bactericidal activity of Defrl, Def-cys and reduced Defrl was measured at a
range of concentrations for all strains presented in Table 6.1. A representation of the
data is shown for PAOl (Fig 6.8) and E. coli ATCC 25922 (Fig 6.9). Bacterial
killing by the CAMPs was shown to be dose dependant. Deffl was found to be most
effective at reducing bacterial viability.
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Table 6.3 MIC values of cationic antimicrobial peptides against a panel of pathogens
Antimicrobial Peptide
Organism Strain MICjig/ml
Pol. Col. Defrl DefCys Defrl Red
P. aeruginosa PA01 0.5 2 6 50 50
PA PA0579/P55 1 1 25 50 100
PA Manchester C3425 1 1 6 50 100
PA Liverpool H183 1 1 6 100 100
PA Brisbane C4269 1 1 6 >100 100
PA Melbourne C3781 0.5 2 6 100 100
PA (Rough) P235 1 2 6 >100 50
B. cepacia ATCC 25416 >512 >512 >100 >100 ND
B. cenocepacia J2315 >512 >512 >100 >100 ND
S. maltophilia C1980 32 64 12.5 >100 >100
S. maltophilia C3625 32 64 6 >100 50
S. maltophilia C3626 32 64 3 >100 >100
S. maltophilia C3627 64 256 6 >100 >100
S. maltophilia C3642 4 8 25 >100 >100
R. pickettii C3079 >512 >512 3 >100 >100
R. eutropha C3081/LMG1199 128 >512 3 >100 >100
E. faecalis ATCC 29212 256 512 6 100 >100
E. coli ATCC 25922 0.25 0.5 6 >100 >100
S. aureus ATCC 25923 256 >512 12.5 >100 >100
MRSA S113/ J2918 64 256 6 >100 25
C. albicans J2922 >512 >512 3 25 25
B. bronchoseptica J3083 0.12 0.5 6 >100 >100
A. baumannii U45 1 1 3 <12.5 ND
Pol: Polymyxin B sulfate, Col: Colistin sulfate, Defrl: Murine p-defensin with 5-cysteine
residues, DefCys: Murine p-defensin analog with 6-cysteine residues, Defrl Reduced: Defrl
chemically reduced with DTT (essentially breaking disulfide bonds). ND: Not done. P.
aeruginosa PA (rough): rough LPS isolate. Experiments were carried out in duplicate and
repeated twice, and the MIC values were based on the average.
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Fig 6.5 Dose response curve. J2315 vs Defrl (black line) and Def-cys (red line)
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■ PA01 control
■ PA01 vs Defrl (25 ng/ml)
90 120 150 180
Time (Minutes)
Fig 6.6 Time-Kill Assay. Defensin killing assay (of PA01 and Defrl at 5 x MIC: 25 pg/ml).
Bacterial samples were removed at 30-minute intervals and plated to determine the viable
count (cfu/ml). The data show that bacterial viability was reduced significantly within the first
30 minutes and completely diminished by 60 minutes.





Fig 6.7 Schematic of disulfide bond formation between two cysteine thiol sulfurs
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Concentration of Reduced Defrl (ng/ml)
Fig 6.8 Defensin dose response curves: PA01 vs CAMPs. A: PA01 vs Defrl (1.5-100
pg/ml). B: PA01 vs Def-cys (1.5-100 pg/ml). C: PA01 vs Reduced Defrl (1.5-100 pg/ml).
Error bars represent the standard error between experimental values.
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Concentration of Defrl (ng/ml)
Concentration of Def-Cys (ng/ml)
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Concentration of Reduced Defrl (ng/ml)
Fig 6.9 Defensin dose response curves: E. coli vs CAMPs. A: E. coli vs Defrl (0.375-100
pg/mi). B: E.coli vs Def-cys (1.5-100 pg/ml). C: E.coli vs Reduced Defrl (1.5-100 pg/ml).
Error bars represent the standard error between experimental values.
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6.6 Results: Salt Sensitivity of Defrl
The salt sensitivity ofDefrl was investigated. The standard killing assay was
performed with 25 pg/ml ofDefrl in the presence ofNaCl (0-300mM). The data
show that the inhibitory activity ofDefrl remained uneffected in the presence of
50mM NaCl (Fig 6.10). However, the antimicrobial activity of Defrl was inhibited
as the concentration ofNaCl rose from 50-300mM.
6.7 Results: The Inhibition of Defrl With LPS and LTA
The ability of LPS and LTA to inhibit the action ofDefrl was investigated. The
standard killing assay was performed with 25 pg/ml ofDeff 1, preincubated with
either LPS (P. aeruginosa PAOl, E. coli 0184", E. coli 0111 :B4 [Sigma], B.
cenocepacia J2315) or LTA (S. aureus: Sigma) for one hour at 37°C, prior to the
addition of 105 cfu/ml P. aeruginosa PAOl. LPS concentrations varied from 0.75-
100 pg/ml. LTA concentrations varied from 1.5-100 pg/ml. The data show that LPS
inhibits the antimicrobial activity ofDefrl (Fig 6.11). The degree of inhibition
varied between the bacterial sources of LPS. Both E. coli samples were found to
have a similar inhibitory effect on Defrl activity, but were less effective than PAOl
and J2315. S. aureus LTA also inhibited the action of Defrl (Fig 6.12). Taken
together, the data show that both LPS and LTA are capable of inhibiting Defrl,
although LTA appears to be more potent.
6.8 Results: Inhibition of Polymyxin B and Colistin With LPS
The ability ofP. aeruginosa PAOl LPS to inhibit the action ofpolymyxin B and
colistin was investigated. The standard killing assay was performed with both
antibiotics (at 4 pg/ml) preincubated with P. aeruginosa PAOl LPS (0.75-100
pg/ml), as described above. P. aeruginosa PAOl LPS (50 pg/ml) inhibited the
bactericidal activity of both conventional cationic peptide antibiotics, but had
increased potency at inhibiting colistin with 4.5 times (Log scale) more bacteria
surviving (Fig 6.13).
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NaCI Concentration (mM)
Fig 6.10 Salt sensitivity of Defrl against PA01. Defrf concentration was approximately 5 x
the MIC (25 pg/ml) and the salt concentration in the reaction buffer varied from 0-300mM
NaCI. Error bars represent the standard error between experimental values.
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LPS Concentration (ng/ml)
Fig 6.11 LPS inhibition of Defrl killing against PAOI. Killing assay using PA01 against
Defri at a concentration approximately 5 x the MIC (25 pg/ml). Defrl was preincubated with
different LPS at varying concentrations (0.75-100 pg/ml). Bacterial survival is directly
proportional to the concentration of LPS added.
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LTA Concentration (jig/ml)
Fig 6.12 LTA inhibition of Defrl killing against PA01. Killing assay using PA01 against
Defrl with a concentration approximately 5 x the MIC (25 pg/mi). LTA was preincubated
with Defrl at varying concentrations (1.5-100 pg/ml). Bacterial survival is directly proportional
to the concentration of LTA added. Error bars represent the standard error between
experimental values.
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Concentration of PA01 LPS (ng/ml)
Fig 6.13 Inhibition of polymyxin B and colistin with PA01 LPS. Killing assay using PA01
against either polymyxin B and colistin at a concentration of 4 pg/ml. PA01 LPS was
preincubated with either polymyxin B and colistin at varying concentrations (0.75-100 pg/ml).
Bacterial survival is proportional to the concentration of LPS added.
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6.9 Results: Recombinant Expression of Defrl
The Defrl gene was amplified from murine cDNA (C57BL/6J) using PCR and the
fragment was subsequently cloned into a pET expression vector with a N-terminal
His6-tag (pET 6-His), for expression in various E. coli strains (DE3 lysogens).
Optimum recovery ofprotein was achieved by using the BL21 (DE3) strain.
Bacteria were grown in shake flasks at 37°C and expression induced with 1 mM
IPTG. The Defrl cell-free lysate was initially subjected to SDS-PAGE and run on a
4-12% gel. Coomassie staining showed no protein band of the expected molecular
weight of approximately 5 kDa (Fig 6.14). The molecular weight of 6-His Defrl was
based on protein analysis software, Vector NTI (Table 6.4). However, 6-His Defrl
fusion protein was not expressed successfully. The 6-His tag was also problematic,
as it could not be proteolytically cleaved from Defrl. A further expression system,
pET-30c (Fig 6.15) was also utilised to help both with expression and to allow
cleavage of the tag. Expression was achieved, but insolubility proved to be a
problem that was not overcome. Subsequently, Defrl was cloned into a pET
expression system (pET 6His-Glutathione-S-Transferase [GST]), which had a
Precission protease site to enable cleavage of the purification tag. This vector was
utilised because GST is a large (~29 kDa), highly soluble protein and it was hoped
that co-expression with Defrl would result in high expression and would solve any
solubility problem. Expression was induced as before, but the fusion protein was
found to be insoluble (Fig 6.16). An alternative route of expression was investigated
using the pET-22b expression vector. This system of expression exports induced
proteins into the periplasm ofE. coli. Interestingly, the periplasm is the location of
disulfide bond isomerases, which catalyse the formation of disulfide bonds in many
E. coli proteins (Hayashi et al.2000). It was hypothesised, that the complex folding
of the two intra-molecular disulfides in Defrl may be contributing to its high
insolubility, thus enzymatic formation may increase the likelihood of soluble protein
expression. The E. coli competent cells (BL21 DE3) were transformed with the
pET-22b plasmid containing the Defrl gene, as described previously. The cells were
grown to OD =1, and then induced with 1 mM IPTG, prior to proteins being
extracted from the periplasm using CTAB. The periplasmic extract was then purified
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S® protocol with FPLC. Forty fractions were collected and the absorbance for each
was measured (Fig 6.17). Fractions were then subjected to SDS-PAGE analysis (Fig
6.18A). A curious band, suspected to be approximately 3 kDa, was identified in
fraction 36, which was concentrated at 4°C, using a 3000 MWCO spin filter, and
analysed by SDS-PAGE (Fig 6.18B). Unfortunately, mass spectrometry analysis did
not confirm the presence ofDeff 1 in fraction 36, suggesting that Defr 1 had not been
successfully purified.
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Fig 6.14 Expression of 6His-Defr1 fusion protein. Lane 1: LMW marker; Lane 2: Control (no
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Fig 6.15 Recombinant expression of Defrl in pET-30c system. A. Schematic of 6His S-Tag
Defrl fusion protein. The thrombin and enterokinase protease sites enabled full cleavage of
6His-S tag. B. pET-30c expression plasmid. C. Protein analysis of 6His S-Tag Defrl prior to
cleavage. D. SDS-PAGE analysis of expressed fusion protein (4-12% SDS-PAGE gel
stained with commassie blue), Lane 1: LMW marker; Lane 2: Control (no IPTG); Lane 3:
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pETSHis GST -Defrl
Fig 6.16 Recombinant expression of Defrl in pET6H-GST system. A. Schematic of 6His-
GST Defrl fusion protein. The Precission protease site enabled cleavage of 6His-GST tag.
B. pET His-GST Defrl expression plasmid. C. Protein analysis of 6His-GST Defrl. D. SDS-
PAGE analysis of expressed fusion protein (4-12% SDS-PAGE gel stained with commassie
blue), Lane 1: LMW marker; Lane 2: Cell pellet showing highly expressed fusion protein.
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Fraction Number
Fig 6.17 Resource S® purification (FPLC) of periplasmic Defrl extract. OD was measured
at 280 nm.
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Fig 6.18 SDS-PAGE analysis of periplasmic extract purified by FPLC. A: Lane 1: LMW
marker; Lane 2: fractions 18/19; Lane 3: fractions 20/21; Lane 4: fractions 22/23; Lane 5:
fractions 24/25; Lane 6: fractions 26/27; Lane 7: fractions 28/29; Lane 8: fractions 30/31;
Lane 9: fractions 32/33; Lane 10: fractions 35/35; Lane 11: fraction 36. B: Lane 1:
concentrated (x2) fraction 36; Lane 2: LMW marker; Lane 3: glucagon (~3 kDa).
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6.10 Discussion
The sensitivity ofbacteria to CAMPs has been described as a potential "Achilles
heel" (Zasloff 2002). In this chapter, the antimicrobial activity of a novel murine
defensin was investigated in relation to structure/function since Defrl is unusual in
containing five cysteine residues (as opposed to six) and initial mass spectrometry
analysis inferred the presence of a covalently linked dimer. The importance of intra-
and inter-molecular disulfide bonds was also examined.
To the author's knowledge, this is the first report of a covalently bound defensin
dimer with broad-spectrum activity against multiresistant Gram-positive, Gram-
negative and fungal pathogens. Recent structural studies have suggested that, in
contrast to HBD1 and HBD2, HD3 forms a non-covalently bound dimer that may
account for its increased activity by increasing the positive surface charge (Schibli et
al. 2002). Thus, the increased activity noted for synthetic Deft 1 may be explained in
a similar manner. The relationship between defensin structure and activity has been
investigated in other studies (Wu et al. 2003). These authors produced protein
homologs lacking cysteine residues, and concluded that intramolecular disulfide
bonds in HBD3 did not contribute to antibacterial activity, although such bonding
appeared essential for the chemotactic properties of the peptide. In contrast to these
findings, the data presented in this thesis suggest that antibacterial activity is
intrinsically linked to disulfide bond formation in Defrl. MIC data for covalently
dimerised synthetic Deffl, its six-cysteine homolog, and a chemically reduced form
ofDeffl support the hypothesis that inter-molecular disulfide bonding increases the
antibacterial activity. Thus, dimerised Defrl is more active. Furthermore, the fact
that many of the bacterial pathogens investigated demonstrated resistance to the
polymyxins yet were sensitive to Deffl suggests that not all CAMPs necessarily have
the same mechanism of action.
Unfortunately, as has been reported for other defensins (Sahly et al. 2003), Bcc
species were not sensitive to the action ofDeffl. This result contradicts a previous
study by Morrison and co-workers who reported 40% killing ofB. cenocepacia
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J2315 by Defrl (Morrison et al. 2002). We were unable to reproduce this activity.
A possible explanation may be that the "batch" ofDefrl used in the earlier study was
not identical to the one used in this thesis. Unfortunately, the original sample was
unavailable for comparison. Other multiresistant CF pathogens, including S.
maltophilia, epidemic P. aeruginosa and MRSA were each found to be sensitive to
Defrl. Since conventional treatments for such pathogens remain limited, novel
antimicrobial molecules could be therapeutically significant. The decision to include
the polymyxins in this study was deliberate and informative. The polymyxins are
amphiphilic cyclic polycationic peptides and constitute a separate class of CAMPs
consisting of five different molecules, polymyxin A-E (Gales et al. 2001). Only two
polymyxins are used therapeutically, polymyxin B and E (colistin), and their activity
extends mainly to Gram-negative bacteria (Conrad and Glanos 1995). Polymyxin B,
a fermentation product from Bacillus polymyxa, has an overall net charge of +5
(Hancock and Chappie 1999). Polymyxin E (colistin), a fermentation product from
Bacillus colistinus, became clinically available in 1959, and exists in two forms:
colistin methanesulfonate and colistin sulfate. The former has a superior therapeutic
ratio, but cannot neutralise endotoxin to the same extent as colistin sulfate which was
used in this thesis (Anonymous 2002, Li et al. 2001).
A major caveat in the use of 'defensins' as therapeutic agents is the development of
bacterial resistance to mammalian derived CAMPs. A recent review outlined the
need for further research prior to the widespread use ofmammalian, and in particular
human, CAMPs (Bell and Gouyon 2003). Much of the concern has focussed on the
possibility that widespread use of human derived CAMPs may result in the
development of resistance in bacteria rendering the human host unable to mount an
effective innate response against bacterial pathogens. The study of a murine defensin
has even greater therapeutic significance therefore, as any resistance generated may
not affect human CAMPs, unless the resistance mechanism to all mammalian
CAMPs is the same. Conventional opinion appears to be that resistance to CAMPs is
both rare and unlikely (Hancock and Chappie 1999, Zasloff 2002). Despite this re¬
assurance, the presence of CAMP resistance has been recognised and cannot be
ignored. The interaction of the CAMP with negatively charged moieties on the
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bacterial surface appears to be the site of resistance. In the case ofGram -negative
bacteria, alterations in LPS structure affect sensitivity to CAMPs. In Salmonella the
PhoP/PhoQ two-component system plays an important role in resistance to CAMPs
and virulence (Miller et al. 1990). This system is widespread in Gram -negative
bacteria and related to virulence via alterations in the bacterial cell membrane
(Oyston et al. 2000). Interestingly, a popular explanation for the intrinsic resistance
of the Bcc to the polymyxins is based on reduced negativity of LPS by the addition
ofAra4N to the lipid A moiety of LPS. This alteration in LPS has been shown to
confer polymyxin resistance in a number of other bacteria, including E. coli (Boll et
al. 1994, Numimila et al. 1995), Salmonella enterica (Vaara et al. 1981), and Proteus
mirabilis (Radziejewska-Lebrecht et al. 1988). Resistance via this mechanism is
assumed to be due to a lower binding efficacy of the positively charged polymyxin
and the reduced negatively charged LPS. Yet, the data presented in this thesis has
shown that Bcc LPS can bind CAMPs (including the polymyxins) and prevent them
from killing sensitive bacteria at five times the MIC. It has been suggested that
CAMPs block binding of LPS to lipopolysaccharide binding protein (LBP) (Scott et
al. 2000). However, the data presented show that free LPS is capable of "mopping
up" CAMPs, suggesting that increased resistance may be achieved by shedding LPS.
Further novel and potentially important evidence of an interaction between Bcc LPS
and polymyxin B was described recently (Shimomura et al. 2003). The authors
demonstrated that polymyxin B can bind Bcc LPS without reducing its ability to
induce TNF-a or IL-6 and, increase its capacity to induce IL-1 (3 at concentrations of
polymyxin B that completely removed the cytokine stimulating effect of Salmonella
typhimurium LPS. Therefore, despite the apparent reduced negativity associated
with the addition ofAra4N, Bcc LPS can bind and alter the interaction between
CAMPs and bacterial membranes. Thus, it could be hypothesised that inherent
resistance in the Bcc to CAMPs is not due to lack ofbinding, but downstream of this
initial interaction.
The recombinant expression of a mammalian defensin was attempted in a
prokaryotic expression system as described. Unfortunately, the expression of an
active defensin was not achieved. There are several reasons that may account for this
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failure. First, this study has shown that synthetic Defrl has antibacterial activity
against E. coli. Therefore expression of a toxic molecule in a system based in E. coli
cells may appear naive. However, recombinant expression was attempted on the
basis of the cost of synthetic Defrl and because successful expression ofHBD3 had
previously been described in E. coli (Harder et al. 2001). However, key points were
omitted from this study and despite the authors' claims, recombinant expression of
HBD3 must remain questionable. Harder and co-workers failed to mention solubility
issues, the refolding conditions for the intra-molecular disulfides, the yield of protein
obtained from recombinant expression, or whether they observed E. coli toxicity
associated with HBD3 expression. In this thesis, attempts to resolve these issues
were unsuccessful since attempts to contact Harder and co-workers electronically or
otherwise failed. The second reason for failure may be related to toxicity. It was
noted, for example, that the expression ofDefrl impaired and slowed bacterial
growth, suggesting that toxicity may play a role in poor expression. A third
explanation is that the E. coli-derived protein lacks post-translational modifications
that may be necessary for successful expression. Fourth, insolubility may be
associated with unchecked over-expression, where protein folding is prone to error.
Fifth, mass spectrometry analysis of synthetic Defrl suggests that it exists as a dimer,
linked covalently by an inter-molecular disulfide bond, in addition to two intra¬
molecular disulfide bonds in each monomer. Disulfide bond formation is a complex
process and misfolding may affect expression and antimicrobial activity.
The therapeutic significance of a novel molecule with an extended spectrum of
activity against multiresistant CF pathogens cannot be understated. The chronic
infections associated with CF lung disease are continuingly being exposed to high
concentrations of antibiotics, including aerosolised colistin and tobramycin. The
selective pressure that such therapy applies to bacteria is considerable and may
contribute to selecting more highly resistant strains (including epidemic and
multiresistant P. aeruginosa), or increase colonisation by multiresistant bacteria such
as S. maltophilia and MRSA. In contrast to CF isolates ofP. aeruginosa, resistance
of non-CF isolates has been shown to be relatively low and unchanged over the last
five years (Henwood et al. 2001). An intriguing explanantion for the high levels of
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resistance in CF isolates is a corresponding high level of hypermutable (mutator)
strains in the CF patients (Oliver et al. 2000). Interestingly, colistin resistance in CF
isolates is thought to be low, with approximately 3% of CF isolates resistant based on
conventional breakpoints (Catchpole et al. 1997). The level of colistin resistance in
CF isolates may, however, be under-estimated, with 33% resistance noted during a
recent clinical trial of nebulised tobramycin versus colistin (Govan 2002, Hodson et
al. 2002). Furthermore, bacterial sputum loads were only partially reduced,
suggesting that colistin may exert both a bactericidal and anti-inflammatory effect
(Hodson et al. 2002). In addition, colistin resistant P. aeruginosa isolates emerged,
and appeared transmissible, after use of IV colistin in a paediatric CF centre in
Leeds, UK (Denton et al. 2002).
Treatment of a CF individual with synthetic Defrl may be beneficial, but not without
hazards. First, resistance to Defrl in sensitive organisms was not observed within
the laboratory, and although it would be naive to assume that it could not arise, it
does appear to be a rare event. Second, multiresistant bacteria have been shown to
be sensitive to the action ofDefrl, even if they are highly resistant to the
polymyxins, thus selection of such organisms would be reduced. It could be argued
that the acquisition of Bcc may be increased, due to their inherent resistance to
CAMPs. However, there is no evidence that the increased use of colistin in the
1990s in early therapy against P. aeruginosa is associated with the emergence of the
Bcc. Nor did Bcc emerge during the recent trial of tobramycin versus colistin
(Govan 2002). Bcc acquisition is reduced, but not eliminated, by strict cross
infection procedures and thus the therapeutic use ofDefrl should not increase the
incidence significantly if suitable cross infection measures are in place. In addition,
bacterial killing is not necessarily all that is desired of a novel therapy. Synthetic
Defrl has been shown to bind to B. cenocepacia (J2315) LPS, suggesting potential
use as an anti-inflammatory agent. However, the recent seminal paper by
Shimomura et al. (2003) emphasises the caution that is required in attributing LPS-




The need for novel antimicrobial agents has seldom been so urgent. The widespread
use (and mis-use) of conventional antibiotics has resulted in an upsurge in infections
caused by multiresistant bacteria. Aggressive and long-term use of antibiotics is
particularly typified during the treatment of CF lung infections, with the benefits of
reduced morbidity and mortality. However, the cost of such therapeutic regimes is
that the bacterial pathogen demonstrates increasing resistance throughout the course
of the disease, and more highly resistant species are acquired. Multiresistant species,
such as members of the Bcc, epidemic P. aeruginosa, S. maltophilia and MRSA are
problematic, and virtually unbeatable. In the case ofP. aeruginosa and Bcc this
situation is exacerbated by potential for epidemic spread and increased virulence
(Jones et al. 2002).
7.2 General Conclusions
This thesis has focussed on three main areas, New Zealand manuka honey,
bacteriophage and their endolysins, and a novel murine (3-defensin: Defrl. The
significance ofboth broad-spectrum agents, NZMh and Defrl, is that antimicrobial
activity extended to highly resistant Gram-negative and Gram-positive bacteria.
NZMh has been shown to be bactericidal for members of the Bcc, as well as other
multiresistant bacteria. The active components were not identified, although
osmolarity, H2O2 and pH were not found to be solely responsible. Interestingly, this
agent was used clinically, and appeared to show considerable promise during an
episode of "cepacia syndrome".
The bacteriophages of the Bcc have been shown to be promiscuous, their spectrum of
activity extending across the complex and to other pseudomonads. This widespread
activity is undesirable for therapeutic agents and may contribute to antibiotic
resistance via horizontal transfer. The recombinant expression of bacteriophage-
derived endolysins was investigated. Although both failed to demonstrate bacterial
killing, further work is required to optimise expression.
The activity of a novel five-cysteine containing murine defensin, Defrl, was found to
extend to multiresistant organisms that demonstrated considerable resistance to
conventional CAMPs, including polymyxin B and colistin. Despite the fact that
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members of the Bcc were resistant, Defrl was capable of binding LPS derived from
B. cenocepacia J2315. This binding was capable of inhibiting the action ofDeffl
against a sensitive strain at five times the MIC suggesting that resistance to Defrl, in
the Bcc, is downstream of LPS binding. The relationship between Defrl structure
and its antimicrobial activity was also investigated. It was found that intra- and inter-
molecular disulfide bridging are important factors in the potency of this molecule as
an antimicrobial agent. Recombinant expression was attempted in a number ofE.
coli based expression systems. The Defrl protein expressed was invariably
insoluble; therefore further work is required to express a denatured form of Defrl
with subsequent refolding steps.
Although some results were not as we would have wished, the use of the novel
agents described could have a significant therapeutic impact in the treatment of CF
lung infections. Possible synergism with conventional therapies may increase their
efficacy, particularly Defrl. Antibiotic resistance in the Bcc can result from reduced
OM permeability, thus agents capable of disturbing the membrane may sensitise the
bacteria to hydrophilic antibiotics. Such "sensitisation" has been suggested for
polymyxin derivatives (Tsubery et al. 2000). Therefore, although Defrl did not
demonstrate killing against the Bcc, it may yet prove to be an important Bcc
antagonist.
Taken together, these results show that resistance against antimicrobial agents varies
within the Bcc. NZMh exerts a promising bactericidal effect on members of the Bcc,
including B. cenocepacia J2315. The novel Bcc bacteriophages may prove to be a
useful panel for further study, either as vectors for horizontal gene transfer or as
therapeutic agents. The results confirm previous reports showing that Bcc isolates
are inherently resistant to CAMPs, including the novel 5-cysteine defensin, Defrl.
However, synthetic Defrl was shown to be active against a panel ofmultiresistant
pathogens associated with infections in CF and the respiratory tract. Further research
is required to optimise the recombinant expression ofBcep781 endolysin, D3 lysin,
and Defrl, to allow investigation of their antimicrobial properties and their potential
as therapeutic agents against multiresistant CF pathogens.
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The Burkholderia cepacia complex comprises a group of nine closely related species that have
emerged as life-threatening pulmonary pathogens in immunocompromised patients, particularly
individuals with cystic fibrosis or chronic granulomatous disease. Attempts to explain the genomic
plasticity, adaptability and virulence of the complex have paid little attention to bacteriophages,
particularly the potential contribution of lysogenic conversion and transduction. In this study,
lysogeny was observed in 10 of 20 representative strains of the B. cepacia complex. Three
temperate phages and five lytic phages isolated from soils, river sediments or the plant rhizosphere
were chosen for further study. Six phages exhibited T-even morphology and two were lambda-like.
The host range of individual phages, when tested against 66 strains of the B. cepacia complex and a
representative panel of other pseudomonads, was not species-specific within the B. cepacia
complex and, in some phages, included Burkholderia gladioliand Pseudomonas aeruginosa. These
Received 11 October 2002 new data indicate a potential role for phages of the B. cepacia complex in the evolution of these soil
Accepted 12 February 2003 bacteria as pathogens of plants, humans and animals, and as novel therapeutic agents.
INTRODUCTION
In the last decade, bacteria previously identified as Burkhol¬
deria cepacia sensu lato have become recognized as important
human pathogens, and particularly as a cause of life-
threatening pulmonary infections in individuals with cystic
fibrosis (CF) or chronic granulomatous disease (Govan era/.,
1996; LiPuma, 1998; Jones et al, 2001; Mahenthiralingam et
al., 2002). Concurrently, polyphasic taxonomic approaches
revealed that B. cepacia sensu lato comprises at least nine
phylogenetically related but genomically distinct species
(genomovars) (Vandamme et al, 1997, 2003; Coenye et al.,
2001). Known as the B. cepacia complex, the group currently
comprises B. cepacia (previously genomovar I), Burkholderia
multivorans (genomovar II), 'Burkholderia cenocepacia' (gen¬
omovar III), Burkholderia stabilis (genomovar IV), Burkhol¬
deria vietnamiensis (genomovarV), B. cepacia genomovarVI,
Burkholderia ambifaria (genomovar VII), Burkholderia an-
thina (genomovar VIII) and Burkholderia pyrrocinia (geno¬
movar IX). All species in the B. cepacia complex have been
isolated from clinical specimens; however, the clinical
significance of individual genomovars in human disease
remains unclear. Approximately 90 % of B. cepacia complex
isolates cultured from CF patients belong to B. multivorans
and 'B. cenocepacia' (Agodi et al., 2001; LiPuma et al., 2001;
Abbreviations: CF, cystic fibrosis; NBYE, nutrient broth with yeast extract
Mahenthiralingam et al., 2002; Speert et al., 2002;
Vandamme et al., 2003). These two species account for most
episodes of epidemic spread in CF and non-CF patients
(Holmes et ah, 1999; Mahenthiralingam et ah, 2002); 'B.
cenocepacia' is also the species most associated with the rapid
pulmonary decline known as cepacia syndrome, and with
post-transplant mortality (Aris et ah, 2001).
Most isolates of the B. cepacia complex exhibit high-level
resistance to all major classes of antibiotics (Lewin et al.,
1993; Pitt et al., 1996; Nzula et al., 2002). The B. cepacia
complex is also one of the few groups of bacteria to exhibit
intrinsic resistance to cationic antimicrobial peptides
(Hancock, 1997). Some strains are susceptible in vitro to
ceftazidime and meropenem, arguably the most potent 'anti-
cepacia' agents; however, the majority of strains, including
the highly transmissible 'B. cenocepacia' lineage ET12, are
resistant to these agents (Lewin et al, 1993; Nzula et al.,
2002).
All bacteria in the B. cepacia complex have large genomes
(mean size approx. 8 Mbp), comprising multiple replicons
that may contribute to genomic plasticity (Lessie et al., 1996;
Wigley & Burton 2000; Parke & Gurian-Sherman, 2001;
Mahenthiralingam et al, 2002). Ironically, the B. cepacia
complex could be considered as both friend and foe, as some
strains are highly effective as biopesticides in the control of
plant fungal diseases and in bioremediation ofcontaminated
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soils (Holmes et al., 1998; Parke & Gurian-Sherman,
2001). These dual roles raise important medical, agricultural
and ecological issues (Govan et al., 1996, 2000; Govan &
Vandamme, 1998; Environmental Protection Agency, 2002),
including the significance of horizontal gene transfer in
assessment of the risk to humans of using these bacteria as
biopesticides or in bioremediation (Holmes et al., 1998;
LiPuma & Mahenthiralingam, 1999; Govan et al., 2000;
Parke & Gurian-Sherman, 2001).
Attempts to explain the genomic plasticity, adaptability and
virulence of the B. cepacia complex have paid little attention
to the potential contribution of bacteriophages. In many
pathogens, these bacterial viruses are recognized as impor¬
tant contributors to virulence, in the form of bacterial
lysogens, or as vectors in horizontal gene transfer. Interest
in the use of phage-induced bacterial lysis for therapeutic
purposes was widespread in the 1920s, but declined with the
arrival of the antibiotic era. However, as antibiotic resistance
increasingly threatens standard therapies against bacterial
infections, there is renewed interest in the antimicrobial
properties of these highly specific agents (Pirisi, 2000;
Sulakvelidze et al., 2001).
Little is known of the phages of the B. cepacia complex. Early
reports on the 'B. cepacia' phages CP1 (Cihlar et al., 1978)
and CP 75 (Matsumoto et al., 1986) predate the revision of
B. cepacia taxonomy. However, a recent report from our
laboratories described two transducing bacteriophages, NS1
and NS2, whose host range included the five genomovars (I-
V) that were known at the time, and also extended to
Pseudomonas aeruginosa (Nzula et al., 2000). Lytic phages
with an interspecies host range within the B. cepacia complex
have also been reported in association with soil-borne strains
of 'B. cenocepacia' (LiPuma etal., 2000). These results suggest
that lysogenic conversion and transduction could play a role
in the evolution ofspecies ofthe B. cepacia complex as human
pathogens, and indicate the need for further studies on the
host range and properties of phages associated with the B.
cepacia complex and related bacteria.
In this study, we investigated the prevalence of lysogeny
within the nine current species of the B. cepacia complex and
isolated lytic phages from natural habitats of these bacteria,
including the plant rhizosphere. Our results show that the
host range of the phage panel includes seven genomovars
and, in the case of individual phages, is not genomovar-
specific.
METHODS
Bacterial strains. The 66 strains of the B. cepacia complex used in this
study are listed in Table 1. The collection comprised environmental and
clinical isolates belonging to genomovars I-V that were included in the
B. cepacia strain panel (Mahenthiralingam et al., 2000a), and isolates
representing the recently identified genomovars VI-IX (Coenye et al.,
2001). Four isolates identified as Burkholderia ubonensis, a putative
tenth genomovar of the B. cepacia complex (Vermis et al., 2002), were
also included. Isolates were identified using recA RFLPs, whole-cell
protein electrophoresis and DNA-DNA hybridization (Mahenthiral¬
ingam etal., 2000b; Coenye etal., 2001). In addition, 55 strains ofrelated
pseudomonad species were screened as potential phage hosts: P.
aeruginosa (30 strains), Stenotrophomonas maltophilia (n = 11), Burk¬
holderia caledonica (n — 1), Burkholderia gladioli (n = 2), Comamonas
acidovorans (n = 2), Pseudomonas fluorescens (n = 2), Pseudomonas
mendocina (n — 1), Pseudomonas stutzeri (n = 2), Pseudomonas putida
(n = 1), Pseudomonas testosteroni (n = 1), Pseudomonas syringae pv.
tabaci (n = 1) and Ralstonia pickettii (n = 1). Clonal relationships were
excluded by PFGE fingerprinting using a Bio-Rad CHEF Mapper PFGE
system (Butler et al., 1995).
Media. Bacteria were grown in nutrient broth with 0-5 % yeast extract
(NBYE) at 37 °C in a shaking incubator. Soft overlay agar for phage
experiments comprised Luria-Bertani (LB) broth with 0-3% bacter¬
iological agar (Difco). The nutrient agar used was Columbia agar base
(39 g 1 1; Oxoid).
Isolation of lysogenic phages. Temperate phages were assayed and
maintained as described previously (Nzula et al., 2000). Lysogeny was
investigated using the following method: the 20 strains designated in
Table 1 with the symbol t were prepared as saline suspensions (approx.
106 c.f.u. ml-1), inoculated onto tryptone soy agar (TSA; Oxoid) using a
multipoint inoculator and incubated at 30 °C for 6 h. Bacterial growth
was inverted over chloroform vapour for 15 min and then allowed to
air-dry for 15 min. Soft agar overlays (2-5 ml), inoculated with 100 pi
exponential-phase culture ofeach of the 20 strains, were layered over the
original bacterial growth and allowed to set; the plates were incubated
overnight at 37 °C. Phage plaques were identified in the overlay in the
proximity of the original inoculum and used to prepare single-plaque
preparations as follows: an agar plug containing a single phage plaque
was removed using a sterile glass pipette, transferred to 10 ml phage
buffer (10 mM Tris/HCl, pH 8-0; 10 mM MgCL), vortexed for 30 s,
centrifuged at 3000 g for 30 min and filtered (pore size 0-2 prn;
Millipore).
Isolation of lytic environmental phage. The natural habitats ofthe B.
cepacia complex include soils, river sediments and plants, particularly
the plant rhizosphere (Fisher et al., 1993; Butler et al., 1995; Parke &
Gurian-Sherman, 2001). Therefore, 20 samples of soil, river sediment
and rhizosphere (soil plus root material) were collected. The presence of
phage was then investigated using a modification of the phage
enrichment technique described by Weiss et al. (1994), as follows:
approximately 10 g sample was suspended in 15 ml LB broth and
dispersed by shaking in an orbital incubator for 30 min at 30 °C. After
removal of soil particles by centrifugation (4000 g for 20 min), the
supernatant was filter-sterilized (pore size 0-2 pm; Acrodisc) and 1 ml
aliquots were added to 15 sterile tubes. To each extract was added 25 pi
exponential-phase culture fromoneofl5 propagating strains chosen to
represent the genomovars of the B. cepacia complex strain panel
(Mahenthiralingam et al., 2000a), and the contents were incubated at
37 °C overnight. The bacterial cells were removed by centrifugation
(4000 g for 30 min), the supernatant was membrane-filtered as before
and 10 pi filtrate was spotted onto single-layer lawns of the propagating
strain. Phage plaques were identified after overnight incubation at
37 °C, and single-plaque stocks were prepared as described in the
previous section.
High-titre phage preparations. High-titre phage preparations were
prepared as follows: 100 pi single-plaque preparation, containing
approximately 105 p.f.u. ml ', was added to 2-5 ml soft nutrient agar,
previously seeded with 100 pi exponential-phase culture of the propa¬
gating strain. The mixture was then overlaid on nutrient agar and
allowed to set. After 18 h at 37 °C, overlays showing semi-confluent lysis
were transferred into 10 ml phage buffer. The lysate was then vortexed
and centrifuged at 3200 g for 30 min and the supernatant was
membrane-filtered. Phage titres were determined, as p.f.u. ml-1, by
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incorporating 100 pi host bacteria (exponential-phase NBYE culture)
and 100 pi phage stock in 2-5 ml soft agar overlay, and lytic plaques were
enumerated after 18 h incubation at 37 °C. Stock preparations were
maintained at 4 °C.
Host range of phages. Stock phage preparations were diluted in phage
buffer to approximately 108 p.f.u. ml 1 against the propagating strain,
and 10 pi was spotted onto single-layer lawns (prepared from expo¬
nential-phase NBYE cultures) of potential host bacteria. Lytic activity
was recorded after 24 h at 37 °C on a scale ranging from < 10 plaques
(+) to confluent lysis (+++) (Table 1).
Electron microscopy. Stock phage preparations (approx.
108 p.f.u. ml ') were centrifuged at 100000 g for 1 h. Phage pellets
were resuspended in 1 M ammonium acetate, negatively stained with
2 % (w/v) potassium phosphotungstate solution (pH 7-0) and examined
with a Hitachi model HU-12A transmission electron microscope.
Phage DNA extraction and RFLP profiling. In preparation for DNA
extraction, high-titre phage stocks (containing at least 1010 p.f.u. ml ')
were prepared using soft agar overlays, as described above. DNA was
extracted from 10 ml phage stock using the Wizard Lambda preparation
DNA purification system in conjunction with the Vac-Man laboratory
vacuum manifold (both from Promega). Extracted DNA was eluted in
sterile distilled water and stored at —20 °C. DNA quality was assessed on
an E-gel pre-cast 0-8% agarose gel (Invitrogen Life Technologies). In
cases where DNA was not of sufficient quality for DNA restriction,
purification was performed using the PCR protocol from the QIAquick
gel extraction kit (Qiagen). Purified DNA was eluted in 30 pi elution
buffer and stored at 4 °C. To determine genome size and to confirm that
the phages were different from one another, approximately 1 pg DNA
was restricted using 10 U Hindlll (Promega), incubated for 3 h at 37 °C
and visualized on 0-6% 05X TBF, agarose gel alongside 1 pi Ready-
Load Lambda DNA/Hmdlll fragments (Invitrogen Life Technologies).
RESULTS
Lysogeny
Of the 20 strains of the B. cepacia complex that were
investigated, 10 strains [ATCC 25416T and ATCC 17759
(genomovar I); C31611, C1576, C1962 and C3163 (B.
multivorans); J2315T, C3166 and C3170 ('B. cenocepacia');
and C3174 (B. stabilis)] were found to be lysogenized. These
provided 14 temperate phages (DK1-DK4 and MM1-
MM10) for further study.
Isolation of environmental phages
Five virulent phages, JB1, JB3, JB5, RLlc and RL2, were
isolated from soils and from the rhizosphere ofvarious plants
(Table 2). Most positive samples included decayed plant
material collected from moist environments, but phages were
also isolated from dry soils.
Host rangeof B. cepacia complex phages NS1, NS2
and newly isolated phages
To confirm that distinct phages were being accumulated and
investigated, we determined the host range of the 19 phages
against a preliminary bacterial panel comprising the 20
isolates of the B. cepacia complex that were used in the
lysogeny screen, and also the HindUl RFLP profile (and
hence an approximate genome size; Table 2). With the
exception of phages JB3, DK2 and DK3, the genomes of the
B. cepacia complex phages were within the range 40-48 kbp
(Table 2). If several phages shared the same host range and
RFLP profile, only one phage was used for further study. An
exception was made for phages RLlc and RLlt, which shared
the same host range and RFLP profile but produced different
plaque morphologies: clear plaques associated with virulent
phage (RLlc) or turbid, temperate phage plaques (RLlt).
Similar host ranges and RFLP profiles were observed with the
temperate phages DK2 and DK3, which had respectively been
isolated from 'B. cenocepacia' C3166 and B. stabilis C3174. As
previously observed for NS1 and NS2, none of the newly
identified phages was inactivated by treatment with chloro¬
form. In addition, no evidence of bacteriocin activity was
found during the search for B. cepacia complex phages.
The host range of phages NS1, NS2 and eight novel phages
(JB1, JB3, JB5, DK1, DK3, RLlc, RLlt and RL2) was then
determined against an enlarged panel of 66 isolates of the
B. cepacia complex and 55 isolates representing other
pseudomonads. The host range of individual phages in¬
cluded multiple species of the B. cepacia complex. Collect¬
ively, the host range of the phage panel included seven of the
presently recognized B. cepacia genomovar species; no phage
activity was detected against the single representatives of B.
cepacia genomovar VI or B. ambifaria (Table 1). However,
within each B. cepacia species, there was wide variation in
susceptibility to an individual phage. B. multivorans ap¬
peared to be least susceptible to phages investigated in this
study: of nine B. multivorans strains examined as potential
phage hosts, only strain C2775 showed susceptibility. As
observed previously for NS1 and NS2, the host range of some
of the phages was not restricted to the B. cepacia complex.
P. aeruginosa strains CI546 and J2852 were susceptible to
phage JB3, and B. gladioli strain C3654 was susceptible to
phages NS2, DK1, RLlc, RLlt and JB5.
Electron microscopy
In accordance with previous studies on phages NS1 and NS2
(Nzula et al., 2000), electron microscopy revealed the novel
phages JB1, JB5, DK2/DK3, RLlc/RLlt and RL2 to be
morphologically T-even-like phages, with hexagonal heads
and contractile tails ofvariable length. In contrast, phages JB3
and DK1 were lambda-like, with hexagonal heads and
flexuous, non-contractile tails.
DISCUSSION
This study confirmed that lysogeny is relatively common in
isolates of the B. cepacia complex and demonstrated the
presence ofvirulent B. cepacia complex phages in the natural
habitats of these bacteria. In agreement with previous
observations of phages NS1 and NS2 (Nzula et al., 2000),
the host range of the newly isolated phages was not
genomovar-specific and, in some phages (for example JB1),
it included the majority of B. cepacia complex species. This
broad host range, which in some phages extended to the
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Table 1. Host range of bacteriophages within the B. cepacia complex
—, Lack of sensitivity to phage; +, < 10 plaques at phage inoculation site; ++, >10 plaques at phage inoculation site; +++, confluent lysis at phage
inoculation site.
Strain JB1 JB3 JB5 DK1 DK3 NS1 NS2 RLlt/RLlc RL2
B. cepacia
ATCC25416t (= LMG 1222T)*t ________
C2970 (= LMG 17997) +- + -- + + +++
C3159 (= LMG 18821) t ________
ATCC 17759 (= LMG 2161)*t _ _ _ _ +++ _
B. multivorans
C2775 — + — + + + + +++
C3161t (= LMG 13010T)*f ________
C3162 (= LMG 18825)t
C3163 (= LMG 18824)»f ________
C3164 (= LMG 18823)t
ATCC 17616 (= LMG 17588) ________
CI 962 (= LMG 16665)*t
C1576 (= LMG 16660)"t ________
C3160 (= LMG 18822)t
'B. cenocepacia'
1415 (= LMG 16654) - - - + - - + - +++
J2315t (= LMG 16656T)*t - - - - - - +++ - -
C1394 (= LMG 16659) - - - - + - + - ++
J2956 +++ +++ +++ - +++ - - + +++
C2836 - - + - - + + - ++
C3165 (= LMG 18826) - - - - - - + - -
C3166 (= LMG 18863)*t - - - - - + + - -
C3167 (= LMG 18827)f - - - - - - - - -
C3168 (= LMG 18828)t - - - - - - - - -
C3169 (= LMG 18829) +++ +++ ++ +++ +++ ++ ++ - +++
C3170 (= LMG 18830)* - - - - - + + - +++
ATCC 17765 (= LMG 18832) ++ - + +++ - - + + -
B. stabilis
C3171t (= LMG 14294T) _____ + _ +++
C3172 (= LMG 18870) +_______
C3173 (= LMG 18888)t . ____ + ___
C3174 (= LMG 14086)*t ____
B. vietnamiensis
C2978 (= LMG 16232)t ----- + + +++
C3175 (= LMG 18835)t
C3176 (= LMG 18836)t ______ + _




J2742t (= LMG 191821) ________
B. anthina
J2552 (= LMG 16670) ________
J2553
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Table 1. cont.
Strain JB1 JB3 JB5 DK1 DK3 NS1 NS2 RLlt/RLlc RL2
J2945 - - - - _____
J2946 - - - - _____
J2949 - - - - _____
J2950 - - - - -----
J2951 +++ - +++ - - + - - +++
J2862 - - - - - - - - +++
C1658 (= LMG 20982) +++ + +++ - _____
CI 765 (= LMG 20983) +++ + ++ - - + — ++ —
B. pyrrocinnia
12536 - - - - _____
J2542 - - - - -----
C1469 - - - - _____
C3909 + + - ++ - _____
C3918 + - + + - + - - +++
C3928 - - - - _____
C3930 +++ - +++ - - +++ - - ++
C3993 +++ - +++ - ----++
C3995 +++ - +++ - ----
C3997 + - - - _____
B. ubonensis
E26 - - - - ----++
E27 - - - - _____
E571 - - - - _____
E551 + ++ - - _____
Genomovar unclassifiable
J2540 (= LMG 16672) - - - - - + + - -
*Lysogenic strains.
fStrains used in lysogeny experiments.
Table 2. Phage genome size, plaque morphology and source
Phage Genome size Source Plaque morphology*
(bp)
JB1 40 000 Soil, the Caribbean Turbid plaques, variable size (0-5-1 mm in diameter)
JB3 34 000 Plant rhizosphere, UK Clear plaques (1 mm in diameter)
JB5 40 000 Plant rhizosphere, UK Turbid plaques, variable size (0-5-1 mm in diameter)
DK1 45 900 Lysogeny Turbid plaques, variable size (0-5-1 mm in diameter)
DK2/DK3 29 300 Lysogeny Turbid plaques (1 mm in diameter)
NS1 48 000f Lysogeny Turbid plaques (0-5-1 mm in diameter)
NS2 48 000t Lysogeny Semi-clear plaques, variable size (0-5-1 mm in diameter)
RLlc/RLlt 44 300 Plant rhizosphere, UK RLlc, clear plaques (1 mm in diameter); RLlt, turbid
plaques (1 mm in diameter)
RL2 40 000 Pond sediment, UK Semi-clear plaques, variable size (0-5-1 mm in diameter)
*Plaque morphology on propagating strains (i.e. strain 12956 for phages JB1, JB3 and )B5; strain C3169 for phages DK1, DK3,
NS2 and RL2; strain C2978 for phages RLlc/RLlt; strain C3166 for phage NS1).
fData from Nzula et al. (2000).
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related pseudomonads P. aeruginosa and B. gladioli, is
interesting. With the exception of unusual phages such as
the plasmid-like 'phasmid' P4 (Gutmann et al, 1990), the
host range of most phages is species-specific. Lack of
bacteriocin activity in our study could be explained by the
techniques and conditions used and the low prevalence of
bacteriocinogeny in B. cepacia sensu lato (Govan & Harris,
1985).
A broad host range for B. cepacia complex phages could
contribute to the genomic plasticity of these bacteria, and
their evolution from highly metabolically active soil sapro¬
phytes to plant and human pathogens and, recently, also
animal pathogens (Berriatua et al., 2001). Lysogenic conver¬
sion and transduction are important processes by which
chromosomal host genes can be acquired and exchanged
between bacteria. We have previously demonstrated in vitro
transfer of antibiotic-resistance genes between B. vietnamen-
sis strains by phages NS1 and NS2 (Nzula et al., 2000).
As reported for Shigella flexneri (Allison & Verma, 2000),
prophages may contribute to O-antigen modification in the
B. cepacia complex (Kenna et al., 2003), and to the role of
B. cepacia complex LPS as a potent virulence determinant
(Shaw et al., 1995; Hughes et al., 1997). Opportunities for
transduction and lysogenic conversion would exist not only
in natural environments shared by various B. cepacia com¬
plex species and related bacteria, but also in CF airway
secretions, where mixed infections are frequent and bacterial
populations can reach densities in excess of 109 c.f.u. ml-1.
Based on a close taxonomic relationship and shared insertion
sequences and environmental habitats, we were particularly
keen to test the phage panel against isolates of Burkholderia
pseudomallei, the causative agent of melioidosis and a
potential agent for bioterrorism (Mack & Titball, 1998). In
collaboration with Dr Ty Pitt (PHLS, Colindale, London,
UK), only phage NS2 was found to be active, lysing 13 of40 B.
pseudomallei strains tested (unpublished results). The po¬
tential importance ofbroad-host-range phages such as NS2 is
also suggested by recent reports of B. pseudomallei infection
in CF patients (including coinfection with B. cepacia)
following travel to Thailand, where melioidosis is endemic
(Schulin & Steinmetz, 2001; Visca et al., 2001).
Further studies are required to determine the transducing
potential and other biological properties (e.g. nucleic acid
content and bacterial receptors) of the B. cepacia complex
phages that were accumulated in this study. Meanwhile,
several preliminary observations merit comment. The shared
host range and RFLP profiles of the temperate phages DK2
and DK3, respectively isolated from strains of'B. cenocepacia'
and B. stahilis, suggest that integration of the same phage can
occur in different species of the B. cepacia complex. While the
presence of multiple prophages within a single strain is
common in P. aeruginosa (Holloway et al., 1960), we found
no evidence of polylysogeny during our investigation of B.
cepacia complex phages. The variable plaque morphology
exhibited by the environmental phages RLlc and RLlt is
interesting and, to our knowledge, has not been reported
previously for B. cepacia complex phages.
The relative lack of susceptibility of B. multivorans to the
phage panel was interesting. Taken together, B. multivorans
and 'B. cenocepacia' account for almost 90% of clinical
isolates of the B. cepacia complex; however, in contrast to
'B. cenocepacia', B. multivorans is rarely isolated from natural
environments (Bevivino et al., 2002; authors' unpublished
data). In our study, of nine B. multivorans strains tested, only
one (C2775) exhibited phage susceptibility. However, this
resistance may be misleading, as a recent study in our
laboratories identified a novel B. cepacia complex phage
(RU2) from soil, which plates on B. multivorans C3164 and
also on three other B. cepacia complex isolates that are
resistant to the primary phage panel (Table 1), namely J2552
and J2553 (both B. anthina) and E571 (B. ubonensis).
Whole-genome sequencing of bacteria provides increasing
evidence for widespread exchange of chromosomal genes
and other extrachromosomal elements, mediated by phages.
Thus, analyses following the recent sequencing and anno¬
tation of'B. cenocepacia' J2315T (= LMG 166561 = NCTC
13227t; http://www.sanger.ac.uk/Projects/B_cepacia/) are
keenly awaited. In relation to the issue of multiple lysogeny
in the B. cepacia complex, we performed a BLAST search of the
provisional J23151 genome sequence and found evidence ofa
single prophage. If confirmed, this would be an interesting
result as, in this study and in a more extensive search for
lysogeny in J23151, we isolated only one temperate phage,
DK4 (authors' unpublished data). The availability of broad-
host-range phages complements the panel of B. cepacia
complex strains (Mahenthiralingam et al., 2000a) and should
facilitate future research on these highly adaptable and
increasingly important bacteria. Furthermore, in addition
to the established therapeutic use of lytic phages, phage-
encoded lytic enzymes may provide novel therapeutic agents
against B. cepacia complex infections (Schuch et al., 2002),
for which there are few antibiotic options at present (Nzula
et al., 2002).
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Abstract
The Burkholderia cepacia complex comprises at least nine phylogenetically related genomic species (genomovars) which cause life-
threatening infection in immunocompromised humans, particularly individuals with cystic fibrosis or chronic granulomatous disease.
Prior to recognition that 'B. cepacia' comprise multiple species, in vitro studies revealed that the lipopolysaccharide (LPS) of these Gram-
negative bacteria is strongly endotoxic. In this study, we used 117 5. cepacia complex isolates to determine if there is a correlation between
O-antigen serotype and genomovar status. Isolates were also tested for their ability to act as bacterial hosts for the LPS-binding
bacteriophages NS1 and NS2. The absence of genomovar II (Burkholderia multivorans) in 'historical B. cepacia' isolates was notable.
Neither O-serotype nor phage susceptibility correlated with genomovar status. We conclude that variability in LPS may contribute to the
success of these highly adaptable bacteria as human pathogens.
© 2002 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The Burkholderia cepacia complex consists of phyloge¬
netically related Gram-negative bacteria that can be divid¬
ed into at least nine genomic species (genomovars) [1]. The
B. cepacia type strain, ATCC 25416, which belongs to
genomovar I, was identified originally as the cause of
onion rot [2], In the last decade, however, these versatile
bacteria have emerged as the cause of life-threatening hu¬
man infections, notably pulmonary infections in individu¬
als with cystic fibrosis (CF) or chronic granulomatous dis¬
ease [3-5], of bacterial ovine mastitis [6] and, ironically as
highly effective biopesticides and bioremediators [7]. All
nine genomovars have been cultured from clinical speci¬
mens, however, the prevalence of individual genomovars is
disproportionate with strains belonging to genomovar III
and Burkholderia multivorans (formerly genomovar II) re¬
* Corresponding author. Tel.: +44 (131) 650 3165;
Fax: +44 (131) 650 6653.
E-mail address: d.kennafffied.ac.uk (D.T. Kenna).
sponsible for almost 90% of isolates from CF patients
[5,8]. In individuals with CF, patient-to-patient spread
and the acute pulmonary deterioration, referred to as 'ce¬
pacia syndrome', are also primarily associated with ge¬
nomovar III and B. multivorans [3-5]. Following lung
transplantation, the prognosis for patients infected with
genomovar III is less favourable than for those infected
by strains belonging to other genomovars [9]. It has been
suggested that this phenomenon reflects differences in lipo¬
polysaccharide (LPS)-mediated proinflammatory activity
between B. cepacia genomovars [10].
LPS (endotoxin) is an important bacterial virulence fac¬
tor whose biological properties include immunostimula-
tion of mononuclear cells, B cells and granulocytes [11],
In vitro studies, performed before it was known that the
B. cepacia complex comprises multiple species, showed
that 'B. cepacia' LPS exhibits a higher endotoxic activity
and a more pronounced proinflammatory cytokine re¬
sponse compared to Pseudomonas aeruginosa LPS [12.
13]. Other studies, at this time, indicated that 'B. cepacia'
LPS may contribute to the inflammatory nature of B.
cepacia infection in CF patients both by promoting in-
0928-8244/02/$22.00 © 2002 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved,
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creased neutrophil recruitment and by priming neutrophil
respiratory burst responses [14]. The presence of a rough
or smooth LPS chemotype was also found to be variable
both within and between genomovars, with clinical isolates
more likely to possess rough LPS than environmental iso¬
lates [15].
The aim of our study was to investigate whether LPS
variability in the B. cepacia complex extends to the O-
antigen, the immunodominant component of LPS, and
whether O-serotype might correlate with genomovar sta¬
tus. Genomovar status was identified by recT-based PCR
[16] in isolates whose LPS endotoxicity had been studied
prior to the identification of the B. cepacia complex [12],
and in a collection of 'historical' isolates whose O-serotype
was known [17-19,20]. In addition, isolates were examined
for their ability to act as hosts for the B. cepacia LPS-
binding bacteriophages NS1 and NS2 [21].
2. Materials and methods
2.1. Bacteria
The bacterial strains used in this study comprised the
five 'B. cepacia' strains investigated by Shaw et al. [12], 98
isolates of known O-serotype used in the Rabkin et al.
study [20], and 19 additional serotyped isolates kindly sup¬
plied by Dr H. Monteil, Strasbourg, France. The majority
of isolates had been cultured from human respiratory se¬
cretions or from contaminated solutions and hospital
equipment. All isolates had previously been identified as
B. cepacia complex using biochemical tests and the API 20
NE system (bioMerieux, Marcy l'Etoile, France). Serotyp-
ing had been performed by the immunisation of rabbits
with O antigen, [17-19] and subsequent agglutination of
heat-treated bacteria with O antisera. Included in the 117
isolates we examined were representatives of the nine
known serotypes (01-09) and the polyagglutinating types,
01/04, and 01/07.
2.2. Media and DNA extraction
Bacteria were grown overnight at 37°C on nutrient agar
(Oxoid Ltd., UK) or on selective agar (Mast cepacia agar,
Mast Diagnostics, Ltd., UK). For genomovar identifica¬
tion by recA PCR [16], DNA was extracted using a modi¬
fied version of the technique supplied with the Puregene
DNA isolation kit (Gentra systems, Minneapolis, MN,
USA). Briefly, 500 pi of an overnight broth culture (nu¬
trient broth +0.5% yeast extract-NBYE) was centrifuged
at 13 000 rpm for 2 min, the supernatant discarded, the
bacteria resuspended in 300 pi of cell lysis solution and the
cells incubated at 80°C for 5 min. Thereafter, 1.5 pi of
RNase A solution was added to the cell lysate, the sample
inverted several times, and incubated at 37°C for 30 min.
The sample was allowed to return to room temperature,
100 pi of protein precipitation solution was added, the
mixture vortexed for 20 s, and centrifuged at 13 000 rpm
for 5 min. The supernatant containing the DNA was re¬
moved, mixed with 300 pi 100% isopropanol, inverted
several times and centrifuged at 13 000 rpm for 2 min,
before the supernatant was discarded. The DNA pellet
was washed with 300 pi of 70% ethanol, the tube inverted
several times, and centrifugation repeated. The ethanol
was discarded, and the pellet left to air dry for 15 min.
100 pi re-hydration solution was added and the DNA in¬
cubated at 65°C for 1 h.
2.3. PCR
DNA amplification was based on the technique of Ma-
henthiralingam et al. [16]. Briefly, a 25-pl reaction was set
up using PCR reagents from Qiagen (Qiagen Ltd., UK):
20 ng of DNA, 250 pM (each) deoxynucleoside triphos¬
phate, 1.5 mM MgCh, lxPCR buffer, 20 pmol each
primer (Cruachem Ltd., UK), 1 U Taq DNA polymerase,
and sterile distilled water. DNA was amplified in a Pro-
gene thermal cycler (Techne Ltd., UK) using the condi¬
tions specified by Mahenthiralingam et al. [16] and visual¬
ised on a 1% 0.5XTBE agarose gel alongside a 1-kb DNA
ladder (Gibco BRL, Life Technologies, Grand Island, NY,
USA). Strains of known genomovar status from the
B. cepacia complex strain panel [22] were used as positive
controls; negative controls consisted of reaction mixture
without DNA.
2.4. Propagation and host range of bacteriophages NS1 and
NS2
Bacteriophages NS1 and NS2 were propagated, main¬
tained, and their host range investigated using the meth¬
ods described previously by Nzula et al. [21].
3. Results
3.1. Genomovar typing using PCR
The genomovar status of 117 '5. cepacia' isolates of
known serotype was identified by recA-based PCR. Two
of the 117 isolates (1.7%) were identified as genomovar I,
while the majority of isolates (48/117; 41%) belonged to
genomovar IIIA. In addition, 17 of the 117 isolates
(14.5%) belonged to genomovar IIIB, 24/117 (20.5%)
were Burkhoiaeria stabilis (formerly genomovar IV), and
26/117 (22.2%) were Burkholderia vietnamiensis (formerly
genomovar V). No B. multivorans (formerly genomovar II)
were identified.
3.2. Serotyping data
Table 1 shows the distribution of B. cepacia complex
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Table 1
Distribution of B. cepacia complex serotypes within genomovars
Genomovar (No.) Number of isolates with each serotype (%)
Ol 02 03 04 05 06 07 08 09 01,7 01,4
1(2) 0 0 0 0 0 0 2 (100) 0 0 0 0
II (0) 0 0 0 0 0 0 0 0 0 0 0
IIIA (48) 6(13) 9 (19) 12 (25) 5(10) 8 (17) 1 (2) 0 4(8) 2(4) 1 (2) 0
IIIB (17) 5(29) 3(18) 6(35) 0 0 0 0 2(12) 1 (6) 0 0
IV (24) 5(21) 3(13) 4(16) 1 (4) 3 (13) 0 0 1 (4) 7(29) 0 0
V (26) 4(15) 6(23) 8(31) 0 2(8) 0 0 3(11) 2(8) 0 1 (4)
serotypes within the genomovars identified. Although 11
serotypes were represented amongst the 117 isolates inves¬
tigated, the majority comprised serotypes 01, 02, 03, 05,
08 and 09. When the data for serotype and genomovar
was combined, there was no correlation between O-sero-
type and genomovar status. For example, strains belong¬
ing to genomovars IIIA, IV, and V were distributed
amongst several serotypes; similarly, each of the major
serotypes comprised multiple genomovars. Nine serotypes
were identified amongst the 48 genomovar IIIA strains,
seven serotypes amongst 24 isolates of genomovar IV
(B. stabilis) and seven serotypes amongst 26 isolates of
genomovar V (B. vietnamiensis).
3.3. Sensitivity of 'B. cepacia' isolates to bacteriophages
NS1 and NS2
The 117 isolates were investigated for their ability to act
as bacterial hosts for the transducing bacteriophages NS1
and NS2. Eleven of the 117 isolates (9.4%) were sensitive
to NS1, but not to NS2, while 10/117 (8.5%) were sensitive
to NS2, but not to NS1. Forty-two isolates (36%) were
sensitive to both bacteriophages, and 54/117 (46%) were
sensitive to neither NS1 nor NS2. Isolates belonging to
each of the major serotypes showed the ability to act as
hosts for NS1 and NS2, but there was no correlation be¬
tween phage susceptibility and an individual serotype (Ta¬
ble 2) or genomovar (Table 3).
4. Discussion
Knowledge of the phenotypic and genomic diversity of
B. cepacia complex isolates is essential to clarify the mo¬
lecular epidemiology and pathogenic potential of this
group of highly adaptable bacteria. In our study, we
were fortunate to have the opportunity to investigate iso¬
lates of 'B. cepacia' which had originally been cultured, in
Europe and North America, more than 20 years ago [17-
19,20]. Although the isolates were well characterised on
the basis of phenotypic properties, their genomovar status
was unknown.
Initial identification of the genomovar status of these
'historical' isolates produced an interesting finding, namely
the absence of B. multivorans. This absence was unex¬
pected since a recent study of clinical isolates submitted
to the United States B. cepacia complex referral laboratory
reported a disproportionate distribution of genomovars
amongst the B. cepacia complex, with B. multivorans
(37.8%) and genomovar IIIA and IIIB (50.0%) accounting
for almost 90% of isolates [8]. In our study, the prevalence
of genomovar III (65 of 117, 55.6%) is similar to that
reported by LiPuma et al., and once more demonstrates
the adaptation this genomovar as a human pathogen. In
contrast, the absence of B. multivorans in our study is
intriguing. Recent reports have indicated that B. multivo¬
rans accounts for 9.3% of B. cepacia complex isolates in
Canada [23] and 5.2% in Italy [24], However, similar to
Table 2
B. cepacia complex serotypes and susceptibility to phages NS1 and NS2
Serotype Number of isolates (%) susceptible to:
NS1 only NS2 only NS1 and NS2 neither NS1 or NS2
Ol 1 (5) 5(25) 7(35) 7(35)
02 2 (9.5) 2 (9.5) 7 (33) 10 (48)
03 6(20) 2(7) 11 (36.5) 11 (36.5)
04 1 (17) 0 1 (17) 4 (66)
05 1 (8) 1 (8) 6 (46) 5 (38)
06 0 0 0 1 (100)
07 0 0 1 (50) 1(50)
08 0 0 4 (40) 6 (60)
09 0 0 4 (33) 8 (66)
01,4 0 0 1 (100) 0
01,7 0 0 0 1 (100)
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Table 3
Phage susceptibility patterns in different genomovars of B. cepacia
Genomovar Number of isolates (%) susceptible to:
NS1 only NS2 only NS1 and NS2 neither NS1 or NS2
1001 (50) 1 (50)
II 0 0 0 0
IIIA 2 (4) 7 (14) 17 (35) 22 (46)
IIIB 1 (6) 1 (6) 2 (12) 13 (76)
IV 2 (8) 2 (8) 10 (42) 10 (42)
V 6 (23) 0 12 (46) 8 (31)
the United States data, isolation of B. multivorans else¬
where is considerably higher, with prevalence rates in
France, United Kingdom, Belgium and Germany ranging
from 47 to 65% (authors unpublished). Our results cannot
be explained by the apparent scarcity of B. multivorans in
natural environments [25] since the isolates we examined
were predominantly clinical in origin, or associated with
contaminated equipment implicated in human infections
[17-19,20]. Since epidemic spread features less strongly
in the epidemiology of B. multivorans compared to that
of genomovar III [3-5], it is probable that the reason(s)
for the apparent emergence and increased prevalence of
B. multivorans is (are) species rather than strain specific.
Furthermore, the suggestion [26] that B. multivorans is of
less importance, as a human pathogen, than genomovar
III needs to be treated with caution. Since B. multivorans is
increasingly recognised as potentially virulent and trans¬
missible [22], it is tempting to speculate that this species
has emerged more recently than genomovar III as a hu¬
man pathogen, and that similar adaptation may occur in
other species of the B. cepacia complex.
In our study, the distribution of O-serotypes amongst
the 117 strains did not correlate with genomovar status. In
most cases, individual serotypes were represented in sev¬
eral genomovars, and no particular serotype predominated
amongst strains of any single genomovar. Of interest, sev¬
en serotypes were identified amongst the 24 genomovar IV
(B. stabilis) isolates. This was another unexpected result.
In contrast to the genomic diversity and plasticity of most
members of the B. cepacia complex, genomic analyses by
random amplified polymorphic DNA analysis and pulsed-
field gel electrophoresis have suggested that the genome of
B. stabilis is highly conserved [27]. Our results confirm
data from a small study by Vinion-Dubiel et al., which
identified serotypes 02, 03, 04 and 09 in four genomovar
III isolates [28]. The authors suggested that multiple sero¬
types may result from transfer of the O antigen locus
between strains from different genomovars, or alterna¬
tively that different genomovars may arise from strains
sharing an identical serotype. Since the latter hypothesis
would require considerable genetic shift, this seems an
unlikely explanation. Alternatively, antigenic variation
within genomovars could occur through mutation and
horizontal gene transfer. Strains exhibiting a hypermutator
phenotype have been identified in several 'B. cepacia' ge¬
nomovars (authors' unpublished results). In addition, evi¬
dence of lysogeny and transducing bacteriophages within
the B. cepacia complex [21,29,30], together with insertion
sequences [31-33], and homologues of the P. aeruginosa
wbp locus [28], provides ample scope for horizontal trans¬
fer and alteration of genes involved in O antigen synthesis.
It is known that P. aeruginosa and Shigella flexneri phages
can alter the serotype of the strain they lysogenise [34,35].
Furthermore, O-antigen variability, involving modification
of sugar moieties or changes in the lengths of the O anti¬
gen side chains, is utilised as a virulence mechanism in
many bacteria, [36-38], In the B. cepacia complex, the
LPS within a particular strain population can exist as a
mixture of smooth and rough chemotypes [15] and in ei¬
ther form be highly endotoxic [12,13]. Thus, it is perhaps
to be expected that this potent virulence factor is utilised
by bacterial pathogens to their advantage resulting in ge¬
nomovars exhibiting multiple serotypes.
Since the bacterial receptor for phages NS1 and NS2 is
LPS [21], we looked for a possible correlation between O-
serotype and sensitivity to these phages. For most sero¬
types, there was little correlation between serotype and
sensitivity to either NS1 or NS2 (Table 3). The small
numbers of isolates available hampered conclusions on
serotypes 06-09, and the polyagglutinating serotypes.
However, our results pose several possibilities. First,
phages NS1 and NS2 may not bind solely to the O antigen
moiety of LPS, but rather to regions within the LPS core.
This would explain why the epidemic ET12 lineage, which
exhibits a rough LPS chemotype [ 15], is capable of acting
as a host for NS2 [21]. LPS core receptors have also been
found with the Escherichia coli phage U3, and the phi
CTX phage of P. aeruginosa [39,40]. This hypothesis
would explain the lack of serotype specificity for NS1
and NS2. Alternatively, the 'B. cepacia' phages may bind
non-specifically or inefficiently to the O antigen, or have
the ability to utilise additional non-LPS receptors on the
bacterial cell surface. Phages that have multiple bacterial
binding sites have been described and include phage P127
which binds reversibly to several cell wall components of
Lactococcus lactis subspecies cremoris [41], A low adsorp¬
tion rate due to inefficient binding of NS1 and NS2 might
also result in failure to detect phage susceptibility.
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Recent results described by Woods and colleagues [42]
suggest another possibility. They observed that lack of
sensitivity of certain strains of Burkholderia mallei to the
Burkholderia thailandensis phage E125 is due to the pres¬
ence of an insertion sequence within the O antigen genes
wbiE and wbiG. Since the isolates used in our study had
been originally cultured over two decades previously, it is
also possible that instability through storage or re-culture
has led to alterations in LPS-associated genes. This phe¬
nomenon has been noted in other bacterial pathogens
[43,44] and may perhaps be more prone to occur in a
region with the potential for variability, resulting in host
populations with mixed LPS chemotype and variable
phage susceptibility.
Combining previous data for LPS activity [12] with ge-
nomovar status from this study showed that the degree of
endotoxicity and tumor necrosis factor-a induction varies
within and between genomovars III and B. multivorans
(data not shown) indicating that endotoxicity is variable
within the B. cepacia complex. Variable endotoxicity and
inflammatory potential may be particularly relevant to CF
patients infected by B. cepacia complex bacteria who are
being considered for lung transplantation. Patients in¬
fected by B. cepacia complex pre-operatively, in particular
genomovar III, exhibit lower post-operative survival
[9,10]. The phenomenon also appears to be genomovar-
rather than strain-specific [9], suggesting that it is not
due to the impact of highly transmissible strains such as
ET12 [3,45,46]. Further studies are required to determine
if LPS endotoxicity plays a role in reduced survival follow¬
ing transplantation, and if strain-specific endotoxicity in
other genomovars, in particular B. multivorans, influences
post-transplantation survival.
In conclusion, whilst taxonomic analyses continue to
reveal the diversity of genomovars within the B. cepacia
complex, our data suggest that the biological activities of
B. cepacia complex LPS, as a major virulence factor, are
strain and not genomovar specific. Furthermore and un¬
fortunately, serotyping based on O-antigenicity does not
provide a simple and rapid alternative to DNA-based and
other molecular approaches to identify genomovar status.
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